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Imaging Based Prediction of Pathology in Adult Diffuse Glioma with
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The overall aggressiveness of a glioma is measured by histologic and molecular analysis
of tissue samples. However, the well-known spatial heterogeneity in gliomas limits the
ability for clinicians to use that information to make spatially specific treatment deci-
sions. Magnetic resonance imaging (MRI) visualizes and assesses the tumor. But, the
exact degree to which MRI correlates with the actual underlying tissue characteristics
is not known.
In this work, we derive quantitative relationships between imaging and underlying
pathology. These relations increase the value of MRI by allowing it to be a better
surrogate for underlying pathology and they allow evaluation of the underlying biolog-
ical heterogeneity via imaging. This provides an approach to answer questions about
how tissue heterogeneity can affect prognosis.
We estimated the local pathology within tumors using imaging data and stereotactically
precise biopsy samples from an ongoing clinical imaging trial. From this data, we trained
a random forest model to reliably predict tumor grade, proliferation, cellularity, and
vascularity, representing tumor aggressiveness. We then made voxel-wise predictions to
map the tumor heterogeneity and identify high-grade malignancy disease.
Next, we used the previously trained models on a cohort of 1,850 glioma patients who
previously underwent surgical resection. High contrast enhancement, proliferation, vas-
cularity, and cellularity were associated with worse prognosis even after controlling for
clinical factors. Patients that had substantial reduction in cellularity between preoper-
ative and postoperative imaging (i.e. due to resection) also showed improved survival.
We developed a clinically implementable model for predicting pathology and prognosis
after surgery based on imaging. Results from imaging pathology correlations enhance
our understanding of disease extent within glioma patients and the relationship between
residual estimated pathology and outcome helps refine our knowledge of the interaction
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Malignant primary brain and central nervous system (CNS) tumors occur at an incidence
rate of approximately 7 cases per 100,000 individuals per year. Gliomas, specifically
glioblastomas, are the most common and make up nearly half of all malignant CNS
tumors [3]. Glioblastoma has one of the worst prognoses of any cancer and a median
overall survival of only 14 months with the best current therapy [4]. However, low-
grade glioma patients have survival statistics measured in years or decades especially
with good treatment [5, 6]. Patients with gliomas are treated by three main methods:
surgical resection and debulking reduces the total tumor burden and provides diagnostic
tissue samples. radiotherapy treats microscopic infiltrative disease in the postoperative
cavity, and chemotherapy is given systemically to slow the progression of the disease.
Despite a multifaceted treatment approach, gliomas are notorious for ultimately re-
curring. This is likely due to the well-known tumor heterogeneity of pathologic and
molecular factors which complicates treatment [7–13]. While a more complete surgical
resection is favorable [14, 15], what constitutes a “total resection” is debated. The mar-
gins applied to radiation plans are largely empiric, because tumor borders on imaging
are so poorly defined. Only a single chemotherapeutic agent, temazolamide, has proven
effective against glioma with an acceptable safety profile, despite much (and ongoing)
work [4].
Many of the difficulties of caring for glioma patients arise from imaging problems. Mag-
netic resonance (MR) is the main modality of imaging for tumor interrogation, but while
tumors are known to be highly heterogenous pathologically, this is only partly reflected
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in current imaging, with different areas of radiographically similar tumor showing diver-
gences in grade [14–17]. There is a great need for improved imaging to better delineate
and characterize tumor in the brain, specifically dealing with spatial heterogeneity to
allow improved biopsy, surgical resection and radiation planning. The goal of this work
is to provide: a) an imaging-pathology translation key for glioma, and b) applied this
as a prognostic tool and c) as a measure of surgical impact on prognosis or outcome.
We do this using imaging-based machine learning models trained on spatially specific
tumor samples extracted during a prospective diagnostic clinical trial (PI: Schellinger-
hout). Having a complete description of both imaging and pathological findings at
selected points in patient brains allowed us to develop models that can translate from
imaging to pathological features and generate parametric maps of predicted patholog-
ical features. This approach maximizes the extraction of clinically useful information
contained in multi-parametric magnetic resonance (MR) imaging, and allows us to more
successfully deal with tumor heterogeneity [18]. MR imaging, especially advanced and
functional techniques are known to correlate globally with tumor malignancy. How-
ever, the point-wise correlation between imaging and pathology is not fully understood
and represents a knowledge gap that we address in this project. This project naturally
divides into two aims:
First, we correlated imaging with local pathology and generate predictive models of
glioma tumor pathology and grade. Our working hypothesis for this aim is that correla-
tions between imaging and tumor pathology are sufficiently consistent across the glioma
patient population to make accurate local predictions of proliferation, vascularity, cellu-
larity, and grade using machine learning models. To overcome the confounding effects of
tumor heterogeneity and allow us to estimate grade at a voxel-wise level, we use pathol-
ogy from of spatially precise stereotactic tissue biopsies, acquired in a clinical trial, that
have a known location in the brain. By including samples from a diverse pool of overall
grades as well as from different regions like enhancing volume or non-enhancing regions,
we trained models to make reliable predictions for new patients using only imaging data.
This provides the foundation for glioma pathological parametric maps.
Second, we evaluated the effect of biological heterogeneity and extent of resection on
prognosis. Current literature establishes the prognostic threshold for gross total resection
(GTR) at 98% removal of enhancing tumor [14]. An example of a total resection is
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shown in Figure 1.1. However, to preserve brain function, GTR is achieved in only
30% to 50% of cases [14, 15]. Without GTR, the chance that highly aggressive disease
remains increases, especially when high grade disease is near the tumor boundary [16].
Our working hypothesis here is that similar survival benefit to GTR will be achieved so
long as the estimated highly malignant disease, as estimated by pathological parametric
maps, is removed. Predicting disease burden pre- and post- operatively gives us a
biologically relevant measure of surgical resection in terms of residual volume of grade
disease. We curated data from a very large historical cohort of > 1000 patients at
our institution to validate the prognostic effect. Using real clinical data makes our
algorithms widely applicable and robust to variations in clinical image quality. As part
of the analysis, we constructed multivariate survival models using estimated pathology
and known prognostic factors like treatment history, age, and genetic markers [19].
Figure 1.1: Contrast enhanced T1w images of a high-grade glioblastoma. Left: A
lobular enhancing tumor component is visible in the posterior portion of the brain.
Right: After surgery, the enhancing tumor is completely removed. Therefore, this
patient is said to have received a gross total resection
1.1 Dissertation Organization
The organization of this dissertation is as follows: Chapter 2 addresses the first aim of
this project and establishes image-based predictive models of tumor pathology. Chap-
ter 3 describes the large-scale curation of historical data used for survival analysis.
Chapter 4 correlates traditional radiomics image features and measurements from esti-
mated pathology maps with survival. Chapter 5 expands the analysis to postoperative
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imaging features and analyzes differences between preoperative and postoperative fea-
tures with respect to survival. Chapter 6 summarizes the conclusions and future work
of this project.
1.2 Background
1.2.1 World Health Organization Grading of Gliomas
This work deals with the diagnosis and treatment of adult diffuse gliomas corresponding
to World Health Organization (WHO) grades II, III, and IV. Grade I tumors are normally
found in pediatric populations, and are thus not represented in our adult study. The
following summary of the WHO grading scale refers to this subset of gliomas in particular
in order to contextualize the analysis and terminology used.
Gliomas are family of proliferative central nervous system diseases that have highly
variable prognosis depending on the level of malignancy. Some patients live 15 or more
years with proper treatment and others have extremely poor prognosis with overall
survival around 12 months [4–6]. Capturing this range in prognosis is the one main
goal of the World Health Organization (WHO) grading scale [20], with the other goal
being the effective and precise classification of similar disease subsets. For decades,
glial tumors were classified based on their histologic appearance and supposed cellular
lineage (e.g. from astrocytes or oligodendrocytes). This was accomplished primarily
using light microscopy and histologic staining. As of the fourth revision of the WHO
grading scale in 2007 [21], tumors were classified using an overall grade and a histologic
type. In short, cellular atypia indicated a WHO grade II tumor and the presence of
anaplasia and mitotic figures (beyond solitary mitoses) indicated a grade III tumor. The
presence of microvascular proliferation or necrosis indicated a highly malignant grade
IV tumor. Along with these grades there were four main histologic types for diffuse
gliomas: astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and glioblastoma.
Glioblastomas were exclusively grade IV but the other histologic types could be either
grade II (i.e. astrocytoma) or grade III (i.e. anaplastic astrocytoma) [21, 22].
More recently, studies discovered key genotypes associated with specific histologic diag-
noses and large differences in prognosis. This led to a major update to the WHO grading
Chapter 1. Introduction 5
scale in 2016 [20, 22, 23]. Oligodendrogliomas were defined explicitly by the presence of
IDH mutation and simultaneous co-deletion of chromosome arms 1p and 19q (1p/19q
codeletion). With this change, the mixed histologic diagnosis of oligoastrocytoma was
essentially removed since these tumors could be genetically classified as either oligoden-
droglioma or astrocytoma with the exception of a few rare cases [24]. The integrated
diagnosis for most diffuse gliomas was also revised to include IDH mutation status,
reflecting the large prognostic differences observed between tumor of the same overall
grade. For example: Glioblastoma, IDH wild-type versus Glioblastoma, IDH mutant.
Other genetic mutations like ATRX or p53 commonly occur alongside IDH mutations.
These are noted as characteristic but not necessary for diagnosis of IDH mutant tumors.
A new update to the WHO grading scale is anticipated to be released in mid-2021 which
will continue to finalize the inclusion of molecular information in the diagnoses of glial
tumors. Much of this information has already been released as a series of statements from
the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
(cIMPACT-NOW) [25–27]. One noteworthy anticipated change is the upgrading of IDH
wild-type grade II and III astrocytic tumors to grade IV if they have EGFR amplification,
chromosome 7 gain and 10 loss, or TERT promotor mutations [26]. It is also anticipated
that the grade nomenclature will change from roman numerals (II, III, IV) to Arabic
numerals (2, 3, 4). Since these changes are not official and since all grading data in this
work was collected prior to 2021 we do not change any of our grading based on the 2021
WHO classifications. It should be noted that the guiding principal of the WHO grading
system has always been to indicate prognosis, and that each successive version of the
grading system represents a refinement of the prior version.
Implications for WHO Grades Used in this Work
The data collected in this work includes biopsy data collected prior to 2016 as well as
historical diagnoses dating back to the 1990s. Since the WHO grading scale has changed
several times in this time frame, we must be precise when referring to tumor grade so
that the assignments are compatible between eras. Although the diagnoses themselves
changed in 2016, the final WHO grade assigned for IDH mutant and wild-type tumors
with the same histology did not [23]. For example, both IDH mutant and IDH wild-type
astrocytoma are WHO grade II, despite the wild-type tumor having a poorer prognosis.
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This means that the WHO grade (without reference to molecular subtype) prior to and
after the WHO 2016 revision are still compatible. In this work, when we refer to
overall WHO grade, we mean the histologic grade alone without reference to
molecular markers like IDH status. This can be thought of as the otherwise specified
(NOS) categories of the WHO 2016 classification. In the historical data, we kept the
antiquated diagnosis of “mixed oligoastrocytoma” as well, this category having been
eliminated only recently, and with technology not available historically.
1.2.2 Radiographic and Histologic Heterogeneity of Gliomas
This work discusses diffuse gliomas which are grades II, III, and IV where IV is the most
malignant. Because the behavior of these tumors varies so much, information on the
individual histology and genetics of a particular patient’s tumor is extremely important.
Most commonly, this is gathered using tissue specimen from biopsy or surgical resection.
Although tissue analysis provides rich histologic and genetic information, it is limited by
the well-known intratumoral heterogeneity of gliomas and thus is vulnerable to sampling
error [9, 11, 28–30]. For example, high grade glioblastomas often contain regions of
both low and grade disease [9]. The overall clinical WHO grade of the tumor (and
corresponding estimate of prognosis) is assigned as the maximum grade found in any
tissue specimen from that tumor. If the highest grade is not sampled (e.g. if a biopsy
is not taken from the most malignant region) there is a risk of “under-grading” which a
previous study has shown to occur in as many as 38% of cases [31]. Sampling a tumor
often has to be limited due to risks of neurological deficits to the patient [14]. This
leads to technical difficulties if the actual grade of un-resected tissue is higher than the
samples extracted.
Diagnostic imaging provides very rich information that can aid diagnosis and treatment.
Magnetic resonance imaging (MRI) is the superior modality for brain tumor imaging
due to strong soft tissue contrast and a plethora of advanced and functional imaging
techniques [32]. Relative to obtaining tissue data, MRI is non-invasive, cheap, safe,
and efficient. Key imaging findings like contrast enhancement or T2-weighted hyper-
intensity strongly correlate with tumor grade. This allows a preliminary diagnosis to
be rendered before tissue data is available [33]. MRI also provides a foundation to plan
interventions: surgery and radiation rely heavily on 3D image guidance to locate disease
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inside the brain. High-resolution MR images are used in conjunction with stereotactic
cranial navigation to help neurosurgeons locate tumor during craniotomy. Similarly,
contrast enhanced and T2-weighted images are used to define gross target volumes for
radiation treatment. All three of these procedures: diagnosis, surgery, and radiotherapy
operate on the fundamental assumption of correspondence between imaging and the
underlying tumor biology.
Radiographic heterogeneity is well established and generally characterized in terms of
the visible sub-regions like enhancing volume, T2 bright regions, and necrosis [34]. Much
work has been done to study the relationship between radiographic appearance and prog-
nosis. This field is generally referred to as “radiomics” [35, 36]. Radiomics operates on
the hypothesis that image heterogeneity, patterns in intensity and contrasts, capture
the underlying biological heterogeneity and helps tease out the differences in clinical
progression [35]. Imaging elucidates some of the histological heterogeneity but there is
still variation with radiographically similar regions [37–39]. Contrast enhancing tumor,
the current target for treatment, is not entirely sensitive nor specific for active malig-
nancy. Thus, there has been considerable research attempting to establish links between
imaging and the true underlying biology (e.g. radiogenomics).
Radiographic heterogeneity is also the basis for guiding surgical treatment. Neurosur-
gical literature has established “gross total resection” (GTR) of tumor as a favorable
prognostic factor for glioma patients [14, 15]. However, there are several definitions of
total resection. The most common is based on removal of disease that demonstrates con-
trast enhancement of T1w MRI, Figure 1.1. The enhancement comes from compromised
blood-brain barrier due to rapid angiogenesis within the tumor. Thus, enhancement is
a surrogate for active tumor tissue. Further definitions of GTR are based on resection
of T2w or T2-FLAIR hyper-intensity, which is useful for low grade or non-enhancing
gliomas [15]. Essentially, all these radiographically based definitions use imaging as a
surrogate to measure the removal of malignant tumor tissue.
Recent work shows that traditional radiomic features based only on preoperative im-
ages may have very limited effectiveness on gross total resection (GTR) subpopulations
where a majority of tumor is removed [40]. The removal of most of the tumor appears
to invalidate predictions made on pre-surgical imaging. This is a major limitation for
Chapter 1. Introduction 8
radiomics studies that use only preoperative data especially considering GTR is recom-
mended for all glioma grades [41]. In Chapter 5 we look at the change in image features
between preoperative and postoperative imaging to examine heterogeneity in the con-
text of treatment. Features that are both prognostic preoperatively and whose change
correlate with outcome provide possible targets for surgical intervention or new defini-
tions for extent of resection. This furthers the extensive work done with preoperative
radiomics to the post-treatment realm. Like the preoperative case, we analyze using
both raw image features and estimated histologic heterogeneity.
1.2.3 Use for Synthetic Pathology Maps in Diagnosis, Surgery, and
Radiation Therapy
Figure 1.2: Example of an estimated proliferation map for a non-enhancing WHO III
glioma. The blue circle highlights a region of heightened proliferation in an otherwise
radiographically homogeneous area. The extra information comes from the inclusion of
extra advanced and functional imaging.
Image-based predictions of glioma pathology can be presented as graphical “synthetic
pathology maps” that can be interpreted directly or used alongside conventional diag-
nostic imaging for treatment planning. An example is shown in Figure 1.2. The first
application is in accurately grading gliomas. The difference in overall survival between
low-grade gliomas and high-grade gliomas (i.e. glioblastoma) is considerable with me-
dian overall survival of 12 months for high grade tumors versus 5 - 11 years for low
grade tumors [4–6]. Surgical specimens from tumor resection (preferred treatment for
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all grades [14, 41]) provide definitive tumor grading, but for inoperable tumors where
only biopsy is possible there is considerable uncertainty in the true tumor grade [31].
After grading, the two therapeutic applications that stand to benefit the most from these
maps are surgery and radiation therapy. Surgical resection is recommended for all glioma
patients. Modern cranial navigation technology used to guide surgery already overlays
conventional MRI with physiologically relevant information from fiber tractography and
functional MRI in order to visualize critical structures in three dimensions. Our maps
of predicted tumor pathology can integrate seamlessly alongside these other advanced
imaging derivates to guide the surgeon towards highly malignant tumor during resection.
Much of the difficulty with surgical resection is identifying glioma cell infiltration into
normal-appearing tissues. There has been some success using diffusion tensor imaging
like the sequences in our study to identify white matter infiltration [42]. Combinations
of diffusion and perfusion imaging were also recently used to prospectively predict the
locations of recurrence within peritumoral edema on a prospectively validated cohort
[43]. With these studies in mind, it is reasonable to expect that disease extent can be
quantified by machine learning models.
After surgery, nearly all glioma patients also complete a course of radiation therapy.
In the radiotherapy planning process, treatment plans are developed using conventional
CT and MR imaging to define tumor margins, outline normal tissue structures, and
calculate the radiation dose to these areas. We envision our maps would be particularly
useful to help define radiation target volumes, ensuring active tumor was adequately
covered. Since the maps are image based, they would be easily to integrate with the
treatment planning system. Additionally, current radiation doses are already near the
limits of normal tissue toxicity. Reducing dose in areas associated with neurological
deficits like the hippocampus will provide more flexibility in treatment planning and
mitigate these potential neurological deficits. In addition to the highest-grade regions
of the tumor, the proposed models can also identify these low-risk areas. Recent work
using advanced diffusion tensor MRI to adjust radiotherapy plans has been presented
by Jena et. al. [44]. However, at this time planning and evaluation radiotherapy plans
is reserved for our future work.
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1.2.4 The Data Processing Inequality
The data processing inequality states that information content from derived or pro-
cessed data is less than or equal to the information in the combined raw data [45].
Specifically, the Shannon entropy [46] H(y) over a series of discrete observations of a
random variable Y = {y1, ..., yn} is defined as




Where p is the probability p(yi) = p(Y = yi). From the Shannon entropy, we can
compute the mutual information I between Y and another random variable Z in terms
of the conditional entropy H(Y |Z) =
∑N
j=1 p(zj)H(Y |zj).
I(Y, Z) = H(Y )−H(Y |Z) = H(Z)−H(Z|Y )
The mutual information provides an upper bound on the amount of communicated of
information from Y to Z. The data processing inequality states that if X → Y → Z is a
markov chain, then I(X,Z) ≤ I(X,Y ) [45]. In other words, the information transmitted
all the way through the chain is less than the information transmitted at each step. In
this work, the steps in the markov process are manifested as transformations of the raw
image data (i.e. by random forests to estimate pathology). By the data processing
inequality, any prognostic stratification obtained by estimates of proliferative activity
etc. are also possible given some combination features from the input images. We can
phrase the search for prognostic biomarkers in terms of finding some function using the
input images and a binary mask to produce a single numerical risk estimate.
f(T1, T2, TC, FLAIR,mask) : R4N × {0, 1}N → R
For an image with N voxels, searching for prognostic biomarkers among all possible
combinations of image features from T1, T1C, T2, and FLAIR images means searching
a space of functions with domain in R4N . Estimated pathology maps represent an
intuitive reduction in the dimensionality of the feature space. A random forest model
trained on imaging and pathology data provides a mapping, for example to Ki67, that
reduces the dimension of the domain of the functions f .
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f(Ki67(T1, T2, TC, FLAIR),mask) : RN × {0, 1}N → R
By using tissue data to estimate Ki67 from T1, T1C, T2, and FLAIR we encode the
relevant information into a single 3D image and reduce the search space to functions over
RN . We can think of the Ki67 model as a biology informed dimensionality reduction.
Alternatively, a Ki67 map can be viewed as a synthesis of existing data from multiple
images into a single, more clinically useful form.
This biological perspective guiding our analysis is of great importance, as it fights against
issues arising from high-dimensional data analysis like the curse of dimensionality and
false detection of biomarkers. This is analogous to unsupervised principle component
analysis which redefines the basis of a space in terms of orthogonal vectors that describe
the greatest proportion of the variance in the data [47, 48]. Examining the prominent
features in the first handful of components is one way to identify candidate features
or biomarkers. In general, the first components with large variance contain the most
information about the target quantities of interest. However, since PCA is unsupervised
this is not necessarily the case.
Furthermore, simultaneously assessing multiple images at once is a very challenging
task for humans. The ability for physicians to assess disease and plan treatment is
much greater when reviewing a synthesis of information like a Ki67 index map versus
trying to comprehend all the input images separately. Also, Ki67 index is a familiar and
interpretable quantity whereas an arbitrary non-linear f(T1, T2, TC, FLAIR,mask) is
unlikely to be meaningfully interpretable.
Chapter 2
Image-Based Prediction of Local
Glioma Pathology
2.1 Introduction
The data discussed here and similar results have been previously published in journal
publications [49–51] and included in a previous doctoral thesis [52]. While some data
reported are the same as previously reported, the analysis methods have been improved
and deepened during the production of this work. To summarize: Jonathan Lin initially
reported on the collection and analysis of stereotactic biopsy data and presented random
forest modeling [52]. Then, in subsequent publications Gates et al. published predic-
tive models trained on the biopsy data using improved, and different, machine learning
techniques [49–51]. Now, in this work we further improve on these publications by im-
plementing a new automated normalization scheme and expanding the cross-validation
procedure beyond a single five-fold split.
Gliomas are highly malignant primary brain tumors and are the most common type
of central nervous system cancer [20]. High-grade gliomas also carry one of the worst
prognosis of any cancer type. Standard of care treatment depends somewhat on the
specific patient’s demographics and disease state, but generally follows a three-pronged
approach. Surgical resection of bulk tumor is now recommended for all glioma pa-
tients, even though a “watchful waiting” approach was previously applied to low grade
cases [41]. Concurrent radiation and temozolomide chemotherapy are almost always
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given: either before surgery to reduce the tumor volume or after surgery to treat micro-
scopic infiltration into the surrounding brain [4]. Despite radical therapy, the increase
in patient survival is modest and often measured in months not years. Thus, in addi-
tion to novel therapies there is room for improvement in existing radiation and surgical
techniques. Such improvements could be in the form of focusing existing therapies on
active tumor or reducing damage to normal brain and cognitive deficits [53, 54].
A main contributor to the difficulty in treating gliomas is their heterogeneous and infil-
trative nature. Diffuse gliomas subtly invade the surrounding normal brain and it is very
difficult, both radiographically and surgically, to define a border between diseased and
healthy tissue. Even within the core of a glioma, especially a high grade glioma, there
is substantial histologic and molecular heterogeneity. This makes focusing treatment on
active tumor areas as opposed to necrotic tissue or peritumoral edema difficult.
Magnetic resonance imaging (MRI) is by far the best imaging modality used to assess
the intratumoral heterogeneity and extent of disease in the brain. Currently, clinicians
use contrast enhanced T1-weighted MRI alongside T2-weighted and T2-FLAIR MRI
to assess this heterogeneity. However, the sensitivity and specificity of these conven-
tional imaging sequences, especially contrast enhancement, is not fully understood [38].
Recently, advanced techniques like diffusion weighted imaging and dynamic contrast
enhanced sequences have shown promise in helping to identify highly malignant tumor
areas [42, 55–57]. These functional imaging techniques generate signal using physical
or physiological properties of the underlying tissues such as restricted diffusion or com-
promised blood-brain barrier. The complementary information aids in the diagnosis
and treatment of glioma patients, but the degree to which these sequences faithfully
represent the true underlying biology is an open question [58].
Extensive research has been performed to correlate clinical imaging and brain tumor
pathology [35]. This includes the compilation of public repositories from The Cancer
Imaging Archive [59, 60] and the organization of international challenges [34]. These data
sources focus on advanced image processing or radiomic feature extraction to discover
correlates with tumor characteristics. With the exception of characteristics which are
known to be homogeneous throughout each glioma like IDH mutation status, image
based analysis alone is fundamentally limited by the ability of the images themselves to
resolve the intratumoral heterogeneity.
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In order to understand these limitations, there is a need to research precise imaging-
pathology correlations using spatial specificity to avoid the confounding effects of het-
erogeneity. To date, several studies have done so using image-guided biopsy sampling
of gliomas [38, 43, 61–63]. Although, few have published successful predictive modeling
of biological targets. In this work, we follow a similar approach using spatially spe-
cific biopsy sampling to estimate local tumor pathology using preoperative MRI data.
Our work includes a comprehensive evaluation of conventional and advanced imaging
techniques and simultaneously analyzes several key pathological characteristics like pro-
liferation, local grade, cellularity, and vascularity. Furthermore, we use the data collected
to train predictive models that can estimate these properties point-wise in new patients.
This allows the translation of the imaging-pathological correlations into useful tools for
informing prognosis and guiding treatment.
2.2 Methods
Data for this work was collected via a HIPAA-compliant IRB-approved MD Anderson
Cancer Center clinical imaging trial (NCT03458676). Adult patients with suspected
supratentorial glioma were recruited prior to surgical resection. Exclusion criteria in-
cluded previous brain tumor treatment; however previous closed biopsy was acceptable.
Patients with contraindication to MRI like metal implants or allergy to gadolinium con-
trast were also excluded. All patients gave informed consent for both the preoperative
magnetic resonance imaging study and the collection of biopsy samples during surgery.
2.2.1 Image Acquisition
Each patient was imaged within the three days prior to surgery. The preoperative MR
study was acquired on either of two GE 3.0 T MRI scanners: a GE Signa HDxt 3T
or GE Discovery MR750 3T (GE Healthcare Technology). The imaging study con-
sisted of both conventional imaging sequence and advanced sequences. Conventional
sequences included T1-weighted pre-contrast spin-echo, T1 post-contrast (both spin-
and gradient-echo), T2-weighted fast spin-echo, T2 FLAIR, T2 weighted gradient echo,
and susceptibility-weighted angiography (SWAN). Both diffusion weighted (DWI) and
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diffusion tensor (DTI) image series were acquired. The DWI were processed into para-
metric maps of apparent diffusion coefficient (ADC, eADC), while DTI were processed to
maps of average diffusion coefficient (AvgDC) and diffusion fractional anisotropy (FA).
The specific acquisition parameters for the study protocol are listed in Table 2.1 and
Table 2.2
T2 FLAIR SWAN 3D T1C T1C SE T1
Slice Orientation Axial Sagittal Axial Axial Sagittal Axial
Pulse Sequence
Name





TR (ms) 5800 7000 46 5.724 –
8.208
700 700
TE (ms) 77 125 23.1 1.736 –
2.1
11 10
TI (ms) – 2060 –
2072
– – – –
FA (◦) 90-125 90 15 20 90 90



















BW (kHz) 162.773 122.07 244.141 195.312 244.141 244.141

















ETL 8 140 6 1 1 1
% Phase FOV 70-85 100 100 80 100 75




Table 2.1: Anatomic image acquisition parameters. *One 3D T1C image had voxel
size 0.5469 x 0.5429 x 1.8 mm. FSE: Fast Spin Echo, FGRE = Fast Gradient Recalled
Echo, ETL: Echo Train Length, MEMP: Multi Echo Multi Planar
Two dynamic acquisitions were acquired each following a bolus of gadolinium contrast.
Contrast was given in a bolus of 0.1 mmol/kg either gadopentetate dimeglumine (Mag-
nevist) or gadobutrol (Gadavist; both Bayer Healthcare, Leverkusen, Germany) at 5
mL/sec, followed by 30 mL saline at 5 mL/sec. First, dynamic contrast enhanced images
were acquired, then the contrast bolus from the DCE acquisition was used to acquire the
T1 weighted post-contrast images. Afterwards, a second bolus was injected and used to
acquire a dynamic susceptibility contrast (DSC) series. DCE images were processed into
metrics describing the contrast uptake curves and leakage constants Ktrans, kep, Peak
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DWI DTI DCE DSC MRS
Slice Orientation Axial Axial Axial Axial Axial
Pulse Seq. Name SE-EPI SE-EPI SPGR GR-EPI Probe-P
TR (ms) 8000 10175 3.1 1500 1000
TE (ms) 88 90 1.1 25 144
FA (◦) 90 90 15 / 30 60 / 90 N/A
FOV (cm) 22 22 16 – 18 22 / 24 20
Matrix 128 × 128 128 × 128 256 × 160 128 × 160 16 × 16














3.5 3.5 2 – 5 3.5 / 5 N/A
No. of
Slices/Volume
24 36 28 16 1
Total No. of
Slices
48 – 192 1008 –
1452
576 – 1700 960 – 1440 1
ETL 1 1 1 1 1
% Phase FOV 100 100 75 100 100
% Sampling 100 100 100 100 100












No. of Phases – – 36 – 60 60 –
Table 2.2: Functional Image acquisition parameters. SE: Spin Echo, GE: Gradient
Echo, EPI: Echo Planar Image, SPGR: Spoiled Gradient Recalled
enhancement, mean transit time (MTT), time to peak (TTP), using NordicICE (Nordic
Neuro Labs). DSC was processed into cerebral perfusion metrics for blood flow (CBF)
and relative volume (rCBV) as well as contrast fractions vp and ve using NordicICE.
Both DCE and DSC were processed using arterial input function (AIF) deconvolution
using semi-automatically selected pixels. The AIF was measured in the middle cerebral
artery ipsilateral to the lesion when possible. The anterior cerebral artery was used
if no suitable AIF in the middle cerebral artery could be found. Magnetic resonance
spectroscopy within a tumor ROI placed by a neuroradiologist was also acquired during
this study but this data is not included in the analysis.
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2.2.2 Image Registration, Normalization, and Extraction of Values
2.2.2.1 Dynamic Contrast Enhanced (DCE) Image Processing
DCE imaging uses a temporal series of T1-weighted images to observe the passage of a
contrast agent throughout the vascular space and across the blood-brain-barrier. In this
case, the contrast agent is a gadolinium chelate which creates T1 shortening effects on
the nearby water molecules. The concentration of tracer (contrast) in Ct in tissue and
Cp in plasma is modeled by a compartment model [64].
dCt
dt
= Ktrans (Cp − Ct/ve) = KtransCp − kepCt
Where Ktrans is the transfer constant into the extravascular-extracellular space and kep
is the back-flow transfer constant. When we apply boundary conditions based on the
incoming bolus of contrast we get








The contrast agent concentration is linear related to the relaxivity of tissue as R1 =
r × Ct|R10 where R10 = 1/T10 is the baseline relaxivity and r is the relaxivity of the
contrast agent [65].
Dynamic contrast enhanced imaging was processed using Nordic ICE software (v.2.3.14,
Nordic Neuro Lab, Bergen, Norway). This software is FDA approved for permeability
and perfusion image analysis. The 4D time series was loaded into the DCE module and
processed using the following procedure: Signal conversion “1/T1 to SPGR” was selected
and the temporal resolution was updated based on the DICOM header tag (0018,1060)
(Trigger Time). Spatial smoothing, temporal smoothing, and noise thresholds were
not applied to the time series data. Next, vascular deconvolution was enabled and an
arterial input function (AIF) was semi-automatically chosen in the middle cerebral artery
ipsilateral to the lesion. The AIF was deemed acceptable if the peak signal intensity
was at least five times the mean intensity. If no acceptable AIF could be found in the
middle cerebral artery, the anterior cerebral artery and basilar artery were searched as
well. In this case, an acceptable AIF is one with peak height at least 5 times greater
than mean curve and in the range ∆R1 ∈ [20, 40] where ∆R1 is the change in relaxation
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due to the contrast. Hematocrit correction factor was set to 0.45, T1 set to 1200 ms,
and the AIF-tissue delay was automatically calculated. The full set of extended Tofts
pharmacokinetic parameters were extracted including Ktrans, kep, vp, ve as well as
additional parameters: Peak enhancement, time-to-peak enhancement, and area under
signal-time curve [64, 66].
2.2.2.2 Dynamic Susceptibility Contrast (DSC) Image Processing
Similarly to DCE, DSC uses a serial acquisition during injection of paramagnetic con-
trast agent to characterize the perfusion, or blood flow, through the tissue. Unlike DCE
which uses the T1 shortening effect, DSC signal takes advantage of differences in mag-
netic susceptibility in the vascular beds of tissue as the contrast agent passes through.
The signal is visible in T∗2-weighted images. The blood volume (BV ) is related to the






0 CT (t) dt∫∞
0 CA(t) dt
Where kh is a hematocrit scaling factor accounting for vessel size and ρ = 1.04 g/mL is









Here, R(t − τ) is a residue function that describes the fraction of contrast remaining.
Solving or blood flow (BF ) is performed by using the experimental tissue concentration
and arterial concentration curves and deconvolving the residue function. To do so,
singular value decomposition is the most common [67–69]. Blood volume and blood flow
are reported as relative values rCBV and rCBF since the true susceptibility calibration
factors are unknown. In addition to blood flow and volume, we also calculate mean
transit time MTT = rCBV/rCBF and the delay time for contrast arrival.
Dynamic susceptibility contrast images were processed by the same procedure as DCE
with a few differences: Signal conversion was set to “SI to delR2” instead of “1/T1 to
SPGR,” temporal resolution was set to 1.5 s, TE set to 25 ms. Furthermore, contrast
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agent leakage correction was applied. The Tofts model parameters exported after pro-
cessing were cerebral blood volume (both corrected and uncorrected), cerebral blood
flow, leakage parameter K2 (with cutoff of 0.1), delay time, and mean transit time.
2.2.2.3 Diffusion Weighted Imaging
Diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI) use diffusion
sensitizing gradient pulses to detect Brownian motion of water in tissue [70]. Measures
of water diffusivity can be a surrogate for architectural disruption in brain structures
like white matter or increased cell packing inside tumors [71]. In short, the diffusion
encoding gradients de-phase and refocus spins after some short delay. Spins that have
moved by diffusion are not perfectly refocused and show reduced signal. The reduction




Where the b-value b = γ2δ2G2(∆ − δ3) is a function of the gyromagnetic ratio γ, and
diffusion gradient duration (δ), amplitude (G), and delay (∆). The ADC is computed by
acquiring several diffusion weighted images and fitting an exponential to the voxel-wise
values. By applying the diffusion encoding gradients in many directions, a 3×3 diffusion







From this matrix, the eigenvector decomposition with associated eigenvalues λ1, λ2, λ3
represent the diffusion along the three principal axes. These give rise to the Average
diffusion Coefficient (AvgDC) and fractional anisotropy (FA).

















The fractional anisotropy is 0 when the diffusion is isotropic (e.g. in free water) and 1
for diffusion that occurs only along a single axis.
2.2.2.4 Registration, Normalization, Measurement
First, DICOM files were converted to NIfTI1 file format for readability by software
packages. Non-brain tissues were removed from each image using image-specific brain
masks. The brain masks were initialized using the brain extraction tool (bet2) from the
FMRIB software library [74] and further refiled in Amira3D (v6.0, FEI, Hillsboro, OR).
The skull-stripped brain volumes for each patient were co-registered that patient’s T2-
weighted image. Image registration was performed using ANTs [75, 76]. Specifically, A 6
degree-of-freedom (DOF) rigid registration followed by a 12 DOF affine registration using
mutual information. After registration, the images were resampled to the same matrix
size as the fixed image using nearest-neighbor interpolation. Results of the registration
procedure have been previously reported with the 12 DOF affine registration providing
the lowest average target registration error [77]. The reported FLAIR to T2w image
registration error was 1.55 ± 0.46 mm and T1 post-contract to T2w image registration
error was 1.06 ± 0.16 mm. Other sequences have similar magnitude errors.
Maps derived from diffusion weighted and diffusion tensor imaging were registered to
the T2w image by skull stripping and registering the b0 image first then applying the
resulting transformation the maps. For DCE, the maximum intensity projection of the
time series was used to perform registration and for DSC the average intensity image
was used.
Intensity normalization was performed on the anatomical MR sequences to provide com-
parable intensity values for quantitative analysis and predictive modeling. Rather than
normalizing using intensity histogram statistics only (e.g. Z-score), we normalized each
image using the intensities of reference tissues. The specifics are inspired by similar
1nifti.nimh.nih.gov
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work in literature [63, 78]. First, a normal tissue mask was derived from the common
space brain mask by subtracting any visible lesion associated with the tumor. Then, a
3D region-of-interest in the cerebrospinal fluid (CSF) was defined using mixture model
clustering. The CSF ROIs were visually inspected to ensure they were completely con-
tained in CSF on all images. Then, the intensities of each image were linearly scaled
such that the modal intensity of the CSF and the modal intensity of the normal brain are
0 and 1. To prevent inverting the image contrast, the CSF is mapped to 0 intensity for
T1-weighted, FLAIR, and SWAN images and mapped to 1 on T2 and T2-star weighted
images. Note, our previously published results used a slightly different normalization
method that scaled using mean intensities in hand-drawn gray matter, white matter,
and CSF ROIs [49, 50]. Given the high similarity between these normalization schemes,
the predictive modeling results are nearly identical. The comparison of values is listed
in appendix Section A.2. Quantitative maps from DWI, DTI, DSC, and DCE were not
normalized using reference tissues and the values were extracted as provided by the
scanner or processing software.
For all images, a 5-mm spherical ROI was placed at the location of each biopsy site
recorded during surgery. The size of the ROI accounts for the physical extent of the tissue
sample, approximately 10x2x2 mm, and the small amount of uncertainty in the sampling
location from the cranial navigation software [79, 80]. For each biopsy ROI, a paired
“virtual” ROI was placed in contralateral normal appearing white matter (NAWM) to
serve as a control and capture the image characteristics of normal brain. The ROIs were
placed in the closest, most ideal, NAWM and reviewed by board-certified neuroradiol-
ogist to ensure they were entirely contained in NAWM. The average intensity for each
biopsy ROI and contralateral ROI was extracted for each of the 25 total co-registered
and normalized images. In other words, each biopsy had 25 independent image mea-
surements associated with it. A full list of parameters is given in Table 2.3
When converting to NifTI format for further processing, scaling factors from the DICOM
headers were explicitly accounted for in order to translate pixel values to quantitative
measurements. For maps derived from DSC and DCE imaging, tag (0077 1001) or
(0077 1101) was used and diffusion imaging a constant scale factor of 10−6 was applied.
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T1 CSF - brain mode T1-weighted image intensity
T2 brain mode - CSF T1-weighted image intensity
TC SE CSF - brain mode Spin-echo T1 weighted post-contrast
image intensity
TC SPGR CSF - brain mode Gradient-echo T1 weighted post-
contrast image intensity
FLAIR CSF - brain mode T2-FLAIR image intensity
T2* CSF - brain mode T2*-weighted image intensity






ADC mm2/s Apparent Diffusion Coefficient from
DWI
AvgDC mm2/s Average Diffusion Coefficient from
DTI: , Equation 2.1
eADC unitless Exponential Apparent Diffusion Coef-
ficient from DWI: exp(−b ·ADC)









on CBV Arbitrary Relative cerebral blood volume
CBF Arbitrary Relative cerebral blood flow
MTT Seconds Average time for blood to pass
through tissue MTT = CBV/CBF
Delay Seconds Time delay to peak signal intensity












Ktrans 1/min Transfer constant from vascular to tis-
sue compartment.
Kep 1/min Backflow ransfer constant from tissue
to vessel compartment.
vp Percent Plasma space voxel fraction
ve Percent extravascular extracellular voxel frac-
tion
Wash-In Arbitrary slope of time-signal curve from con-
trast entry to peak intensity
Wash-Out Arbitrary slope of time-signal curve after peak
intensity
TTP Seconds Time to peak signal intensity
AUC Arbitrary Area under time-signal curve
Peak Arbitrary Magnitude of peak signal intensity
Table 2.3: List of image measurements collected for each biopsy.
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2.2.3 Biopsy Collection and Pathology Analysis
A neuroradiologist and neurosurgeon reviewed the preoperative imaging data to select
targets for biopsy. For each patient, at least one biopsy target was first selected using
conventional imaging like contrast enhancement and T2 hyperintensity while blinded
to the advanced imaging data. Then, the advanced imaging was used to select another
biopsy target in areas of high Ktrans, high rCBV, or restricted diffusion. Up to five total
targets were selected per patient and trajectories to these targets were planned using the
Brainlab IPlan software (Brainlab AG, Feldkirchen, Germany) and subsequently loaded
into the cranial navigation system in the operating room.
Figure 2.1: Screenshot of the Brainlab cranial navigation software during sample
collection. The instrument tip (crosshair) is overlaid on top of a preoperative T1-
weighted image that is co-registered to the patient’s physical space in the operating
room. The coordinates of the instruments are recorded during biopsy.
A primary goal during tissue sample collection was to maximize spatial fidelity between
the cranial navigation software and the physical space of the operating suite. Specifically,
collecting biopsy samples prior to opening of the skull minimized brain shift which
corrupts the spatial accuracy of the cranial navigation system as the brain deforms from
its preoperative position [81]. First, the patient was placed in a Mayfield head frame
(Integra LifeSciences Corp., Plainsboro, NJ). and the stereotaxy was established with
the cranial navigation system. Next, the scalp was retracted and a burr-hole was drilled
in the skull to provide access to the brain. A needle trocar was passed trans-durally into
the brain towards the biopsy pre-planned biopsy targets. When possible, biopsies were
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also collected en-route to the target up to a total of five biopsies per patient. As the
tissue samples were collected, the location of the needle tip and trajectory were recorded
[79, 80]. An example is shown in Figure 2.1. From this data, the location of the side
cutting window was calculated and this exact sampling location, which is near but not
exactly coincident with the original target location, was used for further analysis. For
some cases, the surgeon opted to use a pituitary probe resembling forceps to collect
tissue samples. The location of the instrument’s tip was similarly recorded as samples
were collected.
The tissue samples were paraffin embedded and sectioned at 4 µm thickness for histologic
analysis. The sections were stained with hematoxylin and eosin (H&E) and individually
assessed for tumor presence grade by a board-certified neuropathologist who was blinded
to imaging data. The World Health Organization histologic glioma grading scale with
grades II, III, and IV was used [21]. Note, an individual sample grade is not necessarily
the same as the patient’s clinical tumor grade.
Immunohistochemical (IHC) staining against the proliferation marker Ki67 was applied
the tissue samples using the MIB1 antibody. Ki67 is a nuclear antigen expressed by
actively dividing cells and not expressed by normal brain [82–84]. High Ki67 labelling
index is strongly associated with poor outcomes [85]. After staining, the fraction of
positively stained nuclei was semi-automatically measured to record a Ki67 labeling
index. Another IHC stain using monoclonal antibody 9YF (Biocare Medical, Concord,
CA) was used to stain against the Erythroblast Transformation Specific (ETS) related
gene, called ERG. ERG is a vascularity marker expressed more-so in angiogenic tumors
than in normal brain tissues. After staining, the fraction of slide area positively stained
for ERG was recorded. ERG staining was also used to measure cellular density with
Aperio ImageScope software (Leica Biosystems, Inc., Buffalo Grove IL).
Isocitrate dehydrogenase (IDH) mutation status for the biopsy samples was assumed to
be consistent with the overall IDH mutation status of the tumor since IDH is not het-
erogeneously expressed in gliomas [86, 87]. Tissue samples that were normal appearing
were assumed to be IDH wild-type.
To serve as controls for each of the real biopsy samples, we extracted image intensity
from contralateral VOIs in normal appearing white matter. Since no real tissue data
was available, we assumed the pathology target values using literature values. Ki67 is
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not expressed in normal brain so we assume the labeling index of virtual samples to
be identically 0% [82–84]. ERG expression was randomly imputed using by drawing
from a normal distribution with mean and standard deviation 0.199± 0.114 % positive
area. [88]. Virtual biopsies were assumed to be IDH wild-type.
2.2.3.1 Derivation of Normal White Matter Cell Density
Normal white matter cell density can be estimated using a few methods present in
literature including stereology, isotropic fractionator, and histology. A brief summary
of these methods is given in the Appendix Section A.3. We found the most appropriate
method to be histology based on work by Roetzer et al. who calculated cellularity in
whole-brain sections of brain tumor patients [89]. Cell density is measured in nuclei per
square millimeter meaning it depends on the thickness of the stained section. Translating
between cell density measure at 6 µm thickness in Roetzer [89] and our measurements
at 4 µm thickness can be done using Abercrombie’s formula [90, 91]. Below, we briefly
present a derivation of the formulas and correction of values.
Consider the measured (per area) cell density for nuclei of z-axis height H with no “lost
caps error” sectioned at thickness t. The relation between observed cell nuclei in the
section and the actual number is given by equation (1) in [91].
N = n · t
t+H
(2.3)
Where N is the true number of objects in the sectioned volume (V = A ·t, A is the area),
and n is the observed numbed of nuclei. Note, n > N since nuclei whose centers are not
inside the sectioned volume can still be stained and counted. If we write equation (2.3)
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The left-hand side, assuming constant cell volume density in the area of interest, is just
the ratio of section thicknesses N1/N2 = t1/t2. Simplifying gives a formula for the ratio







This gives us the ability to translate between cell density measurements at different
section thicknesses. As expected, for H  t1, t2 the observed cell density is just pro-
portional to the thickness. We use n1 = 3581 ± 828 nuclei/mm2 in white matter and
t1 = 6 µm from [89] and a nuclear diameter of H = 4.7 µm from [92]. This measure-
ment for H was from the control arm of an Alzheimer aging study with patients mean
age of 88 years. This is a good value to use since the white matter is approximately
80% oligodendrocytes [93]. The next largest fraction is astrocytes which have nuclear
sizes comparable to neurons [94]. These measurements give a correction factor of 0.813
at t2 = 4 µm, slightly larger than the näıve correction factor t2/t1 = 2/3 which does
not take into account the nuclear size. Using this, the corrected cell density we used
for virtual biopsies is n2 = 2912 ± 673 nuclei/mm2 via equation (2.5). For reference,
Roetzer et al. also measured cell density in cortex and tumor regions. Corrected tumor
cell density measurements are 4646± 1452 nuclei/mm2 which is a good comparison for
the real biopsy cellularity values. We previously used these corrected normal cell density
values in published work [51].
2.2.4 Predictive Modeling
Modeling was performed in R version 3.4.3 [95]. The goal of predictive modeling is to
estimate the tissue histologic characteristics of proliferation, cellularity, grade, and cellu-
larity using the imaging inputs. The image features were normalized prior to extraction
of values so no further normalization is needed.
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2.2.4.1 Biopsy-Paired Repeated Stratified Cross Validation
Cross-validation is the procedure meant to estimate a model’s performance on unseen
data. In the most basic form, the data is divided into two disjoint partitions. One
set is used to fit model parameters (training) and the other set is used to evaluate the
accuracy of predictions (testing). An important assumption of cross-validation is that
there is data homogeneity between the partitions. In this case, homogeneity means
having the same distribution of target values (e.g. grades) in each partition. Without
homogeneous partitions, the training data for some folds is not representative of the
testing data which will cause an underestimation of true model performance. To avoid
this issue, we used stratified resampling to generate folds. Instead of dividing the cases
randomly among partitions, equal numbers are sampled from each quartile of the target
variable. Stratification has been shown to reduce bias and variance in cross-validation
accuracy metrics [96, 97]. The specific procedure is implemented in the caret package
(v6.0) [98].
Figure 2.2: a) Each patient has 1-3 biopsies (filled) and each each biopsy has a
paired virtual (hollow). b) 20% of the biopsies are selected as validation data and the
remainder are used for training. Reals are kept in the same set as their paired virtuals.
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Data splitting was first applied to real biopsy samples only. Then, each sample’s paired
virtual biopsy was placed in the same partition. This balanced the number of real and
virtual samples within each partition and prevented data leakage between training and
testing sets. In summary: we performed a biopsy-level stratified resampling scheme
to generate folds for cross validation. We did not however enforce a patient-level split
and allow separate real biopsy sites from the same patient to be split between folds.
A schematic of the data splitting is shown in Figure 2.2. Finally, we repeated the
five-fold cross validation procedure 500 times and tabulated the performance across
multiple rounds. This allowed us to examine the sensitivity of the model performance to
fluctuations in data splitting and calculate the range of expected performance metrics.
2.2.4.2 Variable Selection
The first part of the training procedure was to perform variable selection, reducing the
total number of variables used for prediction. This removed non-informative variables
and reduced the size of the final parameter space. We tested two standard variable
selection techniques: First, remove no variables and simply use all variables as inputs.
The other was univariate testing, where variables not significantly associated with the
outcome were discarded. For continuous outcome variables (Ki67, cell density, ERG) the
test statistic was computed based on the Pearson product moment correlation coefficient.
This is equivalent to the performing linear regression between the output and a single
predictor and testing the significance of the coefficient. All p-values were corrected for
multiple comparisons using the Bonferroni method [99].
Additionally, we applied a heuristic variable selection procedure based on random forest
variable importance metrics. Each tree in the random forest is trained on a subset of
total training data. This means each tree has “out-of-bag” data not used in training
that can estimate the out-of-sample performance. As described in Breiman’s original
paper [100], variable importance for a particular input m is estimated as follows: For
each tree, randomly permute the values of m among the out-of-bag data. This effectively
removes any information about the output quantity given by variable m. Then, run the
out-of-bag data down the tree and compute the prediction using the shuffled values for
variable m. The average change in the error, or misclassification rate for classification
problems, across all trees is the variable importance for variable m. A large increase in
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error indicates that particular variable was important to the overall performance of the
forest.
We performed variable selection as follows: First, we fit a random forest model to all
training data using all variables. Then we selected the most important variable from each
category of imaging (conventional, diffusion, DSC perfusion, and DCE permeability).
The choice to select one predictor from each category is based on the prior knowledge
that these different sequence types provide complementary and orthogonal information.
For models based on conventional imaging only, the top four most important variables
were selected. Using the combined variable selection across all folds risks “leaking”
information between training and testing sets because all the data was used at some
point in the procedure. To see if this was the case, we compared the predictive ability
of this four-variable fixed set was against the performance when using the fold-specific
top ranked variables. Other selection methods like principal component analysis, least
absolute shrinkage and selection operator (LASSO), and Boruta method were considered
but ultimately not tested.
2.2.4.3 Model Types
We tested several types of predictive models to estimate pathology using imaging. For
Ki67 and cell density we used Random Forest [100] with parameters: 500 trees, square
root of number of predictors tried per split, no max tree size, root-mean-square error
metric. We also tried linear models and small dense networks. For predicting tumor
grade we used the same random forest parameters except for: number of predictors
divided by 3 tried per split, Cohen’s kappa metric [101]. We also tested logistic regression
models and neural networks with linear/softmax activation. The description of these
models is summarized in Table 2.4.
As an aside, convolutional neural networks are recently the de facto architectures for
biomedical image analysis tasks [102, 103]. However, they are not appropriate for this
task. The strength of the convolutional network is its ability to use contextual informa-
tion from kernels to evaluate region segmentations or whole-image classifications. Here,
we are interested only in the local image characteristics within a few millimeters of
biopsy sites and have distilled the image data into single average intensity values. Thus,




simple linear regression model fixed intercept: FALSE
Decision Tree
(rpart)
Single decision tree which makes es-
timates on new data based on the









small dense neural network size (tuned), weight decay
(tuned)
Table 2.4: Predictive model types tested for predicting pathology
the spatial information has been removed and the data is better suited to the methods
described.
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2.3 Results
2.3.1 Patient Data, Biopsy Collection, and Pathology Analysis
Thirty-one patients were recruited to the trial. For five patients, tissue harvest was
unsuccessful due to surgical complexity. Among the remaining 26 patients, 64 tissue
biopsy samples were collected. Further patient exclusions occurred due to a lack of
DCE imaging (3 samples), insufficient histology data (2 samples), or lack of samples
grade (2 biopsies). Finally, 5 more biopsies were excluded from the final analysis due to
VOIs that were outside the imaging field of view (3 samples), lack of analyzable tissue
(1 sample), and no tumor grade information (1 sample). For the 23 patients included in
the final analysis, 14 were female and 9 were male. The patients’ age was 44 ± 17 years
(range 21 - 80). The reported ethnicities were 17/2/4/0 white/black/hispanic/asian
respectively. After exclusions, 52 real tissue samples from 23 unique patients remained
in the final analysis. The clinical grades of the patients were fairly evenly distributed
with 7 WHO II, 9 WHO III, and 7 WHO IV. Four of the 7 WHO II gliomas were IDH
mutant, as were 7 of 9 WHO III glioma and 2 of 7 WHO IV gliomas. Lastly, 7 of the
52 biopsy samples were collected from contrast enhancing regions. Of those 7 samples,
3 were graded as WHO II, 1 as WHO III, and 3 as WHO IV. Each tissue sample was
independently graded by a board-certified Neuropathologist. A few biopsies were graded
as II/III based on the pathologist’s assessment that the malignancy exceeded a regular
WHO II [30]. The sample grades for each biopsy were less than or equal to each tumor’s
final clinical grade, Table 2.5. However, there was one exception of a WHO grade IV
biopsy collected from a clinical WHO grade III tumor. We noted this patient’s clinical
grade was upgraded to WHO grade IV shortly after the procedure. The proliferation,
cellularity and ERG expression roughly increased with sample grade which is expected.
The specific values are listed in Table 2.6.
Due to the low number of grade III and II/III samples in the data. We elected to pool
the grades III and IV samples into a “higher” grade category with a total of 7 samples.
The grade II and II/III samples were pooled into a “lower” grade category with a total of
42 samples, and the virtual biopsies were combined with the three histologically normal
samples to form a “normal” category.
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Sample Grade: 0 II II/III III IV
Clinical Grade II: 1 12 0 0 0
Clinical Grade III: 2 16 2 0 1
Clinical Grade IV: 0 11 1 2 4
Table 2.5: Sample grades II - IV listed by the final clinical grade of the tumor each
sample was collected from. Grade 0 indicates non-tumor.
Sample Grade N Ki67 Cell density ERG
0 3 2.417 ± 1.176 1776.714 ± 370.825 1.225 ± 1.444
II 39 4.773 ± 4.346 5789.831 ± 2667.037 2.943 ± 1.598
II/III 3 9.860 ± 2.631 6085.366 ± 2022.448 3.087 ± 1.810
III 2 16.444 ± 12.366 8608.723 ± 8520.914 3.215 ± 0.432
IV 5 25.655 ± 16.185 11546.761 ± 4251.853 4.799 ± 1.647
Table 2.6: Number of samples and mean ± standard deviation for Ki67, cellular
density, and ERG for each sample grade. All three roughly increase with increasing
sample grade. Grade 0 indicates non-tumor.
2.3.2 Image Data
All sequences were successfully acquired for most patients. One patient had no DCE
imaging and three patients had no SWAN imaging as mentioned in Section 2.3.1. All
images were successfully skull stripped, co-registered to the T2w image space, and nor-
malized using brain mode and CSF intensity values. Five biopsies had VOIs that were
outside the field of view on the SWAN image sequences. For these cases the SWAN val-
ues were imputed using the median value among the remaining biopsy samples. After
measurement, all biopsies used in further analysis had all 25 measurements in Table 2.3
available.
2.3.3 Variable Selection
Variable selection identified the subset of possible imaging predictors that were signif-
icantly associated with each pathology outcome. Then, the predictive power of each
subset was tested through modeling and cross-validation. In total, seven variable sub-
sets were tested. Due to the redundancy between ADC from DWI and AvgDC from
DTI, we elected to use the ADC measurements only in variable selection.
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Subset name abbreviaton number of variables selected within each fold
All all 24 NO
univariate dynamic univ.dynamic varies YES
univariate fixed univ.fixed varies NO
random forest dynamic rf.dynamic 4 YES
random forest fixed rf.fixed 4 NO
conventional TCSE conv.TCSE 4 NO
conventional TCSPGR conv.TCSPGR 4 NO
Table 2.7: Description of the variable subsets identified through variable selection
procedures.
2.3.3.1 Variable Selection for Predicting Proliferation (Ki67)
Univariate analysis showed several imaging variables that were significantly correlated
with Ki67.Using the entire data set, the following correlations were significant with
Ki67 (Table 2.8): From conventional imaging: T1, TC SE, T2, TC SPGR, T2*. From
Diffusion imaging: ADC, eADC, FA. From DSC: CBV, CBF, K2. From DCE: Ktrans,
kep, vp, ve, Wash-In, Wash-Out, AUC, and Peak. These are not surprising given such
MR sequences have been developed to help identify regions of heightened malignancy
for clinical practice. For use in predictive modeling, the significant of correlation was
determined on only the training data for each of the 500 × 5 = 2500 folds of cross
validation. We found that the same variables were generally significant across folds.
We also used random-forest variable importance based measures to determine the most
important variables from each class. This selection was performed independently for
each of the 2500 rounds of cross validation. In general, the same few variables were
selected as the most important in their class or were near the top. The fraction of times
each variable was given a specific rank is listed in Table 2.9. Within each variable class
(conventional, diffusion, DSC, DCE), the dominant variables were rank 1 a majority of
the time. They are T2 (selected in 89% of folds), FA (99% of folds), CBF (68% of folds),
and Ktrans (61% of folds). These four predictors were selected as a final set of fixed
inputs.
2.3.3.2 Variable Selection for Predicting Cellular Density
The variables that were significantly correlated with CD in the entire data set were
(Table 2.10): From conventional imaging: T1, TC SE, T2, TC SPGR, FLAIR, T2*.
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variable p value frequency
T2 1.173E-10 1.00
T1 5.430E-04 0.49
TC SE 2.412E-10 0.99
















Wash In 2.021E-10 0.94




Table 2.8: p-values for variables significantly associated with Ki67 in all data and the
fraction of folds (frequency) where each correlation is significant among training data
From Diffusion imaging: ADC, eADC, FA. From DSC: rCBV, CBF, K2. From DCE:
Ktrans, kep, vp, ve, Wash-In, Wash-Out, AUC, and Peak.
Using random forest variable selection, the top variables in each family were T2 (60%
of folds), FA (67% of folds), CBF (67% of folds), and AUC (56% of folds). These four
variables were used in the fixed variable set. Table 2.11 lists the specific proportions of
ranks for each variable.
2.3.3.3 Variable Selection for Predicting Vascularity (ERG)
The variables that were significantly correlated with ERG in the entire data set were
(Table 2.12): From conventional imaging: T1, T2, FLAIR, T2*. From Diffusion imaging:
ADC, eADC, FA. From DSC: rCBV, CBF, K2. From DCE: Ktrans, kep, vp, Wash-In,
Wash-Out, and Peak.
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variable Rank 1 Rank 2 Rank 3 Rank 4 Rank 5 Rank 6 Rank >6 Average rank
T2 0.85 0.13 0.01 0.00 0.00 0.00 0.00 1.16
T1 0.01 0.10 0.31 0.24 0.17 0.11 0.05 3.99
TC SE 0.14 0.64 0.13 0.05 0.03 0.02 0.01 2.27
TC SPGR 0.00 0.04 0.20 0.25 0.22 0.18 0.11 4.64
T2* 0.00 0.05 0.15 0.19 0.21 0.26 0.15 4.94
FLAIR 0.00 0.04 0.18 0.22 0.25 0.20 0.11 4.72
SWAN 0.00 0.01 0.02 0.05 0.12 0.23 0.57 6.27
ADC 0.00 0.14 0.86 0.00 0.00 0.00 0.00 2.86
eADC 0.01 0.85 0.14 0.00 0.00 0.00 0.00 2.13
FA 0.99 0.01 0.00 0.00 0.00 0.00 0.00 1.01
CBV 0.06 0.38 0.30 0.18 0.08 0.00 0.00 2.84
CBF 0.71 0.15 0.07 0.04 0.04 0.00 0.00 1.54
MTT 0.08 0.16 0.25 0.29 0.22 0.00 0.00 3.40
K2 0.03 0.07 0.12 0.24 0.53 0.00 0.00 4.16
Delay 0.12 0.23 0.26 0.26 0.13 0.00 0.00 3.05
Ktrans 0.61 0.27 0.06 0.03 0.01 0.01 0.00 1.59
kep 0.26 0.54 0.12 0.05 0.02 0.01 0.01 2.07
vp 0.00 0.00 0.00 0.00 0.04 0.13 0.83 7.50
ve 0.01 0.01 0.04 0.08 0.33 0.36 0.17 5.53
Wash In 0.00 0.00 0.00 0.02 0.08 0.12 0.77 7.50
Wash Out 0.03 0.02 0.06 0.11 0.27 0.25 0.26 5.54
TTP 0.00 0.00 0.00 0.00 0.01 0.05 0.93 8.09
AUC 0.00 0.02 0.14 0.54 0.21 0.07 0.02 4.23
Peak 0.09 0.13 0.57 0.17 0.04 0.01 0.00 2.97
Table 2.9: Fraction of times each variable was assigned a particular rank relative to
other variables in its class for predicting Ki67
Using random forest variable importance, the highest ranking variables from each family
were T2 (99% of folds), ADC (69% of folds), CBV (52% of folds), and AUC (95% of
folds). These four variables were used in the fixed variable set. Table 2.13 lists the
specific proportions of ranks for each variable.
2.3.3.4 Variable Selection for Predicting Local Grade
The variables that were significantly correlated with grade in the entire data set were
(Table 2.14): From conventional imaging: T1, TC SPGR, T2, FLAIR, T2*, SWAN.
From Diffusion imaging: ADC, eADC, FA. From DSC: rCBV, CBF, K2. From DCE:
Ktrans, kep, vp, ve, AUC, and Peak.
Using random forest variable importance, the highest ranking variables from each family
were T2 (99% of folds), ADC (99% of folds), CBV (49% of folds), and kep (52% of folds).
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variable p value frequency
T2 3.503E-10 1.00
T1 2.684E-04 0.69
TC SE 2.782E-09 1.00
















Wash In 9.920E-06 0.87




Table 2.10: p-values for variables significantly associated with CD in all data and the
fraction of folds (frequency) where each correlation is significant among training data
These four variables were used in the fixed variable set. Table 2.15 lists the specific
proportions of ranks for each variable.
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variable Rank 1 Rank 2 Rank 3 Rank 4 Rank 5 Rank 6 Rank >6 Average rank
T2 0.60 0.34 0.05 0.00 0.00 0.00 0.00 1.45
T1 0.00 0.00 0.08 0.29 0.23 0.22 0.18 5.12
TC SE 0.30 0.38 0.26 0.04 0.01 0.00 0.00 2.10
TC SPGR 0.09 0.27 0.50 0.10 0.03 0.01 0.00 2.73
T2* 0.00 0.00 0.03 0.17 0.24 0.27 0.27 5.57
FLAIR 0.00 0.00 0.01 0.14 0.22 0.26 0.37 5.83
SWAN 0.00 0.01 0.06 0.26 0.27 0.24 0.17 5.20
ADC 0.10 0.32 0.58 0.00 0.00 0.00 0.00 2.48
eADC 0.23 0.49 0.28 0.00 0.00 0.00 0.00 2.06
FA 0.67 0.20 0.14 0.00 0.00 0.00 0.00 1.47
CBV 0.03 0.26 0.44 0.21 0.06 0.00 0.00 3.02
CBF 0.67 0.25 0.06 0.02 0.00 0.00 0.00 1.43
MTT 0.00 0.02 0.09 0.32 0.57 0.00 0.00 4.44
K2 0.27 0.35 0.23 0.12 0.03 0.00 0.00 2.29
Delay 0.04 0.11 0.18 0.34 0.33 0.00 0.00 3.82
Ktrans 0.05 0.24 0.37 0.29 0.04 0.01 0.00 3.05
kep 0.35 0.36 0.19 0.08 0.01 0.00 0.00 2.06
vp 0.00 0.00 0.01 0.01 0.18 0.30 0.50 6.61
ve 0.00 0.01 0.01 0.04 0.41 0.25 0.28 5.90
Wash In 0.00 0.01 0.01 0.02 0.20 0.18 0.57 6.82
Wash Out 0.00 0.00 0.00 0.00 0.04 0.11 0.85 7.90
TTP 0.00 0.00 0.00 0.00 0.06 0.15 0.79 7.53
AUC 0.56 0.21 0.15 0.07 0.01 0.00 0.00 1.76
Peak 0.04 0.17 0.25 0.48 0.05 0.01 0.00 3.37
Table 2.11: Fraction of times each variable was assigned a particular rank relative to
other variables in its class for predicting CD
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variable p value frequency
T2 1.691E-15 1.00
T1 6.595E-07 1.00
TC SE 5.314E-03 0.17
















Wash In 1.528E-04 0.87




Table 2.12: p-values for variables significantly associated with ERG in all data and
the fraction of folds (frequency) where each correlation is significant among training
data
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variable Rank 1 Rank 2 Rank 3 Rank 4 Rank 5 Rank 6 Rank >6 Average rank
T2 0.99 0.01 0.00 0.00 0.00 0.00 0.00 1.01
T1 0.00 0.03 0.08 0.28 0.25 0.21 0.15 4.99
TC SE 0.00 0.00 0.05 0.22 0.28 0.27 0.18 5.31
TC SPGR 0.00 0.00 0.02 0.14 0.19 0.26 0.39 5.85
T2* 0.01 0.73 0.22 0.03 0.01 0.00 0.00 2.31
FLAIR 0.00 0.22 0.58 0.14 0.04 0.01 0.00 3.05
SWAN 0.00 0.01 0.05 0.18 0.22 0.24 0.28 5.48
ADC 0.69 0.26 0.05 0.00 0.00 0.00 0.00 1.36
eADC 0.22 0.56 0.22 0.00 0.00 0.00 0.00 2.00
FA 0.10 0.18 0.73 0.00 0.00 0.00 0.00 2.63
CBV 0.52 0.35 0.11 0.02 0.00 0.00 0.00 1.64
CBF 0.07 0.23 0.52 0.18 0.00 0.00 0.00 2.83
MTT 0.01 0.05 0.18 0.70 0.05 0.00 0.00 3.72
K2 0.40 0.37 0.18 0.04 0.00 0.00 0.00 1.87
Delay 0.00 0.00 0.00 0.05 0.94 0.00 0.00 4.94
Ktrans 0.00 0.02 0.14 0.28 0.27 0.20 0.08 4.76
kep 0.00 0.01 0.09 0.17 0.26 0.28 0.20 5.37
vp 0.00 0.14 0.42 0.22 0.12 0.07 0.04 3.68
ve 0.00 0.04 0.18 0.22 0.22 0.20 0.13 4.76
Wash In 0.00 0.00 0.00 0.00 0.01 0.02 0.97 8.43
Wash Out 0.00 0.00 0.01 0.02 0.03 0.07 0.86 7.72
TTP 0.00 0.00 0.01 0.03 0.07 0.16 0.72 6.95
AUC 0.95 0.05 0.00 0.00 0.00 0.00 0.00 1.05
Peak 0.05 0.73 0.14 0.05 0.02 0.01 0.00 2.30
Table 2.13: Fraction of times each variable was assigned a particular rank relative to
other variables in its class for predicting ERG
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variable p value frequency
T2 9.198E-16 1.00
T1 1.455E-04 0.75
TC SE 2.638E-03 0.20
















Wash In 4.540E-02 0.02




Table 2.14: p-values for variables significantly associated with grade in all data and
the fraction of folds (frequency) where each correlation is significant among training
data
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variable Rank 1 Rank 2 Rank 3 Rank 4 Rank 5 Rank 6 Rank >6 Average rank
T2 0.99 0.01 0.00 0.00 0.00 0.00 0.00 1.01
T1 0.00 0.00 0.00 0.02 0.10 0.45 0.42 6.28
TC SE 0.00 0.00 0.05 0.26 0.50 0.14 0.04 4.85
TC SPGR 0.00 0.00 0.26 0.44 0.23 0.05 0.02 4.12
T2* 0.00 0.03 0.66 0.25 0.06 0.00 0.00 3.36
FLAIR 0.01 0.96 0.03 0.00 0.00 0.00 0.00 2.02
SWAN 0.00 0.00 0.00 0.03 0.11 0.35 0.52 6.35
ADC 0.99 0.01 0.00 0.00 0.00 0.00 0.00 1.01
eADC 0.00 0.66 0.34 0.00 0.00 0.00 0.00 2.33
FA 0.01 0.33 0.66 0.00 0.00 0.00 0.00 2.66
CBV 0.49 0.39 0.11 0.01 0.00 0.00 0.00 1.64
CBF 0.04 0.20 0.63 0.12 0.02 0.00 0.00 2.87
MTT 0.00 0.02 0.11 0.59 0.28 0.00 0.00 4.12
K2 0.47 0.38 0.13 0.02 0.00 0.00 0.00 1.71
Delay 0.00 0.01 0.03 0.26 0.70 0.00 0.00 4.65
Ktrans 0.24 0.34 0.22 0.13 0.06 0.00 0.00 2.45
kep 0.52 0.28 0.12 0.06 0.02 0.00 0.00 1.76
vp 0.00 0.00 0.00 0.02 0.10 0.80 0.07 5.92
ve 0.04 0.10 0.17 0.29 0.34 0.06 0.00 4.00
Wash In 0.00 0.00 0.00 0.00 0.00 0.02 0.98 7.87
Wash Out 0.00 0.00 0.00 0.00 0.00 0.00 1.00 8.52
TTP 0.00 0.00 0.00 0.00 0.00 0.05 0.95 7.53
AUC 0.17 0.22 0.34 0.21 0.06 0.00 0.00 2.78
Peak 0.03 0.06 0.14 0.30 0.41 0.06 0.00 4.17
Table 2.15: Fraction of times each variable was assigned a particular rank relative to
other variables in its class for predicting grade
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2.3.4 Predictive Modeling
For each target variable: Ki67, cell density, ERG, and local grade, We performed 500
repetitions of five-fold cross validation with stratified sampling. Within each round, each
model was trained on four folds and used to predict on the fifth fold. The R2 correlation
and root mean square error (RMSE) metrics were then calculated between the predicted
and observed values.
2.3.4.1 Predictive Modeling of Proliferation (Ki67)
The 2500 metric values are summarized in Tables 2.16. A higher R2 and lower RMSE
indicate better predictions. The random forest trained on four fixed variables (T2, FA,
Ktrans, CBF) had the best overall performance with an R2 value of 0.709 and RMSE of
3.78 Ki67 percentage points. Using the variables selected with each fold lead to slightly
reduced performance (R2 = 0.655, RMSE = 4.15). Selecting variables within each fold
removed the possible bias from overfitting which comes from using all the data in the
variable selection. This means that a final model using the fixed variables probably has
a true error of between 3.72 and 4.11 percentage points. The distribution of the metric
values are shown in Figure 2.3. Interestingly, when we selected univariate significant
predictors using the entire data set or the fold-specific training data we observed the
opposite trend. Most models had better performance using the fold-specific variable
selections rather than the globally significant variables. There was a non-significant
decrease in R2 of about 0.05.
Overall, these results show high predictability of cellular proliferation (Ki67) using imag-
ing data. The high R2 value around 0.65 means that the combination of conventional,
diffusion, perfusion, and permeability imaging (T2, FA, CBF, Ktrans) provides a lot
of the requisite information. The RMSE of 4.15 is also much smaller than the total
range of Ki67 values observed in the data of about 40 percentage points, indicating
precise predictions. Furthermore, we can see that much of the information comes from
the advanced imaging. Using conventional imaging sequences only we found the best
performance dropped to R2 = 0.558 using a linear model trained on TC SE, T1, T2,
and FLAIR. Using random forest the R2 was 0.517. While this is still good predictive
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performance for a biological target variable, the decreased accuracy must be noted since
these conventional-only models are used in subsequent chapters for survival modeling.
Panel A
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 0.582 ± 0.238 0.558 ± 0.207 0.521 ± 0.192 0.582 ± 0.233 0.642 ± 0.216 0.552 ± 0.244 0.539 ± 0.241
nnet 0.354 ± 0.245 0.461 ± 0.258 0.483 ± 0.251 0.682 ± 0.230 0.707 ± 0.197 0.532 ± 0.225 0.157 ± 0.194
rf 0.668 ± 0.206 0.517 ± 0.225 0.486 ± 0.190 0.655 ± 0.223 0.709 ± 0.179 0.678 ± 0.200 0.663 ± 0.206
rpart 0.397 ± 0.243 0.378 ± 0.243 0.387 ± 0.246 0.485 ± 0.236 0.471 ± 0.239 0.446 ± 0.234 0.397 ± 0.243
Panel B
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 5.404 ± 2.163 4.891 ± 1.253 5.189 ± 1.439 4.650 ± 1.484 4.263 ± 1.264 5.321 ± 2.468 5.504 ± 2.476
nnet 6.592 ± 2.241 5.936 ± 2.029 5.884 ± 1.891 3.898 ± 1.616 3.655 ± 0.989 4.943 ± 1.586 7.048 ± 2.197
rf 4.200 ± 1.653 5.018 ± 1.745 5.284 ± 1.684 4.151 ± 1.865 3.778 ± 1.455 4.077 ± 1.542 4.217 ± 1.615
rpart 5.999 ± 2.133 5.998 ± 1.842 5.880 ± 1.763 5.514 ± 1.974 5.571 ± 2.016 5.832 ± 2.020 5.997 ± 2.131
Table 2.16: Panel A: R2 and Panel B: RMSE values for predicting Ki67, values are
mean ± standard deviation. lm = linear model, nnet = neural network, rf = random
forest, rpart = decision tree.
Figure 2.3: Metric values for cross-validated prediction of Ki67
2.3.4.2 Predictive Modeling of Cellular Density
All 2500 metric values for predicting cellularity are summarized in Table 2.17. Overall,
the random forest trained on the univariate significant variables in each fold had the
best performance with R2 = 0.592 and RMSE = 1948 nuclei/mm2. Using a fixed set of
20 univariate variables had comparable performance with R2 = 0.585. We also found
acceptable performance with a random forest trained on just four variables: T2, CBF,
kep, and AUC. The R
2 value was 0.567. The small reduction in R2 is worth using 16
fewer variables in the predictive model since future clinical purposes make requiring
20 inputs infeasible. When the random forest variables were selected within each fold
Chapter 2. Image-Based Prediction of Local Glioma Pathology 44
of cross validation the performance of the random forest decreased considerably from
0.567 to 0.471. This suggests there may be a good deal of overfitting by using all data
in variable selection. Plots of the metric values are shown in Figure 2.4.
While not as high as the R2 value for predicting proliferative index, the R2 of 0.567
also shows good predictive ability of cell density using imaging data. When we used
conventional imaging only we saw almost no decrease in predictive performance. Using
T1, T2, TC SE, and FLAIR we found cross-validated R2 of 0.550. This means that the
benefit of the advanced imaging from diffusion, DSC, and DCE sequences is smaller.
This makes sense because cellularity is a physical property which is observable using
conventional sequences like T2-weighted images.
Panel A
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 0.452 ± 0.225 0.508 ± 0.199 0.527 ± 0.174 0.486 ± 0.226 0.554 ± 0.203 0.460 ± 0.222 0.482 ± 0.224
nnet 0.235 ± 0.173 0.432 ± 0.204 0.407 ± 0.197 0.441 ± 0.197 0.303 ± 0.196 0.345 ± 0.144 0.229 ± 0.157
rf 0.577 ± 0.179 0.550 ± 0.171 0.523 ± 0.161 0.471 ± 0.198 0.567 ± 0.165 0.593 ± 0.174 0.585 ± 0.173
rpart 0.375 ± 0.194 0.508 ± 0.192 0.482 ± 0.207 0.343 ± 0.170 0.400 ± 0.178 0.393 ± 0.195 0.381 ± 0.200
Panel B
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 2332.509 ± 529.136 2143.360 ± 391.281 2115.458 ± 371.488 2154.098 ± 357.335 1988.118 ± 331.659 2284.640 ± 588.994 2222.568 ± 497.964
nnet 2809.088 ± 483.159 2390.925 ± 534.334 2459.946 ± 507.150 2296.573 ± 400.057 2616.314 ± 509.012 2511.036 ± 416.427 2795.429 ± 465.630
rf 1989.849 ± 340.517 2021.873 ± 333.837 2124.614 ± 410.242 2192.233 ± 363.824 1987.769 ± 299.566 1947.562 ± 335.103 1986.690 ± 324.660
rpart 2545.829 ± 495.808 2192.538 ± 411.021 2265.952 ± 462.473 2573.839 ± 456.202 2438.610 ± 479.348 2485.580 ± 465.812 2524.822 ± 499.977
Table 2.17: Panel A: R2 and Panel B: RMSE values for predicting CD, values are
mean ± standard deviation. lm = linear model, nnet = neural network, rf = random
forest, rpart = decision tree.
Figure 2.4: Metric values for cross-validated prediction of CD
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2.3.4.3 Predictive Modeling of Vascularity (ERG)
Similar to Ki67 and CD, the best predictive performance for ERG was the random
forest. While the absolute best performance was with a forest using all 23 input variables
(R2 = 0.677), we found similar results could be achieved with a smaller four variable
set composed of T2, ADC, CBV, and AUC. The R2 using this set was 0.651. Using a
different set of random forest selected variables within each fold had slightly decreased
performance (R2 = 0.630 for random forest) compared to the fixed variables which might
indicate a small amount of overfitting. Plots of the metric values are shown in Figure 2.5.
Like proliferation, the high R2 shows how well imaging data can predict for the ERG
vascularity marker. Intuitively, we would expect perfusion and permeability imaging to
greatly improve the predictability of ERG since they directly image the interaction of
vascular contrast agents with tissue. However, we found that we could achieve essentially
the same predictive performance using conventional imaging only (T1, TC SE, T2,
FLAIR). This is probably due to the use of T1 contrast enhanced image which highlights
leaky vasculature. Using the random forest variable importance, we saw the spin-echo
contrast enhanced image was ranked as the top conventional variable in 30% of folds.
Panel A
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 0.428 ± 0.176 0.521 ± 0.110 0.581 ± 0.099 0.509 ± 0.144 0.548 ± 0.154 0.561 ± 0.135 0.578 ± 0.139
nnet 0.450 ± 0.195 0.567 ± 0.092 0.594 ± 0.092 0.665 ± 0.091 0.636 ± 0.130 0.635 ± 0.112 0.548 ± 0.149
rf 0.677 ± 0.075 0.658 ± 0.096 0.644 ± 0.095 0.630 ± 0.099 0.651 ± 0.086 0.650 ± 0.085 0.650 ± 0.084
rpart 0.582 ± 0.120 0.556 ± 0.114 0.552 ± 0.100 0.648 ± 0.106 0.626 ± 0.117 0.582 ± 0.100 0.533 ± 0.113
Panel B
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
lm 1.687 ± 0.610 1.328 ± 0.184 1.245 ± 0.174 1.398 ± 0.393 1.337 ± 0.399 1.331 ± 0.510 1.319 ± 0.486
nnet 1.434 ± 0.300 1.241 ± 0.171 1.207 ± 0.162 1.091 ± 0.185 1.134 ± 0.217 1.150 ± 0.204 1.282 ± 0.244
rf 1.094 ± 0.177 1.101 ± 0.202 1.121 ± 0.193 1.152 ± 0.190 1.119 ± 0.178 1.115 ± 0.172 1.119 ± 0.172
rpart 1.229 ± 0.220 1.269 ± 0.216 1.270 ± 0.193 1.119 ± 0.201 1.171 ± 0.221 1.225 ± 0.179 1.310 ± 0.199
Table 2.18: Panel A: R2 and Panel B: RMSE values for predicting ERG, values are
mean ± standard deviation. lm = linear model, nnet = neural network, rf = random
forest, rpart = decision tree.
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Figure 2.5: Metric values for cross-validated prediction of ERG
2.3.4.4 Predictive Modeling of Local Grade
The random forest had very high accuracy and kappa values for predicting tumor grade,
binned as normal, lower, and higher grade, using any of the variable subsets. The best
performance was achieved using univariate selected variables within each fold (kappa =
0.903) but excellent performance was also achieved using a small set of fixed variables
chosen by random forest variable selection. They were T2, ADC, CBV, and kep and had
a performance of kappa = 0.895. The full set of metrics are listed in Table 2.19 and
plotted in Figure 2.6.
High accuracy and high kappa values means that imaging has high predictive power over
the local biopsy grade even in the presence of dataset imbalance towards lower grade
samples. While advanced sequences like diffusion or DCE have been shown to correlate
with malignant disease [104], we found that they were not necessarily required to get
good prediction of tumor grade. Using just T1, T2, TC SE, and FLAIR we still achieved
over 90% overall accuracy and kappa of 0.822. Much of the information related to high
grade is likely captured by contrast enhancement whereas the T2 weighted and FLAIR
images help separate the normal and low-grade samples.
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Panel A
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
nnet 0.835 ± 0.076 0.913 ± 0.058 0.898 ± 0.060 0.924 ± 0.046 0.903 ± 0.053 0.892 ± 0.054 0.856 ± 0.069
rf 0.945 ± 0.041 0.904 ± 0.053 0.890 ± 0.058 0.937 ± 0.046 0.943 ± 0.045 0.948 ± 0.041 0.946 ± 0.041
rpart 0.851 ± 0.070 0.856 ± 0.058 0.882 ± 0.061 0.883 ± 0.059 0.871 ± 0.066 0.872 ± 0.056 0.855 ± 0.068
Panel B
Model all conv.TCSE conv.TCSPGR rf.dynamic rf.fixed univ.dynamic univ.fixed
nnet 0.697 ± 0.140 0.839 ± 0.108 0.812 ± 0.111 0.861 ± 0.084 0.818 ± 0.102 0.803 ± 0.099 0.736 ± 0.125
rf 0.898 ± 0.076 0.822 ± 0.099 0.800 ± 0.105 0.885 ± 0.085 0.895 ± 0.084 0.903 ± 0.076 0.901 ± 0.076
rpart 0.736 ± 0.118 0.739 ± 0.100 0.790 ± 0.106 0.786 ± 0.107 0.771 ± 0.113 0.765 ± 0.102 0.742 ± 0.115
Table 2.19: Panel A: Accuracy and Panel B: Kappa values for predicting grade, values
are mean ± standard deviation. lm = linear model, nnet = neural network, rf = random
forest, rpart = decision tree.
Figure 2.6: Metric values for cross-validated prediction of tumor grade
2.3.5 Graphical Synthetic Pathology Maps
The goal of using spatially specific tissue samples and models estimating local pathol-
ogy is to use those models to guide diagnosis and treatment. Towards this goal, we
applied the best performing models voxel-wise throughout the brain to generate “maps”
of estimated pathology. Examples are shown in Figure 2.7 and Figure 2.8 where the pre-
dictions are masked and shown only within the visible lesion. Qualitatively, we see high
proliferative activity is predicted inside the contrast enhancing region which is expected.
Although, even within contrast enhancement there is a range of proliferative values as
indicated by the orange and yellow colors. This suggests that there is additional infor-
mation present beyond the presence or absence of enhancement. In a low-grade case
(Figure 2.8), there is slightly elevated proliferation inside the core of the tumor relative
to the periphery. A similar situation is shown in Figure 2.9 which illustrates pockets
of highly cellular disease within the tumor. Figure 2.10 shows the strong correlation
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between contrast enhancement and the vascularity marker ERG. ERG values are uni-
formly elevated in the enhancing region and overall lower elsewhere. Finally, Figure 2.11
illustrates the heterogeneity present within a single tumor. Most of the clinically high
grade tumor is estimated as low grade disease. However, there is a small focus of pre-
dicted high grade disease within the tumor core. We can also see predictions of normal
brain on the periphery of the radiographically visible lesion.
Figure 2.7: Map of estimated Ki67 in a WHO IV glioblastoma patient alongside a
T2-FLAIR image for reference. The map was generated with conventional imaging only
and has been smoothed by a 1 mm gaussian kernel.
Figure 2.8: Map of estimated Ki67 in a WHO II glioma patient alongside a T2-
weighted image for reference. The map was generated with conventional and advanced
imaging.
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Figure 2.9: Map of estimated Cellular density (CD) in a WHO IV glioblastoma patient
alongside a T2-FLAIR image for reference. The map was generated with conventional
imaging only.
Figure 2.10: Map of estimated ETS related gene (ERG) in a WHO IV glioblastoma
patient alongside The T1 post-contrast image for reference. The map was generated
with conventional imaging only.
Figure 2.11: Map of estimated tumor grade in a WHO IV glioblastoma patient
alongside a T2 FLAIR image for reference. The map was generated with conventional
imaging only and is smoothed by a radium 1 median filter.
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2.4 Discussion
We tested a variety of machine learning methods and variable selection techniques to
estimate local tumor pathology in terms of proliferation (Ki67), cellular density (CD),
vascularity (ERG), and histologic grade. We achieved good performance using a random
forest for predicting Ki67 (R2 = 0.709), ERG (R2 = 0.651), cell density (R2 = 0.567),
and tumor grade (Accuracy = 94.3%). In general, the best or comparable performance
was achieved using a random forest model trained on the best variable from each sequence
family or the best four conventional variables. We used these random forest models
moving forward in subsequent chapters of this work.
Previous results using this image guided biopsy data set to estimate Ki67 have been
previously reported [49]. However, the results presented here are different and extended
in a few key ways: First, the robustness of cross-validation (CV) is improved by using 500
repetitions instead of a single five-fold repetition. This also removes some uncertainty
associated with selecting the best predictors with random forest because more than
5 votes are cast for each image type. Although, ultimately the same final variables
(T2, FA, CBF, Ktrans) were selected. Second, the intensity normalization scheme for
anatomic imaging in [49] uses hand-drawn ROIs in gray matter, white matter, and CSF
whereas the current work used the normal brain mode and automatic CSF ROIs. Overall
the predictive results are similar. Previous work reports R2 values of 0.749 ± 0.137 as
the average of a single five-fold CV. Here, we used 500 repetitions of five-fold CV and
measured R2 = 0.709± 0.179. While the average is smaller, the ranges of R2 values still
overlap considerably.
Similar studies have also used image guided biopsy data to correlate or estimate imaging
and proliferative activity. Barajas et al. [38] found DSC perfusion metrics like CBV
correlated with proliferation in contrast enhancing regions. In non-enhancing regions,
they also found inverse correlations between proliferation, diffusion weighted imaging,
and FLAIR intensity. Our correlation analysis agrees with these results for perfusion
metrics, diffusion metrics, and contrast enhancement. But, we did not find a significant
correlation between FLAIR intensity and proliferation. A possible explanation for this
might be a difference in intensity normalization scheme: brain mode - CSF versus in [38]
where the FLAIR intensity was scaled based on white matter. It may also be due to the
use of virtual biopsies in our work. In another study, Price et al. [61] found significant
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correlation between rCBV metrics (mean, max, 75th percentile, 90th percentile) and
proliferation. This agrees with our results as well, as we found both CBV and CBF were
significantly associated with Ki67, including in more than 97% of cross-validation folds.
More recently, Autry et al. [63] correlated conventional MRI, DSC, and MR spectroscopy
with histopathologic parameters in 100 tissue samples from glioblastomas. Surprisingly,
they found no difference in proliferation between enhancing and non-enhancing samples,
although this may be because the patient population was limited to high-grade gliomas.
Correlation between proliferation and other image metrics were not reported.
Several previous studies have examined the relationship between cellularity and local MR
image characteristics [38, 43, 51, 62, 105, 106]. Overall, they find correlation between
T1 contrast enhancement, DSC, and diffusion metrics with cellularity but no one study
other than our on previous work [51] examines conventional, DWI, DSC, and DCE
simultaneously. The study by Chang et al. [62] perform predictive modeling for CD
using conventional and diffusion metrics and found a reasonable R2 around 0.55. The
study by Durst et al. [105] used conventional, diffusion, and DSC to predict CD with an
in-sample R2 = 0.49. These are comparable to the R2 in this work of 0.567.
One of the best uses for estimating cellularity is to assess tumor infiltration into peritu-
moral regions [20, 89]. This can be done using predictive models applied voxel-wise to
“map” the cellularity across or just outside a visible lesion. Such maps have been shown
by Durst et al. [105], Akbari et al. [43], Chang et al. [62], and our own previous work [51].
To our knowledge, none of these maps have been prospectively clinically validated.
In this work we were able to discriminate between normal, lower, and higher grade glioma
samples using a combination of conventional and advanced MR imaging. As advanced
imaging techniques like diffusion, DSC, or DCE mature, there have been several studies
correlation quantitative findings like ADC or Ktrans with tumor malignancy [104, 107].
However, both image metrics and tissue histology (i.e. grade) are heterogeneous which
confounds whole-tumor based analysis. Overall however, there is evidence that diffusion,
perfusion, and permeability imaging can indicate overall grade or IDH status [108, 109].
In the study by Barajas et al. spatially specific biopsies were used to correlate local CBV
and ADC with histologic markers of high grade disease [38]. As expected, high CBV and
low ADC were markers of heightened tumor infiltration. We found the same metrics,
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CBV and peak height, were significantly associated with sample grade in addition to
several other image features in Table 2.14.
Among our tested model classes, we elected not to include convolutional neural networks.
Convolutional neural networks (CNN) have recently become the de-facto model for ma-
chine learning in medical imaging [102, 103]. The strength of the CNN comes from the
encoding of relevant spatial information via the use of convolutional kernels. This makes
them especially powerful for whole-image classification or segmentation tasks. In our
work, we use spatially specific biopsy samples where ground truth is only available for a
very small volume of interest. While the spatial specificity allows voxel-wise mapping of
estimated pathology (Section 2.3.5), it means that neighborhood image characteristics
may not necessarily hold useful information. Thus, a CNN is not likely to perform better
than a random forest trained on the mean image intensity inside the VOI as we have
done here. Furthermore, CNNs add considerable complexity and computational time to
train. For these reasons, we elected not to explore CNNs for predicting the biopsy-level
pathology.
2.4.1 Limitations
This work estimated the local histologic characteristics of gliomas using magnetic res-
onance imaging. Recently, the importance of genetic and molecular characteristics has
surpassed histology in the diagnosis and classification of gliomas [20]. While mutations
like IDH1 [86] would be interesting to analyze using spatially specific sampling, the
results may not be as useful seeing as IDH1 mutations are homogeneously expressed
throughout a glioma [87]. Analyzing which other molecular markers might be hetero-
geneously expressed and to what degree they correlate with imaging findings would be
highly interesting. Unfortunately, genetic sequencing was not as commonplace at the
conception of this study so that data is not available.
2.4.2 Future Work
We found good predictive performance using a consistent modeling approach to estimate
key pathological parameters. To estimate the generalizability we implemented a repeated
five-fold cross validation scheme. However, the final predictions need to be applied
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prospectively to samples collected from new patients in order to fully characterize the
accuracy. This can be completed alongside additional data collection.
We found that sampling from a fairly uniform distribution of clinical tumor grades
produced an imbalanced distribution of sample grades. Namely, we had far fewer high-
grade samples than low grade samples. While we were still able to predict the biopsy
characteristics, the performance was reduced for these few high-grade samples. Future
data collection efforts should focus in collecting samples that balance the data across the
range of pathology (e.g. proliferation, cellularity, local grade) observed in the clinical
population.
Other worthwhile future work would also be to examine the effect of image acquisition
and processing on the correlation with pathology. These results could be used to improve
the sequences themselves in order to maximize the predictability or serve to standard-
ize processing techniques for advanced sequences like DCE. Currently, DCE processing




Chapter 2 described how magnetic resonance imaging can predict local glioma pathology
using a random forest trained on imaging and tissue data. The central hypothesis of
this work is that the pathological parameters estimated by these predictive models can
estimate overall survival and be useful in the clinical care of patients. Testing this
requires a large patient population with known outcomes and imaging data to use for
predictions. This data needs to be curated, processed, and prepared for further analysis
in Chapter 4 and Chapter 5. While the basic framework for neuro-image processing
such as registration, segmentation, and normalization are well-established, applying this
sort of processing at a large scale is non-trivial. The difficulty is further increased when
using clinical diagnostic imaging with its wide variety in image acquisition parameters,
scanners, and vendors as is the case in this work.
The goal of this chapter is to describe and demonstrate the automated and semi-
automated methods for accomplishing the data curation of our large historical dataset.
Systematic curation of high-quality data has been identified as an essential and rate-
limiting step for development of artificial intelligence [110, 111]. So, this chapter empha-
sizes the use of a custom data review dashboard to rate data quality and exclude failures.
At its conclusion, the availability and quantity of various image types are tabulated for
each patient. We also present the results of data review and stratify the processed cases
by overall quality and acceptability for further analysis. For the good cases, we quantify
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the success in terms of comparisons between image features and “reference” values like
tumor or intracranial volume. These results provide the necessary confidence in the
quality of curated data which is necessary to believe further survival results in later
chapters. Additionally, the failure rates in automated processing are valuable data for
future work developing clinical tools out of these methods.
This chapter is composed of three overall steps: First is the collection and classification
of brain MRI studies from the hospital picture archiving and communication system
(PACS). The key contribution is a custom library of regular expressions acting on study
and series descriptions. Next, we present a data processing pipeline to ferry the raw im-
age data files through registration, segmentation, normalization, pathology estimation,
and feature extraction. Finally, the quality of the data processing is manually assessed
to ensure only high-quality data move on to further analysis. Data quality assurance of
all 3,500+ studies is made feasible by a custom data review dashboard.
3.2 Methods: Clinical Image Processing and Curation
3.2.1 Classification of Image Studies and Series
For the patient cohort we needed to identify relevant imaging to use for processing. Ide-
ally, the inter-patient variability between image sequences would be small. For instance,
similar TR/TE, resolution, and slice orientation. Since these patients are from a single
institution, it is reasonable to expect some consistency. Identifying studies or images
using header metadata is a notoriously difficult problem for PACS administrators and
there is no standardized way to label study and series description DICOM tags. How-
ever, since the historical data set is finite, it is possible to categorize a majority of the
images with iteratively crafted regular expressions.
We started with a database of every diagnostic image available for each patient’s preop-
erative and immediate postoperative image dates. These studies were first filtered using
the “Modality” DICOM tag to remove non-MRI studies like chest x-rays and CT scans.
The remaining studies were further categorized using regular expressions (applied in R
v.3.6.1). The categories and associated case-insensitive regular expressions are listed in
Table 3.2. The regular expressions were tested against each series description one at
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a time until a match is found. Studies classified as intra-operative, spine, non-brain,
or magnetic resonance angiography (MRA) were excluded from further analysis. Any
studies not matching any of these regular expressions were excluded too.
Next, the individual image series in each study were classified with regular expressions.
The full list is given in Table 3.3. These were also applied in order with the first
match taking priority. So, for example a series labeled “Sag Cube FLAIR” matched
“CubeFLAIR” and “FLAIR” regular expressions, but it would have been labeled “Cube-
FLAIR” because that label is tested first. For full processing, each study needed one
of each of the following image contrasts: T1-weighted without intravenous contrast,
T1-weighted post intravenous contrast, T2-weighted, and FLAIR.
Most studies contain multiple images of the same contrast with different characteristics.
This led us to classify image series at a finer level than just T1, T1C, T2, and FLAIR.
The description of each image type is listed in Table 3.1. A benefit of the increased
number of image categories is reduced redundancy. For example, many cases had both
high resolution gradient-echo 3D T1w images with contrast (T13D) and spin-echo post
contrast T1w images (AxT1C). It is useful to retain both since both are advantageous
in different cases. Other subtypes like CubeFLAIR versus FLAIR mostly just have
different resolution or represent images acquired for surgical planning versus diagnostic
purposes. (e.g. WandT2 versus AxT2). When multiple comparable images were present
for a single study the best one was chosen as follows: CubeFLAIR was used over FLAIR,
WandT2 used over AxT2, T13D used over AxT1C for CLARA segmentation and AxT1C
used over T13D for pathology estimation. Images that were not processed and reviewed
were still identified and converted to NifTI format.
After inspection, this regular expression dictionary captures a majority of the series.
Differentiating these sub-types of the four common image sequences (T1, T1C, T2,
FLAIR) allows a fine level of analysis. For example, T13D are almost always gradient
echo whereas AxT1C are spin echo. Despite both being contrast enhanced T1-weighted
images they have different normal tissue contrast and degrees of tumor contrast en-
hancement. CubeFLAIR and WandT2 tend to be higher resolution than the FLAIR or
AxT2 respectively as well. In some cases, there were still multiple image series of the
same type are present in a study. In this case, a series of tie breaks were applied in order
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series type description analyzed
CubeFLAIR High resolution spin echo T2-FLAIR image usually with near
isotropic voxels and used for surgical planning.
YES
T13D 3D gradient echo T1-weighted image after gadolinium con-
trast injection, usually used for surgical planning.
YES
AxT1C Axially acquired spin-echo T1-weighted image post contrast.
Usually contains thick slices.
YES
T1C Spin echo T1-weighted post-contrast. NO
T1 T1-weighted image without gadolinium contrast. Usually ac-
quired by spin-echo with thick slices.
YES
T2star T2* weighted image. NO
FLAIR spin echo T2-weighted fluid attenuated inversion recovery
(FLAIR) sequence. Usually 2 mm or greater slice thickness.
YES
WandT2 High resolution T2-weighted image usually used for surgical
planning.
YES
AxT2 Axially acquired T2-weighted image usually with thick slices. YES
OtherT2 Any other T2-weighted image. NO
DSC Dynamic susceptibility contrast time series. NO
DCE Dynamic contrast enhanced time series. NO
Trace Trace image from diffusion tensor imaging. NO
eADC Exponential apparent diffusion coefficient from diffusion
weighted imaging.
NO
ADC Apparent diffusion coefficient from diffusion weighted imag-
ing.
NO
AvgDC Average diffusion coefficient from diffusion tensor imaging. NO
DWIDTI Diffusion weighted image series or diffusion tensor image se-
ries.
NO
FA Fractional anisotropy map from diffusion tensor imaging. NO
Table 3.1: Short name and description of each image type identified by the historical
data. Image types that were used for survival analysis are indicated by the ’analyzed’
column.










Table 3.2: Regular expressions for classifying MR studies. Spine, intraop, non-brain,
and magnetic resonance angiography (MRA) studies were excluded from further anal-
ysis. ABTI: advanced brain tumor imaging.
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Table 3.3: Regular expressions used to classify MR series by description. The non-
anatomical series are not used for further processing.
to attempt to select the best series of each type for further processing. The tie break
procedure was:
1. Voxel size: the series with smaller product of in-plane pixel size × slice thickness is
used. This favors approximately isotropic images (e.g. 0.9× 0.9× 1.2 mm instead
of 0.5× 0.5× 5.0 mm)
2. Slice thickness: If voxel size is the same, the series with thinner slices is used.
3. Repeat or retake: if one series contains RPT, REPEAT, or REPL in the description
it is assumed to be a retake of the previous acquisition due to poor image quality.
The retake is used.
4. Axial acquisition: if one image has “AX” in the series description it is used.
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5. Series time: In the case where two images have otherwise identical metadata,
choose the series with a later acquisition time. This captures retakes of corrupted
images or images with artifacts.
6. Series time: Use the series with the earliest acquisition time. This captures images
as originally acquired rather than reformats which are given the same acquisition
time.
If none of the tie breaks worked, one series was selected at random. In our experience,
these failed tie breaks were inconsequential and did not needlessly exclude data. Finally,
for each study a high-resolution image was chosen as a fixed image to which all other
images were co-registered. Just like the series tie break, the high-resolution image was
selected based on the product of in-plane pixel width and slice thickness. In the case of
a tie: preference was given in order:
T13D > CubeFLAIR > WandT2 > FLAIR > AxT2
After the best series from each study had been selected, studies from the same day
for each patient were also combined. This happened in cases, for example, where a
preoperative and fMRI study were both acquired. In these cases, as many images as
possible from the best study (having the highest resolution image) were selected and
any missing image types were filled from other studies. This ensured the images used
were all from the same study when possible but still allowed studies to be combined and
enabled further analysis.
3.2.2 Brain Tumor Segmentation Challenge Data
The first part of the data processing and labeling closely followed other neuroimaging
conventions: In particular, the MICCAI Brain Tumor Segmentation Challenge (BraTS)
[34, 103, 112]. The training data for the challenge consisted of 210 high-grade and 75
low grade glioma cases. The image data had been co-registered, skull stripped, and
tumors had been segmented into three classes: 1) peritumoral edema seen as FLAIR
hyperintensity, 2) T1 enhancing tumor, and 3) non-enhancing tumor core and tumor
necrosis. These are the same labels we used on the historical data since NVIDIA’s
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CLARA model is trained on the BraTS data. Examples of the segmentations with the
three disjoint labels are shown in Figure 3.3 and Figure 3.7.
Since 163 of the highigrade cases also had overall survival data, they served as an inde-
pendent test of imaging biomarkers from Chapter 4. The BraTS data was processed in
parallel with the historical data using the pipeline in Figure 3.1. Since it was already
registered and segmented, it entered the pipeline at the Segment normal tissue step.
The data was also reviewed using the data QA app described in Section 3.2.5.
3.2.3 Neuroimaging Pipeline
The data processing pipeline took advantage of existing software for individual steps like
registration and segmentation. These were either stand-alone applications like ANTS
[76, 113] and CLARA1, or as packages available in python or R programming languages.
The goal of constructing the data processing pipeline was to adapt the wide variety of
clinical data, including postoperative and oblique data sets, to the formats expected by
the various software. An overview of the processing workflow is shown in Figure 3.1.
The particular steps roughly in order are:
Figure 3.1: Image processing pipeline for neuroimaging data.
1https://developer.nvidia.com/clara-medical-imaging
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Figure 3.2: Registration procedure including bias correction and skull stripping im-
ages individually to aid the registration. A dilated mask was used for the cost function
as well since it significantly sped up the registration. The other images like T1 and
FLAIR were registered in the same way as the T2 is to the T13D (fixed space image).
Figure 3.3: Sample images for each step of the data processing pipeline. Top left:
brain mask, top right: tumor segmentation, bottom left: 4-class tissue segmentation,
bottom right: post-processed CSF ROI.
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1. Identifying appropriate image series for each patient. First, all imaging data avail-
able no each patient’s preoperative and postopoperative study dates was down-
loaded from the PACS to a DICOM server. Then, the DICOM header tags for a
single image from each series was loaded into an SQL database in order to organize
and query the specific series. Individual studies and series (T1, T2, FLAIR, etc)
were categorized by a custom library of regular expressions as described in Section
3.2.1. Some further categorization used metadata like magnetic field strength of
pixel spacing to identify the best quality imaging.
2. Converting DICOM files to NIFTI format and naming according to the project
convention. This also served as an anonymization since patient information in the
DICOM metadata was not transcribed in the NIfTI header.
3. Registering images. This was done with a 12 degree-of-freedom affine registration
in ANTs. First, images were pre-processed with bias correction over the whole
image and individually skull stripped using a brain mask (Example in Figure 3.3).
A dilated (1 mm) version of the brain mask was used to mask the cost function and
accelerate the registration as well. After registering the skull stripped images, the
transform was applied to the non brain-extracted image so that all image voxels
were retained. This is described in Figure 3.2. Each image was co-registered to
the space of the highest resolution image in the study which was almost always a
gradient echo 3D T1 weighted image or a high-resolution FLAIR image.
4. Creating brain masks for each image. For each study, a single brain mask was gen-
erated in the space of the highest resolution image using a deformable atlas-based
approach [114]. Since multiple image contrasts are available after registration, a
more accurate brain mask is achievable than the single-contrast masks generated
prior to registration. A sample mask is shown in Figure 3.3. After the brain mask
was generated, it was used for all further masking.
5. Segmenting tumor. This step allowed both isolation of normal tissues and feature
calculation within the lesion. The best tool for this was a deep neural network, and
the current pipeline used NVIDIA’s CLARA platform2. The particular model used
a 3D encoder-decoder architecture that produced the winning entry in the 2018
2Model used: br16 full no automatic mixed precision version 1
https://ngc.nvidia.com/catalog/models/nvidia:med:clara mri seg brain tumors br16 full no amp
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Brain Tumor Segmentation Challenge (BraTS) [115]. The model was pre-trained
on the BraTS data and produces segmentations that includes separate regions for
enhancing tumor, non-enhancing tumor, and peri-tumoral edema. Sample segmen-
tations are shown in Figure 3.3 and Figure 3.7. Before applying the model, the
input images were pre-processed by skull stripping, bias correction using a white
matter posterior probability [113, 116], and resampling to 1 mm isotropic resolu-
tion. For the T1 post-contrast input, a gradient echo T13D image is used instead
of spin echo AxT1C when possible. The resulting masks were resampled back
to the original image space via nearest-neighbor interpolation. The predictions
from CLARA were post-processed by filtering out all but the largest connected
components in the resulting segmentation. For multi-focal tumors, more than one
component was retained.
6. Segmenting normal tissue and generating a CSF ROI. In order to normalize using
the mode-csf method, each study needed ROIs for the normal brain tissue and
cerebrospinal fluid. First, the tumor or resection cavity was subtracted from the
whole-brain mask and the resulting non-tumor tissues were clustered using ANTs
Atropos [113] into four categories. The T2-bright CSF category was post-processed
to define an ROI. Full details are given in Section 3.2.4. Examples of the clustering
and CSF ROI are shown in Figure 3.3.
7. Normalize intensities. Anatomic images were linearly scaled such that normal
brain and CSF modal intensities had values 0 and 1. Quantitative imaging was
already be scaled during DICOM conversion. See Section 3.2.4 for details.
8. Generating maps using the trained random forest model. Each model used T1
pre-contrast, T1 post-contrast, T2-weighted, and FLAIR images. Separate models
using AxT1C or T13D image types for a T1 post-contrast image were used depend-
ing on availability with the AxT1C model preferred. The specific implementation
used R scripts to parse the input files and apply the random forest.
9. Computing measurements of the predicted maps and input images using pyra-
diomics. First-order statistical measures and shape measurements were extracted.
A summary of the exact features used is listed in Section 4.2.2.
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Except for the software packages mentioned, the data processing pipeline was imple-
mented in python or R. Processing multiple cases is embarrassingly parallel so we took
advantage of a computing cluster. Each compute node had 2 Intel(R) Xeon(R) Gold
6132 CPUs with 14 cores per CPU at 2.60 GHz and 192 GB RAM.
3.2.4 Mode-CSF Normalization
The original method of normalization, called reference tissue normalization, used one
set of gray matter, white matter, and cerebrospinal fluid (CSF) ROIs per patient [50,
51, 117]. Each image was linearly scaled such that the darkest tissue ROI had mean
intensity 0 and the brightest had intensity 1. For example, of a T2 FLAIR image the
intensities were scaled as follows:
x→ x− CSF
WM − CSF
Where CSF and WM are the mean intensities inside the respective ROIs. The benefits
of this method are that the manual ROIs won’t grossly fail or be misplaced and that the
resulting scale is biologically relevant. Most non-contrast-enhanced images generally fall
in the intensity range roughly [0, 2] which is pleasant.
However, the reference tissue normalization also has some limitations. First, the manual
tissue ROIs are inherently subject to inter-reader variability which adds arbitrariness
to the normalization process since there is no definitive way to choose a “best” ROI.
Small differences in ROIs perturb the mean intensities inside and this propagates to the
resulting normalization. Similarly, there is no automatic way to generate ROIs with
similar mean intensities which technically makes a fully-automated pipeline impossible.
Lastly, differences in tissue contrast at 1.5 T versus 3.0 T field strengths will clearly
affect the normalization. Because of this, it is unclear if this method is sufficient to
normalize between studies with different field strengths.
Due to the limitations of the reference tissue approach, we used a modified method,
called mode-csf (MCSF), inspired by Autry et al. [63] and the reference tissue method.
In this scheme, the modal intensity of the normal brain (whole brain minus tumor) as
in [63] and modal intensity of CSF are mapped to 0 and 1 with the order determined by
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which is greater. This process is summarized by Figure 3.4. We used CSF since it is the
brightest (or darkest) region of MR sequences making it a natural choice to “anchor”
the intensity range.
Figure 3.4: Example of mode-csf normlization. Left: the regions used for normaliza-
tion are the normal brain (red) and CSF (cyan). Voxels within 1% of the modal intensity
are colored extra bright for illustrative purposes. Right: rescaled density plots of the
raw intensity values showing the intensity distributions for the normal brain and CSF.
The vertical bars show the range of 1% around the modal intensity corresponding to
the bright voxels in the ROIs. The mode-csf normalization maps the intensities such
that locations of the peaks are 0 and 1 respectively.
The main advantage is that the mode (compared to the mean) is insensitivity to small
errors in masks or ROIs. Specifically, adding or subtracting a relatively small number
of voxels does not affect the modal intensity, especially if those voxels have extreme
intensity values near the tails of the distribution. In automatic data processing, these
small errors are likely and so methods that are insensitive remove those errors as a source
of variability.
The specific techniques used in this study for defining whole-brain and CSF ROIs
are as follows: A whole-brain mask was generated using a deformable atlas-based ap-
proach [114]. Then, any visible tumor was segmented automatically using a pre-trained
multi-modality deep learning model from the NVIDIA CLARA platform. The lesion was
subtracted from the brain mask resulting in a normal brain mask. More implementation-
specific details are give in Section 3.2.3.
Automatically generating a region of pure CSF to normalize with is not a trivial task.
The steps used in this study were chosen because they worked empirically and gave
values that correlated well with mean CSF intensities from manual ROIs. The steps
were:
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1. Co-register T1-weighted and T2-weighted images. Using both contrasts helped
identify CSF which is bright on T2w images and dark on T1w images.
2. Split the brain into four classes using a Gaussian mixture model. We used ANTs
Atropos, initialized by K-means and smoothed by Markov Random Field [113].
3. Isolate the brightest class on the T2w image and erode by 1 mm isotropically.
This broke the region into a series of disjoint candidate ROIs (Figure 3.5). It
also removed voxels near the boundary of CSF with other tissues that may not be
completely inside the CSF and cause partial volume effects.
4. Among the five largest candidate ROIs with more than 500 voxels, choose the
one with the unweighted center-of-mass closest to the brain center-of-mass. This
almost always selected a ventricular ROI. If none contain > 500 voxels, we used
the largest one.
Figure 3.5: Example of K-means clustering with Atropos. The T2w image with
ventricles highlighted for reference is shown on the left. After clustering (middle), the
yellow class contains mostly CSF. After erosion, the CSF class is broken into several
candidate ROIs in the various CSF pools (right). The ROI closest to the brain center
is selected.
When there are multiple image sequences from the same study, they were mapped to a
common space via registration so that the same normal-brain mask and CSF ROI were
used for each. A global search over is the full range of raw intensity values found the
maximum of the density function (i.e. mode). Since the whole brain mask can contain
upwards of 108 voxels, faster methods based on fast Fourier transforms are preferable
to direct computation using Gaussian kernel convolution. The default implementation
of density() in base R does so.
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3.2.5 Data Quality Assurance with R Shiny
A simplified version of the data QA dashboard which can be used for any MR imaging
data set is available for download at github. com/ EGates1/ MRDQED
Large data sets require a way to quickly visualize and check individual data points to
catch potential processing failures or misrepresentations. This is especially true with
studies like this one where complex images with multiple processing steps are distilled
into relatively few image features. Looking at the population is good for catching outliers
likely representing processing failures. But, we also needed to avoid the more sinister
case where a value is produced that is reasonable with respect to the population range
but is actually due to a processing failure. A good example is bright T1 scalp fat being
erroneously measured as contrast enhancing tumor.
Loading several 3D images is slow, takes a long time to fully review each slice, and
requires stand-alone software to view. So, our solution was a dashboard to quickly and
efficiently visualize all the necessary image data for a single case and record if the various
images, masks, etc. were sufficient quality to trust the measurements. As a compromise,
reviewing just a few perpendicular slices through a segmentation or image was usually
sufficient to screen for bad data quality. So, we rendered a handful of key slices as static
png image files as part of the data processing pipeline: essentially front-loading the cost
to load the data at the expense of the ability to freely scroll through image slices.
Other considerations for a QA tool were usability, especially when other researchers
need to contribute to data review, access, how easy it was to launch/interface with the
tool, and portability, could it be used with other projects in the future. With these
considerations and others in mind we used an R Shiny app. The advantages were:
• Providing visualization and data processing strengths of R and its familiar pack-
ages.
• Requiring no more than R and the R shiny package to run.
• Providing an easy framework for reactive programming and user input or interac-
tion.
• Hosting as a web app accessible from anywhere within the institution’s firewall by
multiple concurrent users.
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• Handling page layout and HTML automatically.
The main disadvantage was that the app was solely for identifying bad data and image
clean up or editing must be done with outside software. Since it relied on pre-rendered
png images, any changes to the underlying data must be re-rendered manually before
they would be displayed. Also, the base R shiny package does not come with user
authentication built in and must be handled separately if controlled access is desired.
Figure 3.6: Shiny app dashboard for data review
3.2.5.1 App Overview
A snapshot of the app is shown in Figure 3.6. First, the left-hand sidebar has two
sections: data display and data review. Most of the screen is then taken up by the data
display itself. This app was designed to be viewed full-screen on a 1920x1080 resolution
19” monitor. A screen that is much smaller might not look as nice or similar to Figure
3.6. If a png images does not exist, a black rectangle would be shown in its place.
Data display panel The first options in data display control which case is being viewed
(HRPID). Each case has a unique identifier of the form HRP####. One way to pick a
case to display is with the drop-down box. Clicking a row on the data table to the right
also selects that case. The radio buttons for study type change the images displayed
between preoperative and postoperative images. Lastly, the check boxes for “variables to
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show” determine which columns are displayed in the data table. Information like tumor
grade may be useful when reviewing the data and features like maximum diameter can
suggest possible processing failures.
Data review panel The next section is titled data review and handles the designation
of good and bad data. For each case and study type the app stores the status of the check
boxes and comment field. If an image or segmentation has one of these characteristics
it can be indicated by checking the corresponding review boxes. In general, each part of
the data processing is free from errors, failed (unacceptable), or acceptable with some
small errors (poor). The various review boxes are:
1. Study artifacted: All images have large artifacts, are corrupted, or are otherwise
not fit for further data processing.
2. Image unusable: One of the images has a large artifact, is corrupted, or is otherwise
not fit for further data processing.
3. Bias correction fail: Either there is a strong bias field on one or more images that
impacts tumor or CSF segmentation or image features, or the bias correction that
was applied corrupted the intensities.
4. Brain mask failure: The brain mask is wrong to such a degree that further pro-
cessing or features are ruined.
5. Brain mask poor: Brain mask does not perfectly segment intracranial contents but
errors are acceptable and not interfere with downstream processing.
6. Tumor segmentation failure: The tumor segmentation misses a large portion of
tumor or grossly over-segments normal appearing brain.
7. Tumor segmentation poor: A small amount of normal appearing brain is segmented
as tumor or a small amount of obvious lesion is missed, within an acceptable limit.
8. CSF failure: The selected CSF ROI is outside the CSF or captures the wrong
modal intensity on one or more images.
9. CSF poor: The CSF ROI is small or closely abutting non-CSF tissues on one or
more images.
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10. Normalization failure: Even though CSF ROI placement is acceptable, the inten-
sity of the CSF causes normalized image intensities to be outside the expected
range.
11. bad Ki67: The maximum intensity Ki67 is outside the visible tumor or the overall
values displayed on the map are unreasonable.
12. no pngs: Some pngs are missing unrelated to data errors.
13. needs review: Accuracy is unable to be determined with the images shown. Closer
inspection is necessary.
After a case has been reviewed, the “save review + next case” button automatically
brings up the next case. After a review session, clicking the “Download review log”
button prompts the web browser to save a comma separated value (CSV) file indicating
which cases were reviewed, what data qualities were selected, and any comments. Ex-
porting this log is the only way to save the review status and any interruption of the
session by navigating away from the app, closing the window, or reconnecting will clear
the review history. On subsequent sessions, the CSV review log can be loaded using the
file browser right below the download button to import the review data back into the
app.
Scatter plots On the top left are two scatter plots comparing the total preoperative
segmented tumor volume (shown in three-planes below) and the reference tumor volume.
The currently selected case is shown with a red point so it’s location relative to the
population can be assessed. Points that are far from the dashed agreement line are
suspicious and are good candidates to review first. Hovering your mouse over a point
will display the ID of that point below the plots and clicking on a point select that case.
Note, these plots are not present in the publicly available version of the dashboard.
Summary data table Below the scatter plots is a table of summary data for each
case. The displayed columns can be adjusted in the data display panel and the number
of entries shown at a time can be adjusted at the top of the table. The search bar on the
top right filters the entries of the table and clicking a row selects that case for review.
This makes searching for a particular ID then selecting it easy.
Segmentation views The bottom left of the data display shows the three critical
annotations that are generated and used for processing: The brain mask shown as a
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single red overlay, tumor segmentation with blue for necrosis and non-enhancing tumor,
green for enhancement, and yellow for edema, and CSF ROI in purple. Each one is
shown in three orthogonal planes centered on the slices with the largest area. The
segmentations and overlaid on the highest resolution image in the study. Most cases will
have either a T1 post-contrast image or FLAIR image shown.
Option 1: Corresponding slice views Using the data display radio button, the
main display area can be toggled between showing matching slices of all images, which
is demonstrated in Figure 3.6, or maximum intensity localizations. The goal of the
matches sliced view is to screen for large artifacts and mis-registration. For all images,
the same maximal cross-section axial and sagittal whole-brain slices are displayed with
brain mask overlaid. Since the slices correspond, salient anatomy (ventricular horns,
vascular bifurcations, etc.) should be in the same location across images. If not, mis-
registration might be the case. Furthermore, the edge of the brain mask should trace
the border of the brain on all images and deviations indicate misalignment. Similarly,
the CSF ROI is also displayed in its maximal cross section axial slice for all images.
This allows its location in CSF for all images to be verified. Below the maximum views
are density plots of the intensity values for each image. The x-axis scale is normalized
so that 0 and 1 are the modal brain intensity and modal CSF intensity. Each curve has
been scaled to peak height 1 to help with comparison and the colors correspond to the
colors shown in the segmentation views (e.g. red for brain, purple for CSF).
Option 2: Maximum intensity (crosshair) views If desired, slice views are re-
placed by three-plane visualization of the maximum intensity within the segmented
tumor region. On each plane, the crosshairs mark the exact location. Maximum image
intensity is a potentially useful prognostic feature as well as a location where processing
failures are likely. For example, spurious vascular or fat structures segmented as tumor
will often have very bright voxels. Note: because the maximum intensity falls in different
places on different images the planes shown are not necessarily the same between images
nor are they the same as the planes with overlaid segmentations on the segmentation
views. The far right columns shows the estimated Ki67 predicted everywhere inside the
brain mask and always has the maximum intensity location shown. The color scale is
the same as the color bar below the density plot.
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Figure 3.7: Sample CLARA segmentation showing the three-class output for two
WHO IV glioblastoma patients. T1 post contrast and FLAIR images are shown with
and without segmentation for reference. The segmented regions are edema (yellow),
non-enhancing tumor core and necrosis (green), and enhancing tumor (blue). Clinically,
the right-hand case has enhancement pattern “both.”
3.2.5.2 Data Review Procedure
All cases were reviewed in the shiny app sequentially following these instructions:
1. In a web browser connect to the app.
2. To use a review log started from and existing session, upload it with the “Load
previous review log” file browser.
3. Select a case to review with the drop down HRPID menu or by clicking a row of
the summary data table. Alternatively, hover over a point on the scatter plots to
reveal its HRPID, search that HRPID in the data table search bar, then select the
row with that ID.
4. Check the data: do the images in the maximum views look reasonable? Do the
brain, tumor, and CSF segmentations look ok? If any are unacceptable check the
corresponding boxes under data review. Inspect the values in the plots and table.
Do the volumes agree with reference values and does the maximum diameter seem
reasonable? If not segmentation errors may be present. Lastly, add any helpful
comments about data failures or this specific case in the Comment field.
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5. When finished with that case, click the “save review + next case” button. This will
bring up the next consecutive HRPID with available data. Alternatively, select a
case manually with the table or scatter plots again.
6. Save a review log at the end of the review session by clicking the “Download review
log” button.
3.3 Results: Processed Data Summary
3.3.1 Image Series Classification
A full description of the clinical data sources is given in Section 4.2.1. In summary, from
1935 patient records that had either preoperative or postoperative imaging available to
download, a majority of the study descriptions were able to be classified by the regular
expressions. The exact numbers are tabulated in Table 3.4. A vast majority were in
the “MRI Brain” category an only 6% were in the excluded categories: intraoperative,
spine, non-brain, or MRA. There were a fairly large number of fMRI studies which
usually contained T1w and FLAIR images among others. The functional data was not












Table 3.4: Total number of studies of each type categorized by the regular expression
library for all patients. OSF: outside facility
A large majority (81.4%) of preoperative studies had a 3D T1w post-contrast image to
use as a high resolution. Only 4.7% of studies had to use a low-resolution Axial T2w
image as a fixed image as well. For postoperative data, under half of studies had high-
resolution postoperative data (39%). The frequency of each image type being used as
the fixed image is listed in Table 3.6.





















Table 3.5: Total number of series of each type categorized by the regular expression







Table 3.6: Fixed image type for each study. T13D, CubeFLAIR, and WandT2 are
usually near 1 mm isotropic resolution or better.
A total of 1370 adult patients with WHO grade II - IV glioma had a complete preopera-
tive imaging study for analysis. Several had more than the four required series. Among
the 1370 cases, 1071 had both gradient echo T1 post-contrast (T13D) and spin-echo
T1 post-contrast (AxT1C) images. 123 had only spin-echo contrast enhanced images,
and 299 had only gradient-echo. Of all the series identified in in the raw data, not
all were used for further analysis. The number of each series that were processed are
listed in Table 3.7. Note: 1370 cases had preoperative imaging available and 1728 had
postoperative imaging available so the entries in Table 3.7 are out of a possible 1728 or
1370.
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AxT1C AxT2 CubeFLAIR FLAIR T1 T13D T2star WandT2
POSTOP 1533 1741 39 1746 1749 681 1337 9
PREOP 1234 1265 325 1563 1566 1487 1144 1050
Table 3.7: Number of images of each type included in the curated data set. Only
cases with a full preoperative or postoperative study were included.
3.3.2 Image Data Processing
On a compute node, registration and brain masking for one case required about one
hour. Tumor segmentation inference took only about 30 seconds per case, and the
overall processing time was about 2 hours per study at most. The actual computation
time varied greatly depending on the image matrix size. The time required for feature
extraction after image processing also varied. A summary of the various run times is
listed in Table 3.8. Feature extraction varies considerably in computational time as well
over all image and mask combinations which varies considerably depending on image
size and ranges up to about 20 minutes.
Processing step Approximate processing time
DICOM to NifTI conversion+ 1 minute
pre-processing and registration 62 minutes
brain masking and skull strip 16 minutes
CLARA (inference, pre + post processing)∗ 5 minutes
Atropos tissue clustering + post processing 3 minutes
Image normalization 5 minutes
Pathology model inference 2 minutes
Pyradiomics feature extraction 17 minutes
png render for data QA 18 minutes
Total: 129 minutes
Table 3.8: Data processing times for a representative image study (fixed image size
512x512x124). Times are for single-node processing, note that many nodes can run
simultaneously. +Dicom conversion is run on a separate workstation not on a computing
cluster. ∗CLARA inference runs all inference sequentially inside a docker which creates
a bottleneck in the processing.
After an initial round of data review, bias correction was noted to have distorted lesion
contrast and harmed subsequent segmentations in 172 studies. These cases were re-
processed with bias correction disabled. Cases with data processing failures due to
failed registrations, failed brain masks, or failed bias correction were also re-processed
from raw image files. After re-processing, those cases were reevaluated using the QA
app.
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The procedure generating cerebrospinal fluid ROIs for normalization performed well.
Generally, the ROI was placed in one of three locations: lateral ventricles, quadrigeminal
cistern superior to the cerebellum, or in the sulci on the brain periphery. Examples of
these locations are shown in Figure 3.8. About 84% of preoperative studies and 78% of
postoperative studies had ROIs including the lateral ventricles as desired. When this
was not the case, it was often due to mass effect compressing the lateral ventricles and
making a clean ROI infeasible. The ROI inclusion rates for the various locations is given
in Table 3.9.
Figure 3.8: The three most common locations for CSF ROI were the lateral ventri-
cles (left), quadrigeminal cistern (middle), or superior to the brain (right). All give
reasonable CSF intensity statistics.
studytype lateral ventricles quadrigeminal cistern other n
1 POSTOP 0.78 0.18 0.17 1721
2 PREOP 0.84 0.18 0.06 1481
Table 3.9: Proportion of cases where the selected CSF ROI included the given loca-
tion. Multiple locations are possible so the totals exceed 100%
3.3.3 Data Quality Assurance
Initial review of the preoperative imaging data (1717) cases took approximately 50 hours
of combined reviewing time. This includes reviewing via the web app interface, manually
reviewing full 3D images when necessary, and investigating unusual failure modes. An
experienced neuroimaging researcher (author EG, 4 years of experience) could review
about 70 - 100 cases per hour on average. Qualitatively, the data review procedure had
a shallow learning curve associated with it as the reviewer became more familiar with
the appearance of the various processing failures. Overall. About 64% of the preop data
and 51% of the postop data was “ok” after initial review. The failure rate was greater in
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the postoperative data (28%) than in the preoperatve data (14%). The exact numbers
are given in table 3.10.
preop data
postop data
exclude acceptable ok NA
exclude 74 41 66 19
acceptable 82 60 128 22
ok 198 163 459 68
NA 94 79 164 0
Table 3.10: Result of data QA for all 1717 cases. Review is NA if a preop or postop
study was not available for that patient.
When counting failure modes, only the most upstream failure was counted. For example,
if tumor segmentation failed due to a corrupted image, then only the “bad image” would
be counted since the tumor segmentation would likely have succeeded had the images
been good quality. Counting all downstream failures would inflate the failure rate for
later pieces of the pipeline. However, if two failure modes were judged to have occurred
independently in the same case, such as a corrupted image and a failed registration on
another image, then both were recorded.
The main unacceptable failure mode was tumor segmentation failure and a majority of
those were due to small, undetectable lesions less than 10 cc in total volume. The other
source of failures occurred in about equal proportion. Exact proportions are listed in
Table 3.11. When corrupted or images or large artifacts were noted, those series were
replaced with a similar series if possible. Seventeen image series were replaced in this
way. This means the cases excluded for corrupted images or artifacts had no suitable
replacement series.
POSTOP PREOP
Corrupted image 0.0032 0.0038
Artifact 0.0086 0.0059
Bias correction failure 0.0081 0.0011
Registration failure 0.0324 0.0346
Brain mask failure 0.0411 0.0162
Tumor segmentation failure 0.1583 0.0502
Tumor undetected 0.0238 0.0216
CSF ROI failure 0.0400 0.0130
Normalization failure 0.0249 0.0151
Unreasonable estimated pathology 0.0016 0.0011
Table 3.11: Proportion of each failure mode in the data processing pipeline. Steps
are listed in the order they occur.
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3.3.4 BraTS Data Processing and Review
In the historical data, we differentiated between gradient echo and spin echo post-
contrast images and trained separate predictive models for each. The BraTS data was
reportedly generated using gradient echo pre-surgical scans [34] so we applied gradient
echo models to all cases. However, it was noted in our data review that 18 cases appeared
to use spin echo T1 post-contrast images.
Overall the BraTS data was good quality with 219 of 285 cases passing QA, see Ta-
ble 3.12. However, 43 cases had image quality that was deemed unacceptable. These
were almost exclusively due to poor single image quality or improper brain-CSF normal-
ization. Exact numbers are in Table 3.13. While normalization failure is a weakness of
our own methods. The base image quality is an issue with the challenge data itself. By
far, the most common image quality issue was excessively short field or cropped fields
of view. This was observed in 14 separate image studies. In extreme cases like the ones
in Figure 3.9 the ground truth tumor segmentation goes beyond the cropped image.








CSF ROI failure 0.0175
Normalization failure 0.0877
Table 3.13: Proportion of each failure mode in the data processing pipeline for the
BraTS data. No other failure modes were observed.
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Figure 3.9: Examples of FLAIR images and ground truth tumor segmentations in-
cluded in the 2018 Brain Tumor Segmentation Challenge. Left: Brats 2013 0 1. Right:
Brats18 2013 6 1. In both cases, the image field of view is so short that the segmenta-
tion is partially outside the brain volume. Both of these were caught by data review.
3.3.5 Comparison with Reference Values: Intracranial and Tumor Vol-
ume
The first step in data analysis is a visualization of raw data. Namely, we generated
several quantities like ROI volumes that we expect to lie within normal ranges or match
independently calculated values. After successful data processing, we expect to repro-
duce known values summarizing the characteristics of neuroimaging data. One such
property is total intracranial volume (TIV), which is the volume of the brain mask. The
distribution here should be consistent with values from literature for a similar popula-
tion. The other value is the patient-specific preoperative tumor volume which has been
previously measured by an independent research study [14, 15].
3.3.5.1 Intracranial Volume
First, each patient has a brain mask associated with each of the preoperative and post-
operative studies. Using the volume of these masks, we compared these values to the
expected population distribution for total intracranial volume (TIV). Note - TIV is the
appropriate comparison since the masks used for image processing include cerebrospinal
fluid and not just brain tissue. Literature values for TIV are fairly consistent between
studies. Lüders 2002 reported a breakdown of brain size (including CSF) by gender in
Table 1 of [1]. It listed 1510 ± 400 cm3 for men (n=50) and 1320 ± 100 cm3 for women
(n=50). All patients were neurologically normal. The standard deviation for males
seemed quite high, though. Recalculating from the constituent components gave a more
reasonable standard deviation of 155 cm3. Table 2 in Jenkins et al. 2000 [118] estimated
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Figure 3.10: Distributions of preoperative intracranial volume for historical cases.
The dashed lines are normal densities from [1], reproduced in Table 3.14.
TIV in 52 control patients to be 1512.5 ± 128.2 cm3 for males (n=24) and 1316.8 ± 97.6
for females (n=28). The volumes for Alzheimers patients was nearly identical. Lastly,
Blatter et al listed TIV for 192 subjects and stated “A significant difference in the TICV
was observed between male (1558 cm3 ± 97 cm3 ) and female (1352 cm3 ± 115 cm3 )
... subjects” [119]. This reference also split the TIV by decade of life. 105 subjects were
female and 89 were male. A summary of these references is given in Table 3.14.
Reference subjects Male TIV in cm3 (n) Female TIV cm3 (n)
Lüders 2002 [1] young, healthy, volun-
teer students
1510 ± 400† (50) 1320 ± 100 (50)
Jenkins 2000 [118] 52 healthy controls age
52 ± 12
1512.5 ± 128.2 (24) 1316.8 ± 97.6 (28)
Blatter 1995 [119] health subjects age 16-
65
1558 ± 97 (89) 1352 ± 115 (105)
This work (2021) 1181 untreated adult
glioma patients
1473 ± 98 (702) 1298 ± 95 (479)
Table 3.14: Total intracranial volume (TIV) measured using 3D imaging for several
different populations. †This value was reported in Table 1 of [1] but it is inconsistent
with the reported mean and range of values. The true value is likely around 155 based
on the other values in that table.
Using the data from Lüdders 2002 reproduced in Table 3.14 our data matches fairly
well, see Figure 3.10. Excessive smoothing might have biased the measurements to be
slightly small compared to population data. For our data we measured TIV to be 1298
± 95 for females (n = 479) and 1473 ± 98 for males (n = 702). These numbers only
include brain masks of acceptable data quality.
Chapter 3. Neuroimaging Data Curation 81
3.3.5.2 Tumor Volume
Preoperative and postoperative tumor volumes for each patient were measured by neuro-
surgery researchers for prior studies [14, 15]: specifically, T1 contrast enhancing volume,
T2 FLAIR lesion volume, and T1 hypointense volume. Enhancing volume measurements
also include necrotic tissue within the enhancing volume when present. These reference
measurements provide excellent benchmark values for automatically segmented tumor
volumes.
To make a proper comparison to the reference values, we combined the appropriate la-
bels from the CLARA three-class segmentation (enhancing tumor, non-enhancing and
necrosis, and edema, Figure 3.7). The specific combination depends on the enhancement
status of the tumor. For purely non-enhancing and enhancing tumors, the reference T1
enhancing volume was compared to the non-enhancing plus enhancing regions. This
accounts for necrosis present in the reference T1 enhancing measurements. For en-
hancement status “both”, the non-enhancing tumor core is not included in the reference
enhancement measurement due to a large amount of non-enhancing tumor in addition
to enhancing tissue. An example of this pattern is shown in the right-hand side of
Figure 3.7. For this case, only the enhancing label is counted as enhancing volume.
Reference T2 FLAIR volume was equivalent to the sum of the three sub-regions from
CLARA for all cases. The part of the tumor measured for the reference T1 hypointen-
sity is not a direct combination of the labels present in the CLARA segmentation which
means a direct comparison was impossible. Summing the non-enhancing and enhancing
sub-regions provided the closest agreement but appears to consistently underestimate
the T1 hypo intense volume, Figure 3.11. This is likely because some of the T1 hy-
pointensity is sufficiently FLAIR hyperintense that it is labeled as edema instead. The
relations between the CLARA subregions and reference measurements are given explic-
itly n Table 3.15.
Enhancement Status T1 enhancing volume T2 FLAIR volume T1 hypointensity
Enhancing neh + enhanc neh + enhanc + edema neh + enhanc
Non-enhancing neh + enhanc neh + enhanc + edema neh + enhanc
Both enhanc neh + enhanc + edema neh + enhanc
Table 3.15: How CLARA segmented volumes are added to compare to reference T1
enhancing and T2 FLAIR volumes. Enhanc is enhancing tumor (blue in Figure 3.7),
neh is nonenhancing tumor core and necrosis (green in Figure 3.7).
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Preoperative volumes agreed quite well with reference measurements. The enhancing
volume measurements mostly agreed well but had more variability that warrants further
investigation. Comparisons of these values are in Figure 3.11. Preoperative values agrees
quite well for both measurements. However, there are still several cases where CLARA
identified some enhancing volume where reference measurements measure no enhancing
volume. This is usually due to small enhancing vessels mistaken for enhancing tumor.
We could have corrected this by excluding enhancement preoperatively for clinically
non-enhancing tumors. But for 75% of cases, it would have adjusted the total volume
by less than 0.2 cm3 so we elected not to.
Postoperative measurements of total tumor volume showed systematic over-estimation,
although the overall correlation was still strong at R = 0.83. Enhancing volume and T1
hypointensity are not well estimated by automatic measurements. Several cases had zero
reference volume but some small non-zero amount segmented, likely due to treatment
effect. The agreement of postoperative enhancing tumor volumes could be improved if
the patient’s clinical designation of gross-total or subtotal resection were used to exclude
the enhancement. But, this potentially the biases the results so a correction was not
made.
Excluding the bad data had a positive effect on the correlation with reference values.
Figure 3.12 shows the agreement between segmented tumor volume and reference tumor
volume for the three data quality levels. As the data quality increases, the correlation
also increases and the points generally fall closer to the agreement line. The root-
mean-square-error also decreases with better data quality, Table 3.16. There were a few
exceptions where there is disagreement between the volumes but the data is otherwise
ok. There are cases that are within the limits of human judgement, such as where to
draw a boundary on faint FLAIR hyper-intensity. In some cases, there was considerable
volume of both non-enhancing tumor and necrosis. Since the reference values only
count necrosis, this inflated the enhancing volume and is not actually an error. It is a
consequence of using three classes in CLARA not four.
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Figure 3.11: Comparison of tumor volumes segmented by CLARA and volumes mea-
sured previously by neurosurgery. T2 FLAIR volume included the entire FLAIR lesion
or total visible tumor volume. Enhancing volume includes both enhancing tissue and
tumor necrosis. T1 hypointense volume includes tumor core outside of enhancing vol-
ume. The dashed lines indicate agreement.
data quality T2-FLAIR RMSE T1-EV RMSE
1 exclude 24.22 19.36
2 acceptable 20.46 9.35
3 ok 12.22 9.31
Table 3.16: Root mean square error in cm3 for preoperative segmented tumor volume
(T2-FLAIR and T1 enhancing) compared to reference tumor volume. Separate values
are given for each level of data quality.
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Figure 3.12: Preoperative T2 (top) and enhancing tumor volumes (bottom) for his-
torical cases compared to reference values. Each plot shows values for a different level
of segmentation quality and the dashed line indicates agreement. “Poor” data is ac-
ceptable with minor errors.
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3.4 Discussion
Using a combination of automated image processing and manual data review the primary
results achieved in this chapter were:
1. Classification and organization of over 3,500 MR imaging studies containing over
46,000 image series from a single institution using a custom library of regular
expressions applied to study and series descriptions.
2. Effective automated processing of image studies including registration, segmenta-
tion, and normalization which produced acceptable results for 86% of preoperative
cases and 72% of postoperative cases.
3. Verification of data quality enabled by a custom R shiny web app.
Identifying the four primary image contrasts (T1w, T1w with contrast, T2w, and FLAIR)
needed for image analysis from an arbitrary study is a challenging task due to lack of
a standardized series naming scheme between vendors or institutions. Rule-based so-
lutions using DICOM metadata or artificial intelligence have been proposed to tackle
this [120]. The goal in this work was to classify a finite total number of series from a
single institution. This allowed a simpler approach based on regular expressions for the
study and series descriptions alone. Because the regular expression libraries in Tables 3.2
and 3.3 were built in conjunction with the finite number of series descriptions contained
in the retrospective data, they may not be flexible enough for prospective classification
of new series.
The curation of this large-scale historical image database with annotations not only
enables the survival analysis discussed in later chapters, but also serves as a resource
for further investigation. The sheer volume necessitated use of a computing cluster in
this work. However, processing a single study, as would be the case in clinical practice,
can be performed in just over a few hours. The most time-consuming step by far is
skull stripping during registration pre-processing since each of four images must have
the brain outlined individually. We chose to use an atlas based multi-contrast skull strip
algorithm [114]. While the results were fairly reliable, this algorithm performs 4 - 9 fully
deformable image registrations per image stripped as well as post-processing with patch
matching. This means the total time could be reduced considerably by substituting a
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faster skull stripping algorithm [121]. However, finding one that works effectively on
many image contrasts (T1w, T2w, and FLAIR) and on postoperative data is difficult.
Preoperative total intracranial volume (TIV) served as a surrogate for the accuracy of the
skull-stripping algorithm. While the individual measurements came from annotations
labeled as “brain mask” the TIV is a more appropriate measure since it includes the
CSF which is part of the mask. On postoperative data, the mask also included any
resection cavity which was not part of the brain but was part of the intracranial contents.
Although, the postoperative data is not included in Figure 3.10 or Table 3.14. Unlike
tumor volumes, we do not have patient specific reference measurements for TIV so we are
instead limited to comparing the overall distribution to population values [1, 118, 119].
We found an underestimation of TIV compared to the reference distributions. This
might be explained by masks with small amounts of inferior cerebellum excluded were
still designated as acceptable quality and hence included in the final data.
We compared segmented tumor volume with a reference tumor volume as an approximate
measure of segmentation quality. Overall, Figure 3.11 showed good agreement with
reference values with a strong correlation of R = 0.97 for total tumor volume. Some
deviation from human-generated reference values is expected even for a perfect algorithm
given that tumor segmentation inexact. In a small study where ten radiation oncologists
were asked to contour four glioblastoma gross tumor volumes, the standard deviations in
the T2-FLAIR volumes ranged from 22.6 cm3 to 62.6 cm3 [122]. This is comparable or
even larger that the RMSE of 12.22 cm3 to 20.46 cm3 for the acceptable segmentations
from CLARA. In other words, the distance from true values (RMSE) is comparable to
the variability in the truth itself.
While the preoperative tumor volumes agreed quite well, Figure 3.11 illustrated a sys-
tematic overestimation of postoperative FLAIR hyperintense volume relative to the ref-
erence measurements. The regression coefficient for postoperative whole tumor volume
versus reference was 1.089. These data suggest that the residual disease is volume is
overestimated by about 9%. This phenomenon is well established in neurosurgical lit-
erature and is generally attributed to edema or ischemia [123–125]. Although, these
studies demonstrate significant differences between early and late posopterative T2w
and FLAIR hyperintensity as groups, there is little data on the expected patient-level
effect. A study in non-enhancing gliomas by Belhawi et al. found a 20% overestimation
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on early vs late postoperative FLAIR volume [126] using linear regression. This is larger
than our observed 9% but may be explained by the difference in tumor grades present.
Intraoperative MRI or ultra-early (immediate after wound closure) is less susceptible to
these treatment effects [124]. But, the retrospective analysis in this work limits us to
the available early preoperative imaging. One solution to mitigate the overestimation
of residual tumor is with diffusion-weighted imaging [125]. A large number of our cases
do have postoperative diffusion weighted imaging that could be incorporated to better
estimate residual disease.
Comparison with reference tumor volume gives an incomplete assessment of the overall
segmentation performance. While agreement in general suggest a good segmentation,
it is not entirely sensitive or specific for segmentation quality since it does not capture
the spatial distribution of the segmentation. To illustrate: we observed some counter-
examples. Figure 3.12 shows some cases where failed (exclude) cases had good agreement
with reference volume. This is due to a segmentation with the correct approximate size
placed in the wrong location in the brain. We also saw cases with a much larger or
smaller total tumor volume than the reference but was acceptable. These were due to
faint T2-FLAIR hyperintensity which creates a large uncertainty in tumor extent. We
expect human readers would have similarly discrepant. Lastly, segmenting the enhancing
or necrotic compartment of a tumor is somewhat arbitrary as well. Many of the cases
with discrepant enhancing volumes in Figures 3.11 and 3.12 have overall total volume
agreement even though the individual labels, i.e. enhancement versus edema, might
disagree.
Ideally, we would have compared the automatic segmentations to a complete manual
segmentation on the historical data set using metrics like Dice similarity or Hausdorff
distance. Unfortunately, such human segmentations were not available. CLARA was
trained on 285 cases from the brain tumor segmentation challenge [34]. On the validation
set it achieved average Dice scores of 0.851 for tumor core, 0.773 for enhancing tumor,
and 0.903 for whole tumor3. Since the historical data was pre-processed to match the
Brain Tumor Segmentation Challenge data, it would be reasonable to assume the Dice
scores with human-generated ground truth would be similar to those values.
3ngc.nvidia.com/catalog/models/nvidia:med:clara_mri_seg_brain_tumors_br16_full_no_amp
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The previous counter examples where good tumor volume agreement was achieved with
bad segmentations and vice versa illustrated the need for careful data review. For
complex image processing basic data quality, annotation accuracy, intensity statistics,
and other properties all need to be assessed for accuracy. Almost every step in Figure 3.1
introduces a failure mode with some frequency. To check all aspects at once we used
a custom data review dashboard and found that the QA procedure, while laborious,
conferred great confidence in the data quality moving forward. Using the dashboard, we
even found instances of bad data quality in the Brain Tumor Segmentation Challenge
data. In fact, we marked about 6% of the 285 cases as having image quality bad
enough to exclude from further analysis. It is unclear how extreme cases like the ones
shown Figure 3.9 have impacted the training and evaluation of the best segmentation
algorithms. Indeed, these cases were used to train the CLARA segmentation model we
applied. In short, this simply underscores the need to carefully review data, even data
coming from popular and well-documented sources.
There are existing tools assess raw image quality [127, 128]. however good image quality
alone does not guarantee the success of downstream processes. Many of these other
processes have some ways to identify uncertainty like test-time dropout for segmen-
tation [129] but ultimately these still require either human intervention for the final
decision. Lastly, when exploring a new data set it is very difficult to know a-priori which
failure modes will be encountered and which metrics can accurately identify them. This
makes automated data review a “chicken and the egg” problem where such methods
cannot be assessed without manually reviewing the data first to get ground truth. For
work such as this one where the goal is to use the curated data for further research,
discovering the best metrics for QA retrospectively provides little benefit for the project
at hand. Although, doing so would be a rich area of future work.
3.5 Summary of Curation Effort
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Step Curation
achieved






















































































23,888 27,000 8 weeks -
TOTAL publishable
results
1,851 3,591 23,888 194,000 12 months 16 TB
Table 3.17: Summary of curation effort. Three steps that take an appreciable amount
of time: A) Downloading raw DICOM data from PACS. This takes took a few weeks
since we throttle and only transferred during nights and weekends. B) Processing the
image data from raw DICOMs to a final data matrix can be done in about 24 hours
on a moderate sized computing cluster. C) Data review takes about 80 human hours
to review all studies. This includes breaks and distractions. Additional time to re-
processed and review bad data included. 1R shiny app. 2Includes to develop and test





Prognosis for glioma patients varies greatly depending on the overall grade of the tu-
mor, clinical factors, and treatment. Clinically, patients that live longer also tend to
be younger and have high mental performance status [14, 15], these two factors are rec-
ognized as independently important and are commonly controlled for as covariates in
survival models. Mental status is measured by the Karnofsky performance status scale
which scores a patient’s ability to independently function in daily life from 0 to 100 in
increments of 10. A score of 80 or above means they are still able to carry out normal
activities without special assistance [2, 130]. The list of possible scores with description
is reproduced from Oken et al. [2] in Table 4.1.
The single most powerful survival factor currently known is the tumor grade described
by the World Health Organization (WHO) scale [20]. The WHO scale grades tumors
from I to IV with a higher grade being more malignant and carrying worse prognosis. In
this work we consider adult patients with tumors of WHO grade II or higher (grade I tu-
mors are usually found in pediatric populations). Historically, the WHO grade has been
determined based on tissue histology, using such pathological features as the presence
of mitoses, microvascular proliferation, or necrosis in order to characterize the tumor.
Some imaging features like contrast enhancement are known to be associated with higher
90
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Description Karnofsky Status
Normal, no complaints 100
Able to carry on normal activities. Minor
signs or symptoms of disease
90
Normal activity with effort 80
Care for self. Unable to carry on normal ac-
tivity or to do active work
70
Requires occasional assistance, but able to
care for most of his needs
60
Requires considerable assistance and frequent
medical care
50
Disabled. Requires special care and assistance 40
Severely disabled. Hospitalization indicated
though death non-imminent
30





Table 4.1: The Karnofsky performance scale, reproduced from: Oken, M.M., Creech,
R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Tox-
icity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin
Oncol 5:649-655, 1982. [2]
WHO grade [33]. As of 2016, the discovery of important mutations or molecular mark-
ers like IDH1/2 mutation [86] have shifted the WHO grading scale from histologically
based to histologic and molecular. In fact, certain histologic subtypes can now be com-
pletely defined based on key genetic markers as is the case with oligodendroglioma with
chromosomal 1p/19q co-deletion [14, 15].
While the prognostic difference between glioma grades is large, the grading system still
depends on having tissue specimens available. Obtaining tissue data is difficult, ex-
pensive, and incurs some risk like all surgery. Furthermore, tissue samples are often
obtained concurrently with tumor debulking so the tumor grade is obtained after treat-
ment decisions (e.g. to operate) have already been made. In contrast with tissue data,
MRI is relatively cheap, safe, and easy to obtain. This is the primary motivation behind
the predictive modeling and imaging-pathology correlations developed in Chapter 2 and
has also spurred the field of “radiomics” searching for strong image-based biomarkers
to inform prognosis and treatment [35]. For gliomas, radiomic analysis is confounded
by well-established intra-tumoral heterogeneity [9]. In short, feature measurements over
whole tumor volumes or even large radiographically distinct sub-regions can fail to ac-
count for differences in underlying histology. This leads to “averaging out” possible
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survival signal. Thus, there is a need to quantify the true biological heterogeneity in
order to discover meaningful biomarkers.
4.1.1 Summary of Analysis
In this chapter, we examine the full histologic heterogeneity using the predictive models
developed in Chapter 2 and applied to curated data from Chapter 3. We address the
following primary hypothesis: Image features provide additional prognostic information
for overall survival relative to age, KPS, and tumor grade. If the hazard ratio in mul-
tivariate proportional hazard models for an image feature is significantly different from
1 then the imaging provides additional prognostic information not captured in grade
or clinical measures. If the primary hypothesis in not supported, a secondary hypoth-
esis is: The prognostic information contained in image features (imaging phenotype) is
non-inferior to the information provided by histologic tumor grade when controlled for
performance status and age.
The results in this chapter are presented roughly in this order: First, we correlated
the baseline clinical characteristics like age, mental status, clinical histologic grade, and
tumor volume with survival and reproduced the known relationships established in the
literature. For tumor volume, we analyzed the automatically segmented tumor volumes
which were used for feature extraction.
Next, we applied survival modeling techniques to raw image feature data. The primary
results are hazard ratios from Cox proportional hazards models for overall survival in
all patients. Inclusion of age, mental status (KPS), WHO grade and image features
as inputs demonstrate the independence of prognostic features. The prognostic value
of each feature is computed individually and the best feature derived from each image
type (T1, T1C, T2, FLAIR) is presented as a candidate biomarker. We repeated this
analysis to include features derived from estimated pathology maps (Ki67, CD, ERG,
local grade). Just like the raw image features, we present mainly the best performing
feature from each map type and list additional results in the appendix. For completeness,
we performed repeat analysis on the subset of patients with each WHO grade (II, III, IV).
However, for clarity we focus our results on the analysis of the combined cohort consisting
of multiple WHO grades. Subset analysis is discussed when it provides noteworthy
results beyond the data presented in the combined analysis.
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In addition to the prognostic value of imaging, we are particularly interested if the
prognostic value of predicted biological heterogeneity is better than features from raw
images in terms of survival stratification. In general, these predictive models synthesize
the existing imaging and encode learned correlations with pathology. So, it is rea-
sonable to expect they will produce strong prognostic biomarkers. However, it is also
possible that the reduction from a four-dimensional space (T1, T1C, T2, FLAIR) to
a one-dimensional space (e.g. Ki67) will lose some important information. There is
also still some error associated with the model predictions and this noise may interfere
with prognostic stratification. Regardless of the differences between raw image features
and predicted pathology features, using the nonlinear random forest to transform the
image data adds significant complexity. The cost of this increased complexity should be
weighed against potential improvement in risk stratification.
4.1.2 Image Feature Complexity
The field of radiomics is concerned with finding imaging measurements that correlate
with a particular diagnosis or outcome [131]. In general, measurements are function
of three parameters: the image being measured, a region being measured over, and
the feature being computed. For example, the mean T2w image intensity over a visible
lesion. Mean intensity is a simple and interpretable feature. But, sometimes information
may be contained in so-called higher order features that measure subtle characteristics
of the image gray levels. For instance, the ”short run low gray level emphasis” measures
how prominent short dark structures are in a region. While these complex features
may have the ability to identify subtle differences between tumor types, the trade-off is
that they are much more difficult to interpret and tend to be highly sensitive to image
acquisition parameters and preprocessing [36, 132, 133].
The complexity of a measurement also depends on the underlying image. Raw diagnostic
images are generally the simplest. But, it is possible to also measure features over derived
or functional images like diffusion anisotropy or pharmacokinetic parameter maps like
Ktrans from DCE. Non-linear combinations of several images, such as the estimated
pathology maps in Chapter 2, are yet even more complex. As complexity increases,
features lose interpretability. Although, regression to a biologically relevant variable
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hedges this complexity by adding interpretability. The ultimate goal is to discover
biomarkers that meet several criteria. Namely we want features that are:
• Reproducible: describing some real quantity that can be accurately described and
reproduced.
• Interpretable: able to be logically defined and visibly connected to some real quan-
tity describing the disease. Hand-crafted features used in this work carry at least
some interpretability by the nature of being human designed. This is in contrast
to deep learning features which are generated entirely based on data.
• Actionable: the value of prognostic stratification is that it can be used to guide
individual patient treatment. As an example, genetic biomarkers may suggest
the use of certain chemotherapeutic agents. For imaging, we prefer biomarkers
that can identify effective targets for spatially focused therapies like surgery and
radiation.
• Testable: the value of quantitative biomarkers should be measurable and consistent
on an individual patient basis so that they can be evaluated prospectively in clinical
trials.
4.2 Methods
4.2.1 Clinical Data Sources and Description
Patient data for the retrospective historical cohort was collected under a HIPAA-compliant
and institutional review board approved retrospective protocol at MD Anderson Cancer
Center (PA12-0753 Chart/Imaging Review of the Patterns of growth in Gliomas, PI
Schellingerhout). The Interdisciplinary Brain and Spine Center database was queried
for patient records between June 1, 1993 and May 31, 2018. The search was limited to
patients who were ultimately diagnosed with glioma and underwent first surgical resec-
tion at MD Anderson. The returned clinical data for each patient included several types
of information.
• Basic information: medical record number, surgery date, date of birth, and sex.
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• Outcome information: follow-up time, vital status at follow-up, mental status, and
post-operative complications if applicable.
• Diagnosis and treatment information: histologic diagnosis, WHO grade, preop-
erative and postoperative imaging dates, surgery date, type of surgery, previous
surgery if applicable.
• Reference tumor measurements: enhancement pattern, T2-FLAIR volume, T1
contrast-enhancing volume, T1 hypointense volume, and extent of resection based
on T1 enhancing or T2-FLAIR volume. Additionally, tumor laterality and eloquent
involvement.
From this information, overall survival was calculated using the surgery date, latest
follow-up time, and vital status. The patient’s age at time of surgery was calculated
using date of birth and surgery date. Unfortunately, information on other treatments
like radiation or chemotherapy before or after surgery was not available. However, treat-
ment courses for glioma patients has been mostly standardized since the introduction of
the Stupp protocol [4] meaning most patients receive the same chemoradiation proto-
cols. Using single-institution data also reduced variability in therapeutic choice which
minimizes confounding.
4.2.1.1 IDH Mutation Data
To obtain genetic information like IDH1 mutations status, we joined the clinical data
with molecular testing results collected through a separate MD Anderson protocol
(Proactive program, PI: Dr. John De Groot). This data was originally gathered using a
combination of molecular diagnostics lab sequencing results and manual data abstraction
of pathology and clinical documentation. IDH mutant status was confirmed by either
codon R132H immunohistochemical staining or IDH1/2 sequencing results. Wild-type
status was confirmed by sequencing which also checks for non-canonical IDH1 mutation
and IDH2 mutations. Four WHO grade IV patients had negative R132H IHC staining
and were assumed to be IDH wild-type since only about 10% of gliomas have non-
canonical IDH1 mutations or IDH2 mutations [86]. In total, IDH mutation status was
present for about 25% of the 2,588 patient records queried.
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Several studies have confirmed that IDH1 mutation rates in glioma vary according to
grade [134–136] and age [19, 137, 138]. In the subset of data with known IDH status we
observed similar rates of mutation by subgroup. The proportions are listed in Table 4.2
and agree well with published values. In a meta-analysis by Sun et al. of 937 low-grade
glioma patients, 744 (79.4 %) had IDH1 mutations [134]. This falls between the two
rates we observed for young and old patients. Studies by Hartmann et al. found that
6.2% (15/237) of GBM patients ≤ 60 years old were IDH1 mutant compared to just
1% (2/237) of GBM patients over 60 years old. We found a much higher mutation rate
among young GBM patients but had a lower age threshold of 55 years. There is also
evidence that IDH1 mutation rates varies with histologic subtype [135, 136] but this
would cause too fine of a distinction to be meaningful given that the differences between
subtypes are smaller than with age and Grade.
Since IDH mutation status is was available for only a fraction of the historical cases,
it posed a substantial missing data problem for survival analysis. One solution would
be to randomly imputed the IDH1 mutation status using the observed mutation rates
among cases with the same WHO grade and age category (above or below 55 years old).
Imputing molecular data in this way has been performed in similar studies [139]. But,
we deemed the proportion of missing data is too large to meaningfully impute. Instead,
we chose to exclude IDH mutation status from the overall analysis and instead report
repeated analysis on the subset with known IDH status as supplementary results in
appendix Section A.5. This decision was also supported by evidence that MR imaging is
strongly predictive of IDH mutation status [109]. Therefore, image information should
also be able to capture the relevant prognostic information contained in IDH mutation
status. For future work, a model like the one presented in [109] could be used to
appropriately impute the missing IDH mutation status.
WHO Grade Age group Observed mutation rate N
II <55 0.878 311
II >55 0.737 46
III <55 0.806 405
III >55 0.300 84
IV <55 0.195 545
IV >55 0.038 923
Table 4.2: IDH mutation rates stratified by patient age (above or below 55 years)
and WHO grade. The number of cases per group is given as N. IDH mutation status
was confirmed by IDH1 R132H immunohistochemical staining or sequencing.
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Figure 4.1: Flowchart for patient selection in the historical data. Ambiguous imaging
time means the imaging and surgery were on the same day. A complete study includes
at least on of each: T1-weighted pre-contrast, T1-weighted post-contrast, T2 weighted,
and FLAIR images.
4.2.1.2 Imaging Data
MR Imaging data was downloaded from the hospital picture archiving and communica-
tion system (PACS) using each patient’s preoperative and postoperative imaging dates.
For many older studies, imaging was unavailable since it was not digitally included in the
patient’s medical record. Additional information on image data curation is in Section
3.2. The final cohort of patients for historical analysis met the following criteria:
1. Adult, age 18 years or older
2. Histologic diagnosis of WHO II, III, or IV glioma
3. At least one full imaging study (preoperative or postoperative) with T1, T2,
FLAIR, and contrast-enhanced images.
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4.2.2 Feature Extraction and Mathematical Description of Image Fea-
tures
We use Pyradiomics (v3.0) to extract image features [36]. The features are described in
the Pyradiomics documentation. To contextualize the features, it is easiest to consider
each image I with K voxels as a function that maps each voxel to a real value. I :
{1, 2, ...,K} → RK We can define a region to measure features over as a subset of the
image’s domain L ⊆ {1, 2, ...K} Let X be the set of image values for the Np voxels
in region L. XL = {I(i) : i ∈ L}, |X| = Np. We use the notation X(i) to denote
the individual values in the set X. All features we consider in this work other than
3D diameter are a functions of the set of voxel intensities X, which means they are
functions that map the I and L to real values. Shape based features like volume do not
use intensity information and instead just use the region indices:




Max 3D Diameter: Dmax = max (‖~vi − ~vj‖2) (4.2)
Where VL is the voxel volume of region (label) L and Vk is the volume of each voxel and
is a constant for each image. The vector ~vk is the vector in 3D space at the location
of voxel i in L. The 3D diameter is the maximum Euclidean distance between pairs
of points. Practically, this is computed using vertices on the convex hull [35]. The
first-order intensity-based features use the image values as computed by pyradiomics:









(X) = max ({X(i), ..., X(Np)}) (4.4)
Minimum: min
L
(X) = min ({X(i), ..., X(Np)}) (4.5)
Percentile: Pk(X) = min{c : |{X(i) : X(i) ≤ c}|/Np ≤ k/100} (4.6)
Median: medL(X) = P50(X) (4.7)
Total Sum: ΣXL = Vk
Np∑
i=1




















Vk is the volume of each voxel and is a constant for each image and Pk(X) is the k-th
percentile of the values of X. The total sum feature was added manually to pyradiomics.
Intensity volume histogram features were also manually computed. The intensity at vol-
ume features are quantile measurements that use volume instead of fraction of total
data. For example, the intensity at Volume V ′ = 5 cm3 for a region with total volume
|L| = NpVk = 250 cm3 is equivalent to the 1 − 5/250 = 0.98 or 98th percentile. Note,
this is technically a different definition than the one given by the IBSI but difference
is negligible. An illustration is shown in Figure 4.2. The purpose of these quantile
measurements is analogous to Windsorizing [140] and is to provide robust alternatives
to maximum and minimum features which rely on the (often unstable) value of a sin-
gle voxel. For simplicity, we refer to the IntensityAtVolume1000 feature as the “1 cc
intensity” and so on for other volumes.
Recall, each image measurement is specified by three attributes: An image being mea-
sured, a region over which the measurement is being made, and the feature being com-
puted. For example, Mean T2 wholetumor is the mean T2-weighted intensity over the
whole visible tumor. We considered 22 intensity features for each of the 7 different
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Figure 4.2: Illustration of Intensity At Volume features. On the density plot of voxel
values the total area of the density plot is equal to the region volume being measured
over. The Intensity At Volume feature for a volume V ′ is the intensity such that the
area in the upper tail (red) has area corresponding to the volume V ′.
images and 5 different regions, plus two shape features over each of the 5 regions as
well as the voxel volume and 3D diameter of the predicted lower-grade and higher-grade
tumor regions. This gives a total of 784 different features measurements. The possible



























Table 4.3: Images, regions (Figure 3.7), and features used to compute image mea-
surements. Shape features Voxel Volume and Max 3D Diameter only depend on the
region being measured over not the underlying image.
The three tumor region measurements mentioned in Table 4.3 correspond to the CLARA
segmented regions. Namely, the non-enhancing tumor, enhancing tumor, and edema
correspond to the green, blue, and yellow labels in Figure 3.7. The whole tumor region
is the union of all three labels. The other three regions are the normal, lower-, and higher-
grade regions from the predicted grade maps. For these, we computed the volumes and
diameters only. In total, we computed 784 features per patient.
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4.2.3 Survival Analysis
We employed standard survival analysis methods including the Kaplan-Meier method
and Cox proportional Hazard modeling [141]. These methods are well established in the
literature including previous analysis of extend the value of extent resection for glioma
patients [14, 15].
4.2.3.1 Concordance Index
We calculated the concordance index or C-index between each feature and overall sur-
vival1. The C-index captures association between the feature and outcome in the pres-
ence of right censoring by estimating the probability that a larger feature value cor-
responds to longer survival. To calculate the C-index, consider all possible pairs of
subjects. Each pair is either concordant, discordant, or tied depending on the values of
the feature x and outcome y. Pairs where the survival times cannot be unambiguously
ranked (e.g. two censored times or tied times) are excluded as incomparable.
yi < yj yi = yj yi > yj
xi < xj concordant Tied Y discordant
xi = xj Tied X Tied XY Tied X
xi > xj discordant Tied Y concordant
Table 4.4: Definition of concordant and discordant pairs in terms of feature values x
and survival times y.
Using the number of pairs in each category, the concordance index C is estimated as
C = P (xi > xj |yi > yj) =
Concordant + Tied X/2
Concordant + Discordant + Tied X
4.2.3.2 Proportional Hazard Model
In addition to computing the C index we use proportional hazards modeling to paramet-
rically examine the relationship between time to an event and an exposure variable [142].
It uses the hazard function h(t) which models the instantaneous failure rate at a time t
for a population. One definition is h(t) = −S′(t)/S(t) where S(t) is the survival function
giving the fraction of the population alive at time t. The proportional hazard model
1See cran.r-project.org/web/packages/survival/vignettes/concordance.pdf
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assumes that the hazard function for a member of the population with covariate vector
Z is of the form




Where h0(t) is the baseline hazard and β is a vector of parameters. The hazard ratio
h(t)/h0(t) represents the increased chance of death relative to the baseline case Z = 0.
A benefit of the proportional hazards model is that by fitting using partial likelihood
the baseline hazard does not need to be known or estimated. For details, see appendix
Section A.6.1.
4.2.3.3 Cross-Validated Binary Thresholds
The proportional hazards model assumes a continuous relationship between feature value
and hazard. However, this may not be the case across the entire range of a given feature’s
values. Instead, there may be a threshold where patients above and below have very
different risk characteristics. For example, a volume of contrast enhancement equal to
0 (i.e. non-enhancing) versus greater than zero (i.e. enhancing). Performing a binary
categorization using a threshold also makes the features clinically useful since they allow
simple categorization of patients into high- and low-risk.
To look for such thresholds, we searched for an optimal stratifying threshold for each
feature. For a specific feature X, the value for a particular patient j is Xj and we find
the optimal stratification HRmax(X) among the training set.
HRmax(X) = argmaxi max {exp (β) , exp (−β)} :
∑
j
δ(Xj ≤ i) > nmin &
∑
j
δ(Xj > i) > nmin
(4.12)
Where β is the coefficient from a Cox proportional hazard model fit using the two
groups of patients with Xj ≤ i and Xj > i. In other words, β maximizes the log
partial likelihood in Equation A.3. Using the maximum of exp(β) and exp(−β) allows
a larger feature value to be associated with either increased or decreased survival. The
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parameter nmin is a minimum group size which we set as 20% of the number of training
cases unless otherwise specified and δ is an indicator function which counts the number
of cases above and below the cutoff i. HRmax(X) can be found with a line search over
the unique values of X. The search is restricted to just the values of X that provide a
significant (log-rank) difference in survival between the two groups when possible. When
no threshold provides a significant survival difference, the largest non-significant hazard
ratio is reported. Since we test many features, we correct the univariate significance level
to account for the number of features tested per base image type using the Benjamini-
Hochberg method which controls the false discovery rate [143]. We report the corrected
p-values for univariate tests. When those features and their high risk/low risk predictions
are used in multivariate analysis against clinical factors, the p-values are not corrected
since there is no longer a multiple comparisons problem.
Since optimizing survival differences carries risk of over-fitting, we wrapped this analysis
in a 10-fold cross validation [144]. The data was split into 10 folds with roughly equal
distributions of survival times and censoring. Then, the cases in each fold were assigned
to the high-risk or low-risk group using a threshold i calibrated on the remaining 9 folds.
We pooled the test set predictions so that every case had one prediction associated with
it. We then measured the hazard ratio between the predicted high risk and low risk
groups. Unless explicitly stated, all survival results reported are based on cross-validated
survival estimates. Statistical differences in between groups is assess using a log-rank
test. Technically, the fold structure introduces a small amount of dependency in the
predictions which violates an assumption of the log-rank test. An ideal solution would
be bootstrap estimation of the distribution of the log-rank test statistic to establish a
significance level [144]. But, this incurs significant computational cost and is the subject
of future work.
We also repeated this procedure using multivariate Cox models that also include known
prognostic clinical factors. First, we included known important clinical factors: low
Karnofsky performance status (KPS < 80) [130], and age > 55. This allows the prog-
nostic capability of each feature to be contextualized. The importance of these other
clinical factors have been previously established [14, 15, 86]. Next, we added tumor
grade (low grade WHO II or high grade III and IV) to age and KPS as third covariate
in the Cox model. This allowed us to evaluate the independent prognostic power of
the image features relative to the WHO grade of the tumor. For the subset analysis of
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patients with known IDH mutation status, IDH mutation status (mutant or wild-type)
is included in the multivariate analysis as well.
Finally, we attempted to validate the best prognostic image features on an independent
data set from the 2018 Brain Tumor Segmentation Challenge (BraTS). For each of the
cases with known survival and acceptable image quality we applied the optimal hazard
ratio from the WHO grade IV historical data to the BraTS cases and calculated the
hazard ratio between groups above and below the cutoff. This external data set for
validation provided a strong challenge to the prognostic power of each feature. The
results of this experiment are listed in the appendix Section A.5.1.
4.3 Results
4.3.1 Key Results
• Advanced age, low KPS, and high WHO grade are all strongly associated with
worse prognosis. These clinical factors are well established by previous neurosur-
gical literature [14, 15].
• Larger contrast enhancing volume and total visible tumor volume are associated
with poor survival. This result holds for both human drawn (known from lit-
erature) and automatically segmented (this work) tumor volumes. As expected,
larger tumor volumes confer a worse prognosis.
• Maximum contrast enhancing brightness was the single best imaging predictive
feature, with a brighter enhancement associated with worse survival. Other fea-
tures that correlated strongly with the volume of enhancing tumor were highly
prognostic as well.
• When maximum contrast enhancement was added to known clinical prognostic
factors (age, KPS, and grade) we found additional predictive information to still
be significant and additive.
• Features from synthetic pathology maps did not perform as well as maximum con-
trast enhancement although heightened cell density, proliferation, and vascularity
were still independently associated with worse prognosis.
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4.3.2 Patient Cohorts and Clinical Data Summary
Of the 6,563 total cases from 5,319 unique patients, there were 2,588 patients whose
first resection was at MD Anderson Cancer Center. Among those, 1851 had imag-
ing suitable for further analysis (Figure 4.1). Among those, 449 patients had previ-
ous surgery listed including “Biopsy-burr hole” (n=2), “Biopsy-stereotactic” (n=160),
“Biopsy-open” (n=57), “Biopsy-NOS” (n=210), “shunt” (n=4), “Resection” (n=3),
“Other” (n=13). Since a majority of patients with previous surgery had just biopsy,
we elected to include these patients in the analysis. Any cases with substantial postop-
erative changes to the brain from prior surgery were excluded during the data review
procedure. For other exclusions: 4 cases were listed as having no imaging and 18 listed
as CT imaging only. No additional filtering is applied based on histology to exclude
diagnoses like pilocytic astrocytoma, gliosarcoma, etc. although these histologies were
rare. The actual histologic diagnoses of the patients are tallied in Table 4.6.
Among the remaining candidate cases, patients were included or excluded based on the
available of MR imaging. Additional cases with pediatric patients, WHO grade 0 (i.e. no
grade), or WHO grade I tumors were included in image processing but excluded from this
survival analysis. A summary of exclusions is given in Figure 4.1. Clinical characteristics
of the resulting 1181 patients with preoperative imaging that also passed data review
and were subsequently included in survival analysis are summarized in Table 4.5. As
expected, patients with higher grade tumors tend to be older, have a decreased rate of
IDH1 mutation, and have larger preoperative tumor volume.













II 207 40 ± 12 121/86 90 91/12 37.16 NA
III 246 43 ± 14 135/111 90 59/24 47.25 498
IV 728 59 ± 13 446/282 90 16/201 72.64 71
Table 4.5: Clinical data summary for all 1181 preoperative cases. IDH1 mutation
status is listed for cases where IDH1 mutation status was explicitly mentioned in the
clinical record. Median overall survival (OS) was not reached for the WHO II group.
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II III IV
Anaplastic Astrocytoma 86 163 0
Oligodendroglioma 91 61 0
Mixed Oligoastrocytoma 14 19 0
Glioblastoma 0 0 712
NOS 5 0 0
Other 11 3 16
Table 4.6: Histologic diagnoses by WHO grade for all patients. The histologic grades
are mostly consistent with the 2012 WHO grading scale. NOS=Not otherwise specified.
4.3.3 Clinical Factors, Tumor Volume, and Survival
Several clinical factors are known to be strongly associated with overall survival including
age, mental status (KPS), and high clinical tumor grade (III or IV). Our data showed this
relationship as well and the hazard ratios are given in Table 4.7 for all cases combined.
The results for each subset of WHO grade are listed in Table A.2, Table A.3, and
Table A.4. These factors serve as the benchmark for the prognostic value of imaging
biomarkers and compare well with published values. Landmark publications by Sawaya
and colleagues analyzed a very similar population (though only Grade IV disease), from
our same institution [14, 15].
HR CI p
KPS < 70 2.142 [1.824, 2.515] 1.41e-20 ***
Age > 55 2.664 [2.264, 3.134] 3.43e-32 ***
Grade WHO III+ 4.251 [3.057, 5.912] 7.70e-18 ***
Table 4.7: Multivariate cox proportional hazards model hazard ratios and significance
for all cases using only clinical factors that strongly influence survival. Confidence
intervals are 95%
One simple image-based survival correlate from literature is tumor volume. Optimal
stratifications are shown in Figure 4.3 for automatic measurements of T1 enhancing
and T2 FLAIR lesion volumes. In the combined patient cohort with all grades, all
tumor volume measurements show significant survival differences, see Figure 3.11. Note,
these automatic volume measurements agree very well with reference measurements as
described in Section 3.3.5. The univariate and multivariate survival stratification based
on tumor volumes are listed in Table 4.8 and the same analysis for each subset of WHO
grades are given in Table A.5, Table A.6, and Table A.7. Note, for WHO II and III cases
there are not enough tumors with and without enhancement to perform a meaningful
survival analysis.
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Figure 4.3: Survival curves with an optimized cutoff based on preoperative tumor
volume. Left: survival stratified by T1 enhancing volume Right: Survival stratified by
total T2 visible tumor volume. p-values from log-rank test.
Univariate Multivariate (age+KPS) Multivariate (age+KPS+grade)
CLARA EV > 5.27 2.117 [1.721, 2.603] 1.21e-12 *** 1.701 [1.378, 2.100] 7.57e-07 *** 1.582 [1.281, 1.955] 2.11e-05 ***
CLARA WT > 35.80 1.830 [1.530, 2.188] 3.50e-11 *** 1.574 [1.312, 1.888] 9.98e-07 *** 1.389 [1.158, 1.668] 4.11e-04 ***
Table 4.8: Cox proportional hazards model hazard ratios and significance for tumor
volumes, multivariate ratios include controls for age, KPS and grade. EV = enhancing
volume, WT = whole tumor
4.3.4 Survival Based on Preoperative Image Features
To investigate relationships between image features, clinical data, and survival we use
the C-index, Cox proportional hazard models, and the Kaplan-Meier method [141].
First, we removed features with Spearman rank correlation greater than 0.8 with either
total tumor volume or enhancing volume. Without this step, most of the best features
are simply reproducing the prognostic effect of tumor volume. Mutual correlations
between some selected features are shown in Figure 4.4. For the remaining features
in Table 4.3 we identified the ones with the greatest univariate cross-validated hazard
ratio for each image type in Table 4.9. In addition to the C-index, we identified the
optimal threshold value for each feature using predicted high- and low-risk patients
from the 10-fold cross-validation. To find the optimal threshold we searched over the
possible values to find the greatest (or smallest) hazard ratio with a (log-rank) significant
survival difference between the groups. A minimum group size of 20% is enforced to avoid
spurious thresholds.
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The following paragraphs describe in detail the single best feature (by hazard ratio) for
each image and synthetic pathology map type. Shape features are considered as their
own “image” type. The results reported in this section are over the combined cohort of
all WHO grades (II, III, and IV). The corresponding results for individual grade subsets
are listed in the appendix, Section A.4.2
Panel A: Univariate analysis
IS Univariate
image region feature C Cut HR 95% CI p
TC wholetumor IntensityAtVolume100 0.681 1.61 5.097 [3.93, 6.61] 1e-33 ***
CD wholetumor IntensityAtVolume10 0.662 7.68e+03 4.209 [3.33, 5.33] 7e-32 ***
- enhanc VoxelVolume 0.642 0.786 3.479 [2.75, 4.40] 3e-24 ***
ERG enhanc IntensityAtVolume10 0.593 3.82 2.936 [2.36, 3.65] 3e-21 ***
Ki67 enhanc IntensityAtVolume10 0.635 13.7 2.645 [2.27, 3.09] 4e-34 ***
T2 enhanc IntensityAtVolume10 0.615 0.623 2.385 [1.93, 2.95] 7e-15 ***
T1 wholetumor Median 0.573 0.74 2.027 [1.64, 2.50] 2e-10 ***
FL enhanc Maximum 0.596 3.55 1.835 [1.56, 2.16] 1e-12 ***
GR higher Maximum3DDiameter 0.591 43.1 1.424 [1.22, 1.66] 1e-05 ***
Panel B: Multivariate analysis
Multivariate (age+KPS) Multivariate (age+KPS+grade)
image region feature HR 95% CI p HR 95% CI p
TC wholetumor IntensityAtVolume100 3.549 [2.72, 4.63] 1e-20 *** 2.777 [2.12, 3.64] 1e-13 ***
CD wholetumor IntensityAtVolume10 2.909 [2.28, 3.71] 7e-18 *** 2.274 [1.78, 2.91] 7e-11 ***
- enhanc VoxelVolume 0.642 [1.92, 3.12] 4e-13 *** 1.923 [1.50, 2.46] 2e-07 ***
ERG enhanc IntensityAtVolume10 2.151 [1.72, 2.69] 2e-11 *** 1.741 [1.39, 2.18] 2e-06 ***
Ki67 enhanc IntensityAtVolume10 1.650 [1.40, 1.95] 4e-09 *** 1.339 [1.13, 1.58] 6e-04 ***
T2 enhanc IntensityAtVolume10 1.807 [1.45, 2.25] 1e-07 *** 1.559 [1.25, 1.94] 7e-05 ***
T1 wholetumor Median 1.643 [1.33, 2.03] 5e-06 *** 1.598 [1.29, 1.98] 2e-05 ***
FL enhanc Maximum 1.453 [1.23, 1.72] 1e-05 *** 1.333 [1.13, 1.57] 7e-04 ***
GR higher Maximum3DDiameter 1.219 [1.04, 1.42] 1e-02 * 1.106 [0.95, 1.29] 2e-01
Table 4.9: Best image features from each image type among patients with all WHO
grades (II III IV) in terms of univariate hazard ratio. For each feature, the concordance
index (C) is listed alongside hazard ratios between high-risk and low-risk groups using
an optimized threshold. The same threshold is used for the univariate (Panel A) and
multivariate (Panel B) models. p-values are listed along with significance levels (0 ***
0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for
multiple comparisons.
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Figure 4.4: Visualization of the correlation matrix between the features with largest
hazard ratios, Table 4.9. Individual Pearson correlations are listed as percentages (i.e.
85 instead of 0.85). The mutual correlations are reduced since we only select features
which are correlates less than 0.8 with enhancing or total tumor volume.
TC: Maximum T1 Enhanced Intensity A stabilized maximum intensity of >1.624
on T1 contrast enhanced images using a whole tumor volume of interest is a poor prog-
nostic indicator with a univariate hazard ratio of 5.305, Figure 4.5. This was the largest
univariate hazard ratio observed among all image features. The maximum contrast
enhanced intensity (with 0.1 cc volume constraint) also had the strongest overall corre-
lation with survival (C = 0.681). Furthermore, we found good stability of the optimal
cutoff value with a standard deviation of just 0.034 (2%). The in-sample cutoff of 1.61
falls less than one standard deviation from the mean cross-validated cutoff of 1.624,
showing good generalization. Figure 4.5 visually shows this good agreement between
the in-sample survival cutoff for high risk/low risk cases and the 10 individual cutoffs
from cross-validation since the pooled across folds predictions line up almost exactly
with the in-sample predictions.
The survival difference remained significant in multivariate analysis with age and KPS
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taken into account, although the hazard ratio was reduced to 3.55. This is a large
survival difference, exceeding in magnitude that of age or KPS, but still smaller than
the comparable hazard ratio for high WHO grade of 4.25 (Table 4.7). Multivariate
analysis accounting for tumor grade and contrast enhancement at the same time, showed
the hazard ratio for high maximum TC to decrease somewhat to 2.78. However, the
relation is still significant indicating that the contrast enhancement adds prognostic
value even after tumor grade information is taken into account.
The strong performance on maximum contrast enhancement is not surprising because
enhancement is a hallmark characteristic of high-grade gliomas and these high-grade
gliomas have much worse prognosis. However, the max TC feature captures more than
just the presence of contrast enhancement, it provides a threshold for the maximum
brightness of the enhancement at about 1.6 times the brightness white mater relative to
CSF.
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Figure 4.5: Best feature for stratifying survival for WHO grades II, III, and IV cases
for TC image. Transparent blue curves are the predictions from each of the 10 folds
of cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
Cell Density: Maximum Cell Density Maximum cell density >7680 nuclei/mm2
over the visible tumor volume was a strong indicator of poor prognosis with a univariate
hazard ratio of 4.209, Figure 4.6. The maximum feature was stabilized by enforcing
a 0.01 cm3 volume constraint. Maximum cell density also showed a high concordance
with survival (C = 0.662), which is comparable to the best overall feature from con-
trast enhancement, Table 4.9. The optimal threshold was incredibly stable in cross-
validation with only one patient switching between high and low risk groups between
cross-validation and in-sample results.
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The large hazard ratio of 4.2 was moderated by the inclusion of clinical factors age and
KPS which reduced the independent hazard ratio to 2.91 while maintaining statistical
significance. This multivariate hazard ratio is larger than both age and KPS (2.66, 2.14)
which suggests maximum cellularity may be a stronger prognostic factor than these
clinical covariates. It is, however, still smaller than the effect of WHO grade with a
hazard ratio of 4.25. When max CD and high WHO grade are considered together, CD
still maintains an independent hazard ratio of 2.27, comparable to age and KPS. So,
maximum cellularity clearly represents independent prognostic information.
Heightened cellular density (CD) is caused by tumor growth constrained by brain anatomy
as well as infiltration into surrounding normal brain. This feature essentially measures
the maximum cellularity inside the visible tumor lesion. As previously mentioned, this
heightened cellularity is a hallmark of highly malignant tumor hence the large hazard
ratio between groups. Interestingly however, the effect was not quite as strong as is seen
with contrast enhancement (Table 4.9) despite the two being 0.85 rank correlated.
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Figure 4.6: Best feature for stratifying survival for WHO grades II, III, and IV cases
using the estimated cell density map. Transparent blue curves are the predictions
from each of the 10 folds of cross-validation. Solid blue curves are the pooled cross-
validation predictions. Black curves are in-sample survival predictions. Ideally, the
cross-validation and in-sample predictions coincide perfectly and appear superimposed.
Bottom: Histogram of the feature values with the in-sample cutoff value shown with a
black line.
Shape: Enhancing Tumor Volume The best shape feature was the volume of the
enhancing tumor region >0.786 cm3 which indicated a worse prognosis with univari-
ate hazard ratio of 3.48, Figure 4.7. The small cutoff near zero means this feature is
essentially detecting the presence or absence of contrast enhancement. We saw a high
concordance index of C = 0.642 and a very stable optimal cutoff value. The in-sample
value of 0.786 was nearly identical to the mean of the cross-validated thresholds at 0.788
(standard deviation 0.007). In Figure 4.7 the in-sample and cross-validated survival
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curves are indistinguishable meaning there was effectively no overfitting.
In binarized cross-validation, hazard ratio was 3.48 between groups. This generally
agrees with the tumor volume analysis (Table 4.8). But, the cross-validated hazard
ratio of 3.48 is much larger than the in-sample hazard ratio of 2.11 in Table 4.8. This
is likely because of the difference in volumes being measured. In order to compare
to reference values, the CLARA segmented enhancing volume in Table 4.8 combined
enhancing and non-enhancing labels as described in Table 3.15. However, the enhancing
voxel volume image feature in Table 4.9 counts only the enhancing label shown in blue
in Figure 3.7. Note that the prognostic information in the enhancing tumor volume is
more predictive of survival than the total tumor volume.
The univariate hazard ratio for enhancing volume was reduced by the multivariate in-
clusion of age and KPS, falling to 2.45. This put in on approximately equal footing with
age and KPS (hazard ratios 2.7 and 2.1 respectively) but still much smaller than the
hazard ratio of 4.3 for WHO grade. In multivariate analysis accounting for grade and
presence of contrast enhancement, we still found an independent hazard ratio of 1.92,
which supports enhancing volume as an independent predictor. Similarly to the previ-
ously mentioned max TC feature, these results make sense due to the known importance
of contrast enhancement. While Max TC is a measure of enhancing brightness, this fea-
ture captures its presence or absence which can indicate fundamental differences in the
tumor vasculature. The presence of a biologic “switch” for angiogenesis is well known
for gliomas, and is the biologic feature that corresponds most closely higher grade and
poor prognosis [145].
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Figure 4.7: Best shape feature for stratifying survival for WHO grades II, III, and
IV cases. Transparent blue curves are the predictions from each of the 10 folds of
cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
ERG: Maximum ERG Expression Similar to the cell density and Ki67, we found
a maximum ERG expression (> 3.82 % positive area) in the enhancing tumor sub-region
to be a negative prognostic factor with a univariate hazard ratio of 2.96. This is lower
than the best features based on contrast enhancement and cell density with hazard ratios
> 4 but still very considerable, Figure 4.8.
The maximum ERG (with 0.01 cm3) constraint had a C-index of 0.593 which was com-
parable to many of the other features in Table 4.9. The optimal threshold of 3.82 was
also very stable under cross-validation as evidenced by almost perfectly superimposed
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survival curves in Figure 4.8. The univariate hazard ratio was reduced in multivariate
modeling with age and KPS to 2.15, although statistical significance was retained. This
means a fair portion of the information is redundant with these clinical factors. The
hazard was reduced further by the inclusion of age, KPS, and high WHO grade to 1.74.
Again, there is some overlap between maximum ERG and WHO grade, but nonetheless
it retains significance as an independent prognostic factor.
It makes intuitive sense that ERG expression, related to vascularity, would correlate
with prognosis. High grade gliomas tend to have increased vascular recruitment and
angiogenesis as part of their aggressive profiles. Interestingly however, the univariate
hazard ratio for maximum ERG is not as large as for contrast enhancement which is
based on tissue vascular permeability. The overall correlation is also fairly small at
just 0.37 (Figure 4.4). It may be the case that the presence of vascular proliferation
measured by ERG is not generally sufficient to create the leaky vasculature necessary for
contrast extravasation. Overall though, the 0.1 cc max ERG intensity showed significant
prognostic value relative to age, KPS, and grade with a multivariate hazard ratio of 1.74.
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Figure 4.8: Best feature for stratifying survival for WHO grades II, III, and IV cases
for the estimated ERG map. Transparent blue curves are the predictions from each of
the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation predic-
tions. Black curves are in-sample survival predictions. Ideally, the cross-validation and
in-sample predictions coincide perfectly and appear superimposed. Bottom: Histogram
of the feature values with the in-sample cutoff value shown with a black line.
Ki67: Maximum Ki67 Expression We found estimated Ki67 >13.7% in the en-
hancing tumor sub-region was associated with poor prognosis and a univariate hazard
ratio of 2.65. The C-index for max Ki67 (0.01 cm3 volume) was fairly high at 0.635 and
the optimal threshold was stable under cross-validation having a standard deviation of
just 0.6 percentage points. The optimal threshold also falls nicely around the center
of the data set with 45% of the data in the high-risk category and 55% in the low-risk
category, Figure 4.9.
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With the inclusion of age and KPS, the hazard ratio between groups was reduced con-
siderably to 1.65 although it retained statistical significance. This suggests that the
highly proliferative tumors may preferentially occur in older patients or correlate with
deteriorating mental status. Including WHO grade only reduced the multivariate hazard
ratio a small amount to 1.34, which was still significant. Interestingly, the multivariate
hazard ratio for the Ki67 feature was smaller than the multivariate ratios for T2 and T1
features which had smaller univariate hazard ratios.
The correlation with clinical factors makes sense based on the fact that older patients
tend to present with IDH wild-type high-grade tumors which are more aggressive (prolif-
erative) than the IDH mutant counterparts. So, clinical factors have more overlap with
the effect of proliferation. Overall though, this focal measure of proliferation indeed
represented an independent prognostic factor. However, note that even small pockets
of about 0.01 cc of highly proliferative tissue could indicate poorer prognosis, which is
expected given that heightened proliferation is a hallmark of aggressive disease [13, 30].
Chapter 4. Preoperative Imaging-Pathologic Estimators of Survival 119
Figure 4.9: Best feature for stratifying survival for WHO grades II, III, and IV cases
for the estimated Ki67 map. Transparent blue curves are the predictions from each of
the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation predic-
tions. Black curves are in-sample survival predictions. Ideally, the cross-validation and
in-sample predictions coincide perfectly and appear superimposed. Bottom: Histogram
of the feature values with the in-sample cutoff value shown with a black line.
T2: Maximum T2-Weighted Intensity The best T2-weighted image feature was
the maximum intensity over the enhancing tumor sub-region. A value of 0.623 or greater
was associated with a worse prognosis with univariate hazard ratio 2.39, Figure 4.10.
This was a smaller hazard ratio than the best features from Ki67, CD, and ERG which
suggests there may be less prognostic information than is contained in the synthetic
pathology maps. Nonetheless, we observed a good concordance index of 0.615 for maxi-
mum (0.01 cm3 constraint) as well as excellent generalization. The cross-validated cutoff
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values were 0.624 ± 0.003 and the in-sample optimal cutoff was 0.623. Again, the sur-
vival curves in Figure 4.10 show indistinguishable in-sample and cross-validated survival
curves.
The difference in survival remained significant with age and KPS accounted for in mul-
tivariate modeling. The hazard ratio for high max T2 decreased to 1.81, making it less
prognostic than age and KPS which have hazard ratios > 2. With tumor grade also
accounted for, the hazard ratio only slightly decreased to 1.56 and retained significance
which again suggests that the T2w image adds independent prognostic information to
tumor grade.
This feature is similar to the best overall feature of 0.1 cc TC intensity as it represents
maximum intensity within a sub-region of the tumor. There is a moderately high cor-
relation between these two features of 0.43 as illustrated in Figure 4.4 which suggests
some redundancy of information. Although, the 0.1 cc TC intensity picks up strongly
on the differences between enhancing and non-enhancing tumors whereas the 0.01 cc T2
intensity is more general since all gliomas generally appear T2 bright. The in-sample
optimal cutoff value around 0.62 (on a scale from modal brain intensity to CSF intensity)
suggests a maximum T2 brightness threshold for identifying highly aggressive pathology
with worse prognosis.
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Figure 4.10: Best feature for stratifying survival for WHO grades II, III, and IV cases
for T2 image. Transparent blue curves are the predictions from each of the 10 folds of
cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
FLAIR: Pointwise Maximum FLAIR Intensity The best feature based on the
FLAIR image a voxel-wise brightness inside the segmented enhancing volume > 3.55
which was associated with a worse prognosis with univariate hazard ratio of 1.84. The
intensity scale is CSF mode to brain mode so this number corresponds to a maximum
tumor intensity which is about 3.5 times as bright as the brain overall. The point-wise
maximum had a good C index of 0.596 and good agreement between the in-sample
threshold (3.548) and the mean cross-validated cutoff of 3.554. Figure 4.11 shows a very
slight separation of the in-sample and cross validated curves in the high-risk group but
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this is negligible.
Comparing point-wise maximum FLAIR alongside age and KPS moderated the hazard
ratio down to about 1.45. This was still significant but smaller than the effects of KPS
and age (hazard ratios 2.7 and 2.1). Further inclusion of tumor grade in the multivariate
model alongside age, KPS, and max FLAIR pushed the hazard ratio down just a little
more to 1.33. This effect was still significant and so the max FLAIR does indeed provide
independent information to tumor grade.
This feature can be interpreted much in the same way as the T2 intensity: representing a
focal T2-weighted hyperintensity. Interestingly though, the rank correlation between the
maximum FLAIR intensity and 0.01 cc T2 intensity is very small at 0.16 (Figure 4.4).
This might be due to instability in the point-wise maximum feature.
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Figure 4.11: Best feature for stratifying survival for WHO grades II, III, and IV cases
for FLAIR image. Transparent blue curves are the predictions from each of the 10 folds
of cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
T1: Median T1-Weighted Pre-Contrast Intensity The median T1 pre-contrast
brightness over the whole tumor volume of interest was the best performing feature
from the T1w image. A brighter median >0.740 was associated with a worse prognosis
with univariate hazard ratio 2.037, Figure 4.12. This was slightly better than the best
FLAIR feature (HR 1.83) but lower than all the other raw image features. Concordance
between median T1 intensity and survival was more modest at 0.573, the smallest among
all features in Table 4.9. However, there was still very good generalization shown with
the cross-validated thresholds (mean 0.739) and the in-sample threshold of 0.740.
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The univariate hazard ratio of 2.04 was reduced slightly in multivariate analysis com-
pared with age and KPS to 1.64, which is smaller than the hazard ratios for KPS and
age but still considerable and significantly prognostic. Further, when grade was also in-
cluded as a covariate, the hazard ratio only decreased to 1.60 and remained significant.
This means that tumor grade does not account for much of the effect of high median T1
intensity that is not already accounted for by age and KPS.
The hazard ratios greater than 1 suggest brighter T1w intensity corresponds to worse
prognosis. This is contrary to the usual appearance of gliomas which is T1 hypo-intense.
More investigation is needed to discover what is being detected, possibly the presence of
methemoglobin or other blood products. Petechial hemorrhages are frequently apparent
in high grade gliomas on pathology. The difference in survival may be due to differences
in the various grades above and below the 0.74 threshold value. About two-thirds of
the WHO II and WHO III cases are above the threshold but nearly 87% of WHO IV
cases are above the cutoff. So, the survival difference may be due in part to separation
of the WHO IV cases. This may not have been detected by our multivariate analysis
that groups the WHO grades III and IV into a single high-grade class.
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Figure 4.12: Best feature for stratifying survival for WHO grades II, III, and IV cases
for T1 image. Transparent blue curves are the predictions from each of the 10 folds of
cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
Local Grade: Diameter of Higher-Grade Region When using a binary thresh-
old, the maximum diameter of predicted high grade disease was significantly prognostic
with a hazard ratio of 1.42 in cross-validation. This corresponded to a threshold of
43.1 mm, Figure 4.13, and a larger diameter meant worse prognosis. Although this was
the smallest univariate hazard ratio in Table 4.9, high-grade diameter had a C-index
of 0.591 which was only the second smallest and comparable to features with larger
hazard ratios like maximum ERG. There was some instability observed in the 43.1 mm
threshold though. The mean cross-validated threshold of 43.72 mm agreed with the
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in-sample of 43.12, however the standard deviation was 9.99 mm. We can also see some
overfitting in Figure 4.13 since the in-sample black curves are clearly outside the pooled
cross-validated predictions (dark blue). So, the in-sample results should be used with
caution.
Grade diameter was still prognostic in multivariate modeling with age and KPS, although
with a comparable small hazard ratio of 1.22. Interestingly but expected, higher grade
diameter was the only image feature in Table 4.9 which was not independently prognostic
when compared against high tumor grade. Being redundant with tumor grade fairly
expected since the WHO grading scale is meant to separate groups of tumors based
on whether they contain high grade disease. Overall, diameter of predicted high grade
disease was a univariate significant predictor although it did show some overfitting.
It seems to be capturing much of the same information as high WHO grade which is
expected based on its design.
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Figure 4.13: Best feature for stratifying survival for WHO grades II, III, and IV cases
for the estimated grade map. Transparent blue curves are the predictions from each of
the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation predic-
tions. Black curves are in-sample survival predictions. Ideally, the cross-validation and
in-sample predictions coincide perfectly and appear superimposed. Bottom: Histogram
of the feature values with the in-sample cutoff value shown with a black line.
Subset Analysis Overall the T1 contrast enhanced features outperform the esti-
mated pathology features. However, one case where the estimated pathology maps
performed substantially better than the raw image features was for WHO II cases. The
10th percentile of Ki67 and CD over the whole tumor provided very strong stratification
with hazard ratios of 6.28 and 10.24 respectively. See appendix Table A.8 and survival
curves in Figure A.8. The univariate p values associated with these features does not
cross the significant threshold corrected for multiple comparisons among features. How-
ever this is likely due to the small number of deaths in the low-risk group. Further
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investigation is needed to validate or confirm these interesting results.
Nonetheless this is consistent with clinical intuition that low grade tumors that have
overall higher proliferative activity of cellularity tend to be more aggressive and hence
have worse prognosis. A higher value in a low percentile means there is an overall
increase in cellularity or proliferative activity.
4.3.5 Summary
In summary, the results using predicted pathology maps are similar to the results using
raw image features. However, the best features are the ones that correlate with contrast
enhancing volume. This confirms that the biology of enhancement (angiogenesis as
measured by enhancement) outweighs the biology of proliferation (CD and Ki67) in
terms of prognostic significance, and is consistent with the clinical evolution of low to
higher grade disease observed in some patients. Contrast enhanced features were highly
significant across the whole population. Features derived from cell density were highly
prognostic across as well and showed some promise among WHO II cases. This is likely
because the pathology estimate maps synthesize the complementary information in the
raw images themselves.
4.4 Discussion
We retrospectively examined 1181 untreated glioma patients from MD Anderson Can-
cer Center and evaluated the prognostic stratification of imaging biomarkers. We found
several simple image metrics that provided strong survival stratification, even when ac-
counting for differing preoperative demographics. Specifically, we found the best prog-
nostic stratification among all patients had a hazard ratio of 5.10 (multivariate 2.77)
using the 0.1 cc TC intensity over the whole tumor. This is likely due to the enhancing
characteristics between high versus low grade tumors which explains the drop in hazard
ratio in the multivariate analysis. For WHO grade II cases, the 10th percentile of whole
tumor estimated cell density showed an impressive hazard ratio of 10.2 (multivariate
10.8) which far exceeds the best hazard ratio of 4.592 using maximum T2 brightness.
Unfortunately, statistical significance was not reached.
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We attempted to validate the survival biomarker predictions using cases from the MIC-
CAI Brain Tumor Segmentation Challenge (Section A.5.1). This data set is widely
used to benchmark tumor segmentation algorithms and imaging biomarkers. Although,
historically the survival prediction task has been very difficult [103]. Unfortunately,
we found that the optimal thresholds on prognostic image features trained on the his-
torical data generally failed to validate on the BraTS data. This could be due to a
variety of reasons: First, while the BraTS data was processed similarly to the historical
data, it was provided already co-registered and skull stripped which might have been
performed slightly differently. Also, we extracted features from the provided “ground-
truth” segmentations instead of the automatically segmented ROIs from CLARA. While
all segmentations were acceptable, the manual versus automatic segmentation procedure
might have systematically affected the image features.
Overall, our work confirms the established relationships between clinical factors and
survival. In general, patients who are older, have more symptoms at presentation, and
have IDH wild-type tumors have a poorer prognosis [14, 15]. An exception is for WHO
II cases, where the effect of age is less prominent. However, this may simply be due to
the fact that patients with low grade tumors tend to be younger (Table 4.5).
Some previous studies in the neurosurgical literature have examined enhancement bright-
ness and survival. Lacroix et al. measured “enhancement grade” in glioblastoma as the
relative brightness of contrast enhancement on T1w images [14]. The grades are low
signal intensity, high signal intensity, and signal intensity equal to fat. Only the high-
est grade was significantly associated with survival (univariate) in untreated patients.
This is analogous to the maximum T1 enhancing intensity or the 0.1 cc intensity fea-
ture, which we also found to be a strong significant predictor of overall survival in the
combined patient cohort.
There is a large body of work examining correlation between image features in glioma,
especially glioblastoma, and survival. In general, the “radiomics” field follows the same
methodology we employ here [35, 36, 146]. Namely, image processing, feature extraction,
and a search over al features for candidate biomarkers. More recently, these features
have incorporated into survival predicting models. Bae et al. used a random survival
forest trained on several intensity, shape, and texture features to predict progression
free and overall survival in 217 glioblastoma patients [147]. However, the complexity of
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the features needed and incremental results shows the need for continued research [148].
Another addition to radiomics is the use of “deep” features based on neural network
features. Lao et al. computed nearly 100,000 such features and found a substantial
stratification in survival among 112 total patients [149]. The authors employed a LASSO,
which uses L1 and L2 regularization on the cox partial likelihood to perform joint variable
selection and model training. In this work, we focused on the prognostic ability of
individual features, choosing to improve the quality of our building blocks, rather than
adding to the complexity of nonlinear feature combinations. Estimated pathology maps
already combine multiple sources of information in the same way models like LASSO
can use features from multiple MR contrasts.
Perhaps the most similar work to our synthetic pathology estimates is one study by Li
et al. who used radiomic features to predict high and low Ki67 expression (±10%) in
WHO II and III tumors [150]. They found that the strongest radiographic correlate
with high Ki67 was spherical disproportion and a multivariate hazard ratio of 2.37 for
high Ki67. Note: they used the actual Ki67 not the Ki67 as predicted by a model.
4.4.1 Limitations
Our preoperative survival analysis is subject to a few common limitations of such studies.
First, we had no control over the specific imaging sequences used in the historical data.
This is in contrast to the tightly controlled research protocol used to generate data
in Chapter 2. While intensity normalization handles much of the variability in image
contrast due to different scanners and acquisition parameters, the question of the true
accuracy of models estimating proliferation, grade, CD, and ERG on the retrospective
data is not entirely answered.
Next, we were only able to acquire ground truth IDH mutation status data for around
25% of the cases analyzed. This is primarily because IDH1 status was not routinely
collected before 2015. A similar problem precluded gathering other key molecular factors
like 1p19q co-deletion, MGMT methylation, P53, or ATRX mutations [13, 87, 135].
Molecular factors including IDH1 have become extremely important to the diagnosis
and prognosis of glioma patients [20] and not having detailed information is a limitation.
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4.4.2 Future work
Future work primarily includes expanding the scope of biomarkers to include higher-
order texture or deep filter features which may contain additional information. Further-
more, imaging like diffusion-weighted imaging and T2* weighted images were curated
as part of Chapter 3 but the image features were not analyzed against survival. In
addition, it may be beneficial to continue exploring the interaction between features
from different MR contrasts, for instance mean T2w intensity and max T1C intensity
together. Although, this adds considerable complexity to the analysis.
Additionally, it may be useful to further subset the patients based on histologic diagnosis
or other clinical features which define significant subpopulations. This includes removing
patients with NOS or ”other” histologic diagnoses in Table 4.6. For now, the analysis is
carried out stratifying on WHO grade only with the various subgroups like astrocytoma
and oligodendroglioma merged together.
Chapter 5
Biologically Based Extent of
Resection
5.1 Introduction
Biomarkers from Chapter 4 show that preoperative quantitative image measurements
can identify subsets of patients with differences in baseline risk. This is consistent with
the underlying radiomics hypothesis that imaging captures tumor characteristics and
heterogeneity that reflect the underlying biology. We explicitly modeled this relationship
by predicting the underlying tumor biology via synthetic pathology maps. This allowed
us to focus in low-complexity intensity and shape features rather than rely on obscure
texture or deep filter features to find meaningful prognostic stratification. Furthermore,
using simplified features like mean or maximum intensity makes the resulting biomarkers
clearly actionable. For example, maximum proliferation being unfavorable suggests that
removing the highly proliferative disease with surgery would be beneficial. Beyond
peroperative biomarkers, postoperative and extent of resection (EOR) features present
a paradigm to evaluate and potentially guide therapy.
The goal of this chapter is to define and evaluate postoperative image features and extent
of resection based on the difference, or “delta” between postoperative and preoperative
features. By doing so, we reinforce the prognostic value of image features by showing
that they reflect prognosis at more than just the time of diagnosis. Additionally, this
improves our understanding of how surgical resection interacts with the heterogeneous
132
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nature of gliomas. As of now, maximal resection is recommended for all glioma patients
but is often not possible due to the risk of neurological deficits [41]. It is unclear how
the characteristics of residual disease factor into the likelihood of recurrence or death
and this complicates decision making during treatment. Furthermore, extent of resection
using radiographic findings is poorly defined and inconsistent in its evaluation [151, 152].
Using quantitative image features will help disambiguate this evaluation.
Established literature on extent of resection focuses on removal of contrast enhancement.
The benefit of gross total resection (GTR) has been overwhelmingly confirmed by ob-
servational and retrospective studies, especially for Glioblastoma [14, 15, 41, 151, 152].
However, there is still no consensus on what constitutes GTR, even for quantitative
studies measuring percentage of enhancing tumor removed [152]. Recent evidence has
pointed to no difference in benefit from GTR within molecular subgroups of glioma [139].
This suggests that the variance in GTR definitions is not due to differences in effective-
ness on different populations, but instead points to a need for a better, clearer, definition
of extent of resection.
5.1.1 Summary of Analysis
This chapter examines the prognostic effect of radiographic and histologic heterogeneity
in the context of surgical resection. Given the results in Chapter 4 that indeed show MR
image features hold prognostic information, we now approach a new hypothesis: Changes
in image features measured before and after surgery inform survival differences for glioma
patients. These “delta features” provide new potential definitions for extent of resection.
Furthermore, we expect to find that features quantifying changes in disease burden as
estimated from graphical pathology maps will provide better extent of resection measures
than raw image features alone.
In this chapter, we collected and processed postoperative data for a large portion of
the patients in Chapter 4. The methods for data curation are mostly the same with
the addition of a deep learning segmentation model for excluding postoperative cavities.
Using the matched preoperative and postoperative data, we first evaluated the postop-
erative features in the same way as preoperative features. Then, we evaluated the delta
features to examine the impact of surgery. We evaluated these postoperative imaging
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features and EOR features in the same way as the preoperative features: using the C-
index and proportional hazards model. This includes both univariate and multivariate
Cox modeling with age KPS, and grade as covariates. For clarity, we focus on the most
prognostic feature for each image type (T1, T2, T1C, FLAIR) and estimated pathology
map (Ki67, CD, ERG, local grade) over the combined cohort. Alongside the feature
analysis we also recreate the classical extent of resection (EOR) measurements based on
contrast enhancement in order to compare with known values from literature. This is
analogous to tumor volume comparisons from Chapter 4 in the sense that it illustrates
how the large-scale feature analysis includes these established results as a subset.
For preoperative features, a larger feature value is generally associated with worse prog-
nosis so hazard ratios were reported using the below-cutoff group as a reference. When
measuring extent of resection, the opposite is the case: A larger value (greater delta
between pre- and post-resection) corresponds to a better prognosis. Thus, the hazard
ratios reported in this section are made > 1 by using the above-cutoff group as the
reference.
5.2 Methods
5.2.1 Patient Cohorts and Data
Among the 1380 with preoperative imaging suitable for analysis, 1271 (92%) also had
immediate postoperative imaging (within 72 hours) available which allowed measure-
ment of extent of resection. The proportions of WHO grades for these patients were
roughly the same as the preoperative data with 241 WHO II gliomas, 256 WHO III,
and 774 WHO IV cases. Overall, the postoperative imaging data was of slightly lower
quality and fewer high-resolution sequences were available. This is primarily because the
purpose of immediate postoperative imaging is to identify any residual enhancing tumor
volume and screen for complications like intracerebral hemorrhage or cerebrospinal fluid
leaks [153]. Having recently received craniotomy, these patients are also less tolerant to
the long scan times needed for high-resolution imaging and often cannot be aligned per-
fectly in the bore of the scanner. These issues led to increased rates of motion artifacts
and more difficult image registrations.
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5.2.2 Definitions and Mathematical Description of Extent of Resection
The individual features in Section 4.2.2 define disease burdens in terms of the under-
lying image (e.g. Volume of T2-FLAIR or Maximum Ki67). An illustration of what
EOR captures is illustrated in Figure 5.1. Comparing preoperative (PRE) and postop-
erative (POST) features for the same patient gives rise to two ways to quantify extent
of resection (EOR) as a difference in features. For each feature in Section 4.2.2, we
independently calculated the values on the preoperative and postoperative images using
their own set of labeled regions. Then we computed the difference of feature values
either as a difference or a fraction of the preoperative value.
Reduction: XPREL −XPOSTL (5.1)
Fractional Reduction:
XPREL −XPOSTL∣∣XPREL ∣∣ (5.2)
Where XPREL and X
POST
L are real numbers corresponding a feature listed in Table 4.3,
for some fixed image type and region type, on preoperative and postoperative images
respectively. The absolute value in the denominator of Equation 5.2 ensures that a
greater resection corresponds to a reduction in image feature regardless of sign. In total,
1256 such delta features were extracted. These EOR features are labeled with either
EORreduc- to notate the signed reduction in feature or EORfrac- to denote fractional
reduction. For example: EORreduc-VoxelVolume enhanc is the difference of the preop-
erative contrast enhanced volume and postoperative contrast enhanced volume.
These definitions serve as a logical extension of clinical EOR measurements. Any EOR
feature that provided significant risk stratification naturally gives rise to a definition of
gross total resection (GTR) and subtotal resection (STR). Clinically, GTR is defined
using 98% - 100% of contrast enhancing volume removed [14, 15]. This corresponds
to a fractional reduction (Equation 5.2) of the voxel volume feature measured over the
enhancing tumor region.
Note, because the preoperative and postoperative images occupied different physical
spaces, the voxel values of the images themselves were not directly compared. Each
study (preop and postop) also had its own set of labels for brain, tumor, enhancement,
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Figure 5.1: Estimated Ki67 maps on preoperative and postoperative imaging overlaid
on a T1w contrast enhanced image. The high Ki67 areas on the preoperative image have
been removed by surgery and a resection cavity is seen. We hypothesized that surgical
removal of high-proliferative activity areas would lead to improved survival. The images
shown are of the same patient at roughly the same axial location but appear differently
due to slice orientation.
etc. Furthermore, these definitions of EOR features do not take into account locality of
the image characteristics. For example, a reduction in maximum intensity may be using
voxel values that correspond to different anatomical locations in the brain on preoper-
ative and postoperative imaging. Therefore a lot of these features, especially fractional
reductions, often took on negative values. Since we are searching specifically for mean-
ingful and interpretable EOR measures, in survival analysis we excluded features that
have optimal EOR thresholds less than 0 or show increased overall survival with de-
creasing EOR feature values. These cases were likely caused by instability in the image
features and are not biologically meaningful.
5.2.3 Curation of Postoperative Data
Postoperative images were processed using the same data processing pipeline in Sec-
tion 3.2.3. The tumor segmentation step was modified for postoperative data to exclude
the resection cavity from the residual disease segmentation. The NVIDIA CLARA model
was trained to identify gliomas on preoperative using the Brain Tumor Segmentation
Challenge data. So, the training data did not contain postoperative changes. In practice,
we saw that the model almost always segmented postoperative changes, including the
resection cavity, as non-enhancing tumor and gave unacceptable residual disease segmen-
tations. As a solution, we trained a small U-net based deep learning model to roughly
segment out the postoperative cavity. We then subtracted the cavity mask from the
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tumor segmentation. An example is shown in Figure 5.2. Normal tissue segmentation
is performed over brain mask minus any voxels identified as either tumor or resection
cavity.
5.2.3.1 Resection Cavity Segmentation Model
The resection cavity segmentation model utilized a modified ”pocket” version of the
widely used DenseNet architecture [154, 155]. DenseNet uses convolution blocks ar-
ranged in down sampling and an up sampling paths. Each path has either four max-
pooling or four transposed convolution layers. A channel-wise concatenation operation
links each layer in the down sampling and up sampling paths. The blocks consist of
two densely connected convolutions followed by point-wise convolution. Each convolu-
tion is followed by rectified linear unit (ReLU) activation. However, instead of using a
standard DenseNet, where the number of feature maps doubles at each downsampling
layer, we used a modified DenseNet where the number of feature maps was kept constant
throughout the network. This modification reduced the computational footprint of the
model while also retaining segmentation performance.
The dataset used for training the model contained 64 patients, where each patient has a
set of T1, T2, T1C, and FLAIR images. Segmentation masks were manually drawn by a
neuroimaging researcher (1 year experience) using ITK-SNAP [156]. Of the 64 patients,
15 came from publicly available datasets (BraTS 2013 [34], Ivy GAP, TCGA-GBM, and
TCGA-LGG [59]), and the remaining 49 were curated from internal a sample of the
historical patients analyzed in this study. For pre-processing, each image was resampled
to an isotropic voxel resolution of 1x1x1 mm3, zero-padded to size 240x240x160, and
normalized using z-score intensity normalization. We trained on 80% of the images and
use the excluded 20% as a validation set. After training the model to convergence, the
mean validation Dice score was roughly 0.80. The model was implemented in Python
using the Keras toolkit (version 2.1.6-tf) and trained on an NVIDIA Quadro RTX 6000
GPU.
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Figure 5.2: T2-weighted postoperative image and illustration of residual disease seg-
mentation. CLARA (top right) provides a segmentation of residual tumor that also
falsely segments the resection cavity as disease. A custom-made U-net identifies the
postoperative cavity (bottom right) and the cavity is subtracted from the tumor segmen-
tation to more accurately label the residual volume (bottom right). Red: non-enhancing
tumor, yellow: enhancing tumor, green: edema, blue: resection cavity.
5.2.4 Survival Analysis
Survival analysis of postoperative and extent of resection (EOR) features followed the
same methodology as the preoperative features, Section 4.2.3. In short, we evaluated
the C-index and optimal binary threshold for each feature in both univariate and mul-
tivariate (age, KPS, WHO grade) analyses. As before, we applied some basic filtering
on the features as well. First, any features highly correlated (Spearman > 0.8) with
postoperative enhancing volume, total residual volume, or reduction in tumor volume
were removed, except the enhancing and total volume features themselves. We also re-
moved features that were undefined or missing for more than 25% of the cases in a given
patient cohort. These were almost exclusively 1 cc and 10 cc Intensity Volume features
that are undefined if the given sub-region is less than 1 or 10 cc respectively. Lastly, we
also filtered out features that showed unrealistic correlations with survival due to the
unstable nature of some EOR features. These features had EOR thresholds less than
zero or had greater extent of resection conferring a worse prognosis. This allowed our
search for the best features to identify the most useful and independently prognostic
candidates.
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5.3 Results
5.3.1 Key Results
• Reduction in enhancing volume, measured manually or automatically, led to im-
provement in survival. For patents with total resection of enhancement, reduc-
tion in automatically segmented T2-FLAIR volume also showed survival benefit
in high-grade (WHO IV) cases with hazard ratio 1.42. This is consistent with
literature [14, 15].
• Postoperative image features from raw images were significantly associated with
survival independent of clinical factors whereas features from synthetic pathology
measurements were generally not.
• EOR features based on estimated biological heterogeneity of cell density was more
prognostically significant than raw-image based features. Reduction in overall cel-
lularity gave a univariate hazard ratio of 1.9, which is larger than the conventional
measure based on contrast enhancement at a hazard ratio 1.7.
• Further investigation is necessary to validate these findings due to the large amount
of treatment effect on postoperative data.
5.3.2 Patient Data Summary
Among 1271 patients with paired preoperative and postoperative imaging, 811 had pro-
cessed imaging that passed both preoperative and postoperative review. A greater pro-
portion of the postoperative data failed the review procedure due to image quality issues.
Specifics are given in Section 3.3: Table 3.10 and Table 3.11. Among the cases in the
final cohort, 564 had a high-resolution 3D T1 post-contrast or FLAIR image used as a
fixed image. The remainder used lower-resolution T2 weighted or FLAIR images. Sum-
maries of the clinical data and tumor histologies included in the final analysis are given
in Table 5.1 and Table 5.2.
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Grade N Age (mean
± sd)





II 144 40 ± 13 86/58 90.00 63/8 8.96
III 164 43 ± 13 89/75 90.00 44/17 12.70
IV 502 59 ± 12 307/195 90.00 9/148 22.89
Table 5.1: Clinical data summary for all cases with preoperative and postoperative
imaging. IDH1 mutation status is listed for cases where IDH1 mutation status was
explicitly mentioned in the clinical record.
II III IV
Anaplastic Astrocytoma 62 106 0
Oligodendroglioma 63 45 0
Mixed Oligoastrocytoma 8 11 0
Glioblastoma 0 0 491
NOS 3 0 0
Other 8 2 12
Table 5.2: Histologic diagnoses by WHO grade for all patients with preoperative and
postoperative imaging. NOS=Not otherwise specified.
5.3.3 Survival Based on Postoperative Image Features
After removing features that were strongly correlated with postoperative tumor volume
or postoperative enhancing volume (Spearman r > 0.8), several image features were
significantly associated with survival. Table 5.3 shows the features from each image
type with the highest highest hazard ratio between binarized groups. These methods
are described fully in Section 4.2.3. On the postoperative imaging several features from
local pathology estimates were significantly associated with survival although the results
were not as strong as the raw image features. The results reported in this section are
over the combined cohort of all WHO grades (II III IV). The corresponding results for
individual grade subsets are listed in the appendix, Section A.4.3.
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Panel A: Univariate analysis
IS Univariate
image region feature C Cut HR 95% CI p
T1 enhanc 10Percentile 0.590 0.343 2.120 [1.63, 2.76] 3e-07 ***
FL edema 10Percentile 0.578 1.28 1.781 [1.48, 2.14] 2e-08 ***
- wholetumor VoxelVolume 0.613 66.3 1.753 [1.45, 2.12] 1e-07
TC wholetumor IntensityAtVolume1000 0.584 1.43 1.657 [1.36, 2.02] 5e-06 ***
T2 wholetumor IntensityAtVolume1000 0.554 0.545 1.614 [1.25, 2.09] 1e-03 **
ERG enhanc Maximum 0.522 4 1.523 [1.20, 1.93] 2e-03 **
CD wholetumor IntensityAtVolume1000 0.569 6.34e+03 1.506 [1.19, 1.91] 2e-03 **
Ki67 nonenh TotalSum 0.557 1.74e+04 1.403 [1.17, 1.68] 1e-03 **
GR higher Maximum3DDiameter 0.575 61.5 1.290 [1.05, 1.58] 3e-02 *
Panel B: Multivariate analysis
Multivariate (age+KPS) Multivariate (age+KPS+grade)
image region feature HR 95% CI p HR 95% CI p
T1 enhanc 10Percentile 1.838 [1.41, 2.40] 7e-06 *** 1.728 [1.33, 2.25] 5e-05 ***
FL edema 10Percentile 1.482 [1.23, 1.78] 3e-05 *** 1.473 [1.23, 1.77] 4e-05 ***
- wholetumor VoxelVolume 1.439 [1.19, 1.75] 2e-04 *** 1.289 [1.06, 1.56] 1e-02 *
TC wholetumor IntensityAtVolume1000 1.359 [1.11, 1.66] 3e-03 ** 1.240 [1.01, 1.52] 4e-02 *
T2 wholetumor IntensityAtVolume1000 1.377 [1.06, 1.78] 2e-02 * 1.352 [1.04, 1.75] 2e-02 *
ERG enhanc Maximum 1.170 [0.92, 1.49] 2e-01 1.112 [0.87, 1.42] 4e-01
CD wholetumor IntensityAtVolume1000 1.255 [0.99, 1.59] 6e-02 . 1.136 [0.89, 1.44] 3e-01
Ki67 nonenh TotalSum 1.130 [0.94, 1.36] 2e-01 1.108 [0.92, 1.33] 3e-01
GR higher Maximum3DDiameter 1.084 [0.88, 1.33] 4e-01 1.031 [0.84, 1.27] 8e-01
Table 5.3: Best postoperative image features from each image type among patients
with all WHO grades (II III IV) in terms of univariate hazard ratio. For each feature,
the concordance index (C) is listed alongside hazard ratios between high-risk and low-
risk groups using an optimized threshold. The same threshold is used for the univariate
(Panel A) and multivariate (Panel B) models. p-values are listed along with significance
levels (0 *** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is
corrected for multiple comparisons. IS = in sample.
T1: Overall T1-Weighted Pre-Contrast Brightness A 10th percentile intensity
>0.343 over the enhancing sub-region on a T1-weighted pre contrast image was associ-
ated with a worse prognosis and univariate hazard ratio of 2.120. Having a higher 10th
percentile means that the region is overall brighter and almost entirely above the 0.343
cutoff. This feature had a reasonable concordance with survival at 0.590 and had a very
stable optimal cutoff value (Figure 5.3) with the in-sample and mean cross-validated
cutoffs differing by just 0.001.
When preoperative age and KPS are taken into account alongside bright T1, the hazard
ratio was reduce somewhat to 1.838. This is slightly smaller than the HR for age and
KPS (> 2) and much smaller than the preoperative HR for WHO Grade (>3) but still
remained significant. Furthermore, when high WHO grade (III/IV) was also used as
a covariate the hazard ratio only decreased slightly to 1.728. This is larger than the
hazard ratio of 1.55 for tumor volume EOR (Table 5.6). So, not only is there is quite a
bit of independent prognostic information present in the postoperative imaging relative
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to tumor grade, the postoperative T1 brightness may be more prognostic than just
reduction in tumor volume. Interestingly, the relation between the threshold >0.343
and worse prognosis suggests that brighter T1 pre-contrast values correspond to worse
prognosis which is opposite clinical intuition. It is possible that the feature is detecting
bright treatment effect or blood products that happen to correlate with prognosis as
well. Although, the optimal cutoff (Figure 5.3) is about 0.35 on the scale from CSF to
brain mode so it is still in the hypo-intense range.
Figure 5.3: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for T1 image. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
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FLAIR: Overall Edema Brightness The 10th percentile FLAIR intensity over the
edema region being greater than 1.28 was associated with worse prognosis with univariate
hazard ratio 1.781, Figure 5.4. Like the T1w feature, this feature effectively captures
the overall brightness and the threshold indicates that postoperative peritumoral edema
more than about 28% brighter than the rest of the brain confers a poor prognosis. This
feature had a moderate C-index of 0.578 which is comparable to the rest of the rest
of the postoperative features. Figure 5.4 shows possible a small amount of overfitting
by in-sample results since the black in-sample curves are clearly outside the blue cross-
validated curves. However, there is still good agreement in the cutoff values and hazard
ratios which are on the order of 1% different.
Like other features, the hazard ratio was reduced some to 1.482 in multivariate analysis
taking into account age and preoperative KPS. This means the effect is smaller than age
and KPS but still remains significant. The multivariate hazard ratio is also quite similar
to the multivariate hazard ratio for reduction in tumor volume (1.55, Table 5.6). This
suggests that the brightness of edema on FLAIR imaging may be similarly prognostic.
This result makes sense because brighter FLAIR intensity is suggestive of residual tumor.
The same patients with extensive resections in terms of volume are also likely to have less
FLAIR hyperinteisity. Also note, the FLAIR image performed better than the base T2w
image possibly due to better suppressing some treatment effects that could confound the
feature measurements.
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Figure 5.4: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for FLAIR image. Transparent blue curves are the predictions from each of
the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation predic-
tions. Black curves are in-sample survival predictions. Ideally, the cross-validation and
in-sample predictions coincide perfectly and appear superimposed. Bottom: Histogram
of the feature values with the in-sample cutoff value shown with a black line.
Shape: Total Residual Volume The best postoperative shape feature was the
volume of the residual visible tumor edema. A volume >66.3 cm3 was associated with a
univariate hazard ratio of 1.753, Figure 5.5. Among all the postoperative features, this
one had the highest C-index of 0.613. However, we did observe some overfitting, shown
in Figure 5.5 by the separation of black and blue survival curves. This just means the
in-sample hazard ratio of 2.03 may be overly optimistic, and the true optimal cutoff may
be closer to the average cross-validated value of 60.3 cm3.
However, the postoperative residual volume remained significant in relation to age and
Chapter 5. Biologically Based Extent of Resection 145
KPS with a slightly reduced hazard ratio of 1.44 (smaller than either age or KPS them-
selves). The hazard ratio was only reduced slightly with further comparison to tumor
grade, having a final significant multivariate hazard ratio of 1.29. This is smaller than
the comparable hazard ratio based on reduction in tumor volume (1.55) which sug-
gests that the information contained in the postoperative volume alone is not enough
to encompass the full prognosis. Nonetheless, it did provide significant and independent
information to age, KPS, and grade. Overall this feature makes sense as a prognos-
tic indicator based on the extensive literature studying extent of resection in terms of
radiographically visible tumor [14, 15].
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Figure 5.5: Best postoperative shape feature for stratifying survival for WHO grades
II, III, and IV. Transparent blue curves are the predictions from each of the 10 folds
of cross-validation. Solid blue curves are the pooled cross-validation predictions. Black
curves are in-sample survival predictions. Ideally, the cross-validation and in-sample
predictions coincide perfectly and appear superimposed. Bottom: Histogram of the
feature values with the in-sample cutoff value shown with a black line.
TC: Maximum Contrast Enhanced Intensity Similarly to the preoperative re-
sults, we found the most prognostic contrast enhanced postoperative image feature to
be the standardized (1 cc) maximum intensity over a whole tumor VOI. A value greater
than 1.4 was associated with a worse prognosis and hazard ratio of 1.657, Figure 5.6.
The concordance (C-index) between max postoperative TC and survival was still good
at 0.584 and the optimal cutoff showed good stability in cross-validation analysis with
a standard deviation of just 0.006.
The hazard ratio remained significant in multivariate analysis against age and KPS and
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reduced slightly to 1.36 which was similar to other postoperative features. When tumor
grade was included as a covariate the maximum postoperative enhancing intensity still
remained significant with a hazard ratio of just 1.24. This is much smaller than the
comparable hazard ratios for any of the clinical factors including reduction in tumor
volume.
It is worth noting that this feature is only defined for cases with at least 1 cc of residual
enhancing volume as a consequence of the feature definition (and to de-noise the more
complex postoperative imaging, where small areas of T1 hyperintensity and enhance-
ment are frequently seen, and difficult to interpret). This means patients without any
residual enhancement were excluded from the calculation of hazard ratios and C-index,
so the interpretation of the 1 cc T1C should be taken with caution. However, the re-
sult is consistent with the preoperative results in Section 4.3.4 where the best survival
stratification between thresholded groups was achieved using the 0.1 cc T1C intensity.
On the preoperative data the hazard ratio was much larger (5.1, Table 4.9) which may
be due to the better preoperative image quality or the presence of treatment effect on
postoperative imaging. Further investigation to exclude treatment effect and quantify
true enhancing behavior should identify similar results to the preoperative case.
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Figure 5.6: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for TC image. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
T2: Maximum T2-Weighted intensity The best postoperative T2-weighted im-
age feature was the same feature for the postoperative contrast enhanced image: the
maximum intensity in the whole tumor VOI. Patients with a maximum intensity >0.545
had a worse prognosis with hazard ratio 1.614, Figure 5.7, which was the smallest post-
operative hazard ratio among the raw image types. This threshold corresponds to a
brightness about half-way between normal brain and CSF. The 1 cc T2w intensity over
the residual tumor had a moderate C-index of 0.554 but we observed excellent stability
of the optimal threshold value, recovering 0.545 both in-sample and in cross-validation.
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When compared against age and KPS the relationship between maximum postoperative
T2w intensity and survival remained significant with a hazard ratio of 1.377 and was
nearly unchanged with the inclusion of grade (HR 1.35). This may be due to the fact that
gliomas of all grades are T2 hyperintense so there is little redundant information provided
by grade. This supports the use of max T2 intensity as an independent prognostic factor
with a slightly smaller hazard ratio than whole-tumor extent of resection. However, the
same caveat as the TC results still holds, the 1 cc volume constraint means the feature is
only defined for patients with 1 cc or more of residual tumor. But, this is almost always
the case.
Large T2-weighted brightness makes clear sense as a prognostic factor since T2 brightness
is a standard radiographic finding. Brighter T2 intensity likely signals malignant or
active tumor compared to more moderate signal from edema or treatment related effects.
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Figure 5.7: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for T2 image. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
ERG: Maximum ERG Expression Patients with maximum postoperative ERG
>4.00% in the residual enhancing sub-region had worse prognosis with a univariate
hazard ratio of 1.523, Figure 5.8, which was the highest among the synthetic pathology
features. Despite good generalization of the optimal threshold and univariate hazard
ratio, the C-index with survival was only moderate at 0.554.
Unlike the raw image features, the maximum ERG was not significant compared against
age and KPS (or grade). This may be due to the already smaller hazard ratio in univari-
ate analysis that is redundant with other clinical factors. We expected maximum ERG
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to be prognostic because ERG is a vascularity marker and angiogenic tumor with com-
promised blood-brain-barrier tends to be contrast enhancing. However, we know that
enhancing subregion measurements on the postoperative data are potentially unreliable
due to treatment effect. This may have weakened the ability to detect pockets of vas-
cular tissue. Although, this postoperative result is still consistent with the preoperative
results where the best performing ERG feature (maximum within enhancing subregion)
was associated with a univariate hazard ratio of 2.94.
Figure 5.8: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for ERG map. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
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Cell Density: Maximum Cell Density The best postoperative feature for cel-
lularity was the maximum (with 1 cm3 constraint) over the whole tumor VOI at a
threshold of 6343 nuclei/mm2. This was a smaller threshold than the preoperative data
of 7680 nuclei/mm2 which makes sense because the overall cellularity of these tumor has
been reduced by surgery. A maximum cell density >6343 nuclei/mm2 was associated
with a worse prognosis and univariate hazard ratio of 1.506 and C-index of 0.569. The
threshold and hazard ratio was stable between in-sample and cross-validation as shown
in Figure 5.9.
Like the other simulated pathology estimates, the maximum cell density was not inde-
pendently prognostic of age and KPS (or grade). This is surprising since the preoperative
maximum cell density had some of the best performance among all features. We can
attribute the lack of multivariate significance to either confounding of the cell density
estimates by postoperative treatment effect or to redundancy with the clinical factors.
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Figure 5.9: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for CD map. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
Ki67: Proliferation-Weighted Non-Enhancing Volume For estimated prolifer-
ation (Ki67), the best feature by hazard ratio was the total sum of Ki67 over residual
non-enhancing tumor core, which can be interpreted as weighting the voxels in the resid-
ual non-enhancing tumor by their Ki67 expression. A value > 1740 was associated with
a worse survival and univariate hazard ratio of 1.403, Figure 5.10. The concordance with
survival was modest at 0.557 however the stability in cross-validation was very good as
shown by overlap of black and blue curves in Figure 5.10.
Again, we observed that the sum of Ki67 was not prognostic when compared to clinical
Chapter 5. Biologically Based Extent of Resection 154
factors age, KPS, and grade. We expected to find that residual proliferating tumor (or
its summation) would be a crucial prognostic factor. After all, dividing tumor cells are
what lead to recurrence after treatment. However, we found only univariate significant
results based on the postoperative measurements alone. Like cell density measurements,
one explanation may be confounding by postoperative treatment effect.
Figure 5.10: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for Ki67 map. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
Local Grade: Diameter of Higher-Grade Region The largest hazard ratio
among local grade features was the maximum diameter (i.e. size) of estimated higher
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grade disease. However, the relation was non-significant even in univariate analysis.
One reason may be due to instability in the 3D diameter feature which does not en-
force the distance be between contiguous points. For example, a complete resection
with just two small pieces of residual high grade can have a very large diameter if they
are separated spatially. This is less likely to happen in the preoperative case where the
tumor is one contiguous unit. Indeed we found the diameter of high grade disease was
strongly univariate significant (HR 1.42) on the preoperative data. For completeness,
the cross-validated survival curves are shown in Figure 5.11.
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Figure 5.11: Best postoperative feature for stratifying survival for WHO grades II, III,
and IV cases for grade map. Transparent blue curves are the predictions from each of the
10 folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Note: the survival
difference from this feature was non-significant after multiple comparison correction.
Bottom: Histogram of the feature values with the in-sample cutoff value shown with a
black line.
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Subset Analysis Like the preoperative results, we found that estimated pathology
performed markedly better on the subset of WHO II cases (appendix Table A.11). How-
ever, the median CD values over the edema sub-region had so few events in the low-risk
category that the hazard ratio could not be meaningfully estimated. This shows the
potential to use Median CD as a powerful biomarker for detecting long term survivors
after surgery in the low-grade subset based on the survival curves in Figure A.14 even
though statistical significance was not reached. Similarly, the maximum ERG in the
edema subregion had an impressive point-estimate of hazard ratio of 7.2 but did not
achieve statistical significance. Survival curves are shown in the appendix Figure A.14.
5.3.4 Clinical Extent of Resection
Several studies have examined extent of tumor resection for glioma patients using conven-
tional radiographic findings. In particular, fractional reduction of contrast enhancement
and T2-FLAIR abnormality. We replicated this analysis using the segmented tumor
volumes and measured the volume EOR (Equation 5.2). For comparison, we also ana-
lyzed the reference EOR measurements provided alongside clinical data. These results
are similar given the agreement between segmented and reference tumor volumes in
Figure 3.11.
Lacroix et al [14] found that extent of resection of T1 enhancing volume was still a
significant prognostic factor in a multivariate cox model after controlling for advanced
age (greater than 55 years) and low preoperative performance status (KPS). Specifically,
for grade IV tumors they found a hazard ratio of 1.4 associated with removal of 98% or
more of enhancing volume. We duplicated this analysis, subset on our Grade IV cases,
and computed the EOR measurements done by the software algorithm (Table 5.4).
We found the optimal cut-off threshold using the segmented result to be 93% with a
univariate hazard ratio of 1.66. Figure 5.12 shows survival curves for cases above and
below the 93% EOR threshold. In multivariate analysis with preoperative age and KPS
included, the hazard ratio was decreased slightly to 1.42, Table 5.4. In summary, we were
able to duplicate the results from Lacroix et al [14], using a machine based segmentation
approach, giving us confidence in the algorithm. The hazard ratios of 1.7 (multivariate
1.4) serve as benchmark values to compare the effectiveness of postoperative and EOR
image features on the high grade subset. Features that achieve comparable or greater
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hazard ratios potentially have a stronger prognostic effect than the traditional extent of
resection measure based on contrast enhancement.
We also looked at the effect of contrast enhanced EOR for the combined subset. The
optimal threshold was also 93% corresponding to a hazard ratio of 0.812 for gross-
total resection. The corresponding multivariate analysis against age, KPS, and grade
is given in Table 5.5 and surprisingly shows EOR based on T1C as non-significant in
the combined cohort. We also evaluated reduction in overall tumor volume based on
T2-FLAIR size. A reduction of 67% or more in total tumor volume was significantly
associated with survival in univariate analysis (HR = 2.0) and multivariate analysis (HR
= 1.55) against age, KPS, and grade, Table 5.6. This value of 1.55 is a benchmark to
compare the prognostic power of postoperative features.
HR CI p
KPS < 70 1.526 [1.231, 1.892] 1.18e-04 ***
Age > 55 1.831 [1.445, 2.321] 5.55e-07 ***
T1C EOR < 93% 1.420 [1.073, 1.880] 1.42e-02 *
Table 5.4: Multivariate Cox proportional hazards model for WHO IV cases using
CLARA segmented enhancing volume EOR measurements and clinical factors that
strongly influence survival. Confidence intervals are 95%
HR CI p
KPS < 70 1.879 [1.514, 2.332] 1.01e-08 ***
Age > 55 2.678 [2.139, 3.352] 8.05e-18 ***
WHO III/IV 3.511 [2.295, 5.371] 7.10e-09 ***
T1C EOR < 93% 1.232 [0.963, 1.576] 9.75e-02 .
Table 5.5: Multivariate Cox proportional hazards model for all WHO grades (II III
IV) cases using CLARA segmented enhancing volume EOR measurements and clinical
factors that strongly influence survival. Confidence intervals are 95%
HR CI p
KPS < 70 1.861 [1.500, 2.309] 1.67e-08 ***
Age > 55 2.582 [2.062, 3.233] 1.38e-16 ***
WHO III/IV 3.521 [2.302, 5.385] 6.41e-09 ***
T2 EOR < 67% 1.551 [1.154, 2.084] 3.63e-03 **
Table 5.6: Multivariate Cox proportional hazards model for all WHO grades (II III
IV) cases using CLARA segmented total tumor volume EOR measurements and clinical
factors that strongly influence survival. Confidence intervals are 95%
This study of extent of resection by Lacroix et al. [14] was further extended by Li
et al. [15] by evaluating extent of resection of FLAIR hyperintensity in addition to
enhancing volume. The main result was that resection 53.2% of the T2-FLAIR volume
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in addition to 100% of enhancing volume conferred a survival benefit. We attempted
to reproduce this result, but with some adjustments. Very few high grade cases have
identically zero enhancing volume segmented, so the total resection requirement of 100%
enhancement removed was relaxed. For the T2-FLAIR analysis, we used the subset of
patients with enhancing volume resection >93%: the GTR threshold in Table 5.4. The
effect of further FLAIR resection is shown in Figure 5.13. We found an optimal threshold
of 75% resection of T2-FLAIR volume in addition to total resection of enhancing volume
led to a significant survival difference.
Figure 5.12: Survival curves for WHO IV cases based on extent of resection for T1
enhancing volume. Left: using automatically segmented tumor volumes. Right: using
reference values. The cutoffs are selected to optimize the hazard ratio between groups.
(p-value from log-rank test)
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Figure 5.13: Survival curves based on T2 FLAIR resection for WHO IV cases with
complete resection of enhancing volume. Left: using automatic volume measurements.
Right: using reference values. Interestingly, the literature value is not reproduced. Note
that the patient populations in each plot are not necessarily the same.
5.3.5 Extent of Resection Based on Image Features
The survival analysis proceeded in the same way as in Chapter 4 with the EOR features
in place of the preoperative image features. For each feature we computed the C-index
and optimal cross-validated threshold. Then, the prognostic information was compared
with clinical factors using multivariate cox modeling while adjusting for covariates of
age (>55 years), KPS (<80), and tumor grade. Table 5.7 lists the best feature for
each base image and synthetic pathology map. For this analysis, we excluded TotalSum
and TotalEnergy features since they all show very strong correlation with reduction in
tumor volume and we are focused on potential features that do not simply recapitu-
late this known result. Overall, we found similar results to the preoperative survival.
EOR features based on estimated pathology, especially proliferation and cell density,
showed significant cross-validated survival stratification across all glioma grades. The
results reported in this section are over the combined cohort of all WHO grades (II III
IV). The corresponding results for individual grade subsets are listed in the appendix,
Section A.4.4.
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Panel A: Univariate analysis
IS Univariate
image region feature C Cut HR 95% CI p
CD wholetumor EORfrac-10Percentile 0.535 0.205 1.894 [1.46, 2.46] 4e-05 ***
T2 wholetumor EORreduc-Median 0.577 0.233 1.861 [1.44, 2.41] 5e-05 ***
- nonenh EORfrac-VoxelVolume 0.417 0.931 1.810 [1.41, 2.32] 5e-05 ***
ERG wholetumor EORreduc-IntensityAtVolume100 0.515 0.479 1.751 [1.38, 2.23] 9e-05 ***
Ki67 wholetumor EORfrac-10Percentile 0.546 0.446 1.616 [1.29, 2.03] 4e-04 ***
FL wholetumor EORfrac-Median 0.479 0.21 1.549 [1.22, 1.96] 2e-03 **
T1 enhanc EORreduc-10Percentile 0.529 0.286 1.446 [1.15, 1.82] 7e-03 **
Panel B: Multivariate analysis
Multivariate (age+KPS) Multivariate (age+KPS+grade)
image region feature HR 95% CI p
CD wholetumor EORfrac-10Percentile 1.597 [1.23, 2.08] 5e-04 *** 1.640 [1.26, 2.13] 2e-04 ***
T2 wholetumor EORreduc-Median 1.539 [1.19, 2.00] 1e-03 ** 1.568 [1.21, 2.03] 7e-04 ***
- nonenh EORfrac-VoxelVolume 1.278 [0.99, 1.65] 6e-02 . 1.218 [0.94, 1.57] 1e-01
ERG wholetumor EORreduc-IntensityAtVolume100 1.426 [1.12, 1.82] 4e-03 ** 1.452 [1.14, 1.85] 3e-03 **
Ki67 wholetumor EORfrac-10Percentile 1.455 [1.16, 1.83] 1e-03 ** 1.574 [1.25, 1.98] 1e-04 ***
FL wholetumor EORfrac-Median 1.388 [1.10, 1.76] 6e-03 ** 1.442 [1.14, 1.83] 2e-03 **
T1 enhanc EORreduc-10Percentile 1.349 [1.07, 1.70] 1e-02 * 1.317 [1.05, 1.66] 2e-02 *
Table 5.7: Best extent of resection features from each image type among patients with
all WHO grades (II III IV) in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate
(Panel A) and multivariate (Panel B) models. Uncorrected p-values are listed along
with significance levels (0 *** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only,
significance is corrected for multiple comparisons. For local grade (GR) and T1 post-
contrast (TC) no remaining features were univariate significant so they are omitted
from the table. IS = in sample.
Cell Density: Overall Reduction in Cellularity For preoperative image features,
we found that cell density (CD) was highly prognostic for the combined cohort and
especially for low grade (WHO II) tumors. With respect to EOR, a 21% reduction in
10th percentile CD in the whole tumor ROI was also strongly prognostic with a hazard
ratio of 1.894, Figure 5.14. The 21% threshold, which was on the higher end of the
range of values observed in the cohort, was quite stable in cross-validated analysis and
we found the same average cutoff among the 10 folds and in-sample. The correlation
between reduction in 10th percentile CD and overall survival was smaller than many
other EOR features though at just 0.535.
The hazard ratio was reduced in multivariate analysis alongside age and KPS to 1.597
but remained significant. Interestingly, the hazard ratio then increased slightly to 1.640
when WHO grade was included as a covariate. This means that the reduction in overall
CD is an independent prognostic measure of prognosis relative to clinical factors and
grade. We can interpret this feature (reduction in 10th percentile CD) as a reduction
in the overall cellularity of the tumor. The 10th percentile CD is reduced when voxels
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with values greater than the 10th percentile are preferentially removed, i.e. by targeting
highly cellular regions for resection.
Figure 5.14: Best extent of resection feature for stratifying survival for WHO grades
II, III, and IV cases for CD map. Transparent blue curves are the predictions from each
of the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation pre-
dictions. Black curves are in-sample survival predictions. Ideally, the cross-validation
and in-sample predictions coincide perfectly and appear superimposed. Bottom: His-
togram of the feature values with the in-sample cutoff value shown with a black line.
T2: Reduction in Median T2-Weighted Brightness A reduction of 0.233 (on
the brain - CSF scale) in median T2-weighted image intensity was associated with a
hazard ratio of 1.861, Figure 5.15. Although the hazard ratio was slightly smaller than
the best overall EOR feature (based on CD), the C-index was slightly higher at 0.577.
We found the optimal threshold of 0.233 was very stable in cross-validation and the
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average among the 10 folds was less than 3% different from the in-sample threshold.
The survival curves in Figure 5.15 also showed good agreement.
The hazard ratio associated with reduction in median T2w intensity was reduced slightly
with the inclusion of age and KPS in multivariate analysis to 1.539, but interestingly re-
covered slightly to 1.568 when WHO grade was also included. For all models, reduction
in T2w intensity was a significant independent predictor of overall survival. The inde-
pendent hazard ratio of 1.568 is comparable to the hazard ratio for reduction in tumor
volume of 1.6. Reduction in median T2w intensity has a straightforward interpretation.
Reducing the median intensity is accomplished by preferentially reducing the bright T2w
tumor regions. This is consistent with the current practice of targeting T2-bright tumor
for resection. Indeed the histogram in Figure 5.15 shows that a majority of cases have
a reduction in median T2w intensity between 0 and 0.5.
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Figure 5.15: Best extent of resection feature for stratifying survival for WHO grades
II, III, and IV cases for T2 image. Transparent blue curves are the predictions from each
of the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation pre-
dictions. Black curves are in-sample survival predictions. Ideally, the cross-validation
and in-sample predictions coincide perfectly and appear superimposed. Bottom: His-
togram of the feature values with the in-sample cutoff value shown with a black line.
Shape: Fractional Reduction in Non-Enhancing Tumor Volume The best
EOR shape feature by hazard ratio in the combined patient data set was for fractional
reduction in non-enhancing tumor volume, Figure 5.16. We found that less than 93%
reduction in non-enhancing tumor volume was associated with a worse prognosis and
hazard ratio of 1.81. Although the 93% cutoff was quite stable in cross-validation the
survival curves in Figure 5.16 show some possible overfitting since the black and blue
curves separate slightly.
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Conventional extent of resection is based on reduction of contrast enhancement. How-
ever, we found a larger hazard ratio for non-enhancing volume reduction. This is likely
because the lower grade tumors are non-enhancing so a reduction in enhancing volume
is not measurable. The difference in survival was not significant in multivariate analysis
when controlled for age and KPS (or grade).
Figure 5.16: Best extent of resection shape feature for stratifying survival for all
WHO grades (II III IV). Transparent blue curves are the predictions from each of the 10
folds of cross-validation. Solid blue curves are the pooled cross-validation predictions.
Black curves are in-sample survival predictions. Ideally, the cross-validation and in-
sample predictions coincide perfectly and appear superimposed. Bottom: Histogram of
the feature values with the in-sample cutoff value shown with a black line.
ERG: Reduction in Maximum ERG Expression Reduction in maximum ERG
(0.1 cc constraint) over the whole-tumor VOI by less than 0.479 percentage points was
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associated with a worse prognosis and hazard ratio of 1.751, Figure 5.17. The C-index
was modest C-index at 0.515. The cutoff was identical between all 10 folds and the in-
sample which means it was extremely stable. A majority of patients had the maximum
ERG expression change by 1 percentage point or less which is why the optimal threshold
is so small.
The hazard ratio remained significant in multivariate analysis alongside age and KPS
and reduced slightly to 1.426 while remaining significant. This trend continued when
high WHO grade was also included in the multivariate model. The hazard ratio for
reduction in maximum ERG then was 1.452. This means that then small reduction in
maximum ERG by less than 0.5 percentage points is still an independent prognostic
factor to tumor grade with a comparable hazard ratio to the clinical factors.
Although the magnitude of reduction associated with the greatest hazard ratio is small,
A reduction in ERG expression can be interpreted as targeting vascular tissue which
is likely more aggressive. However, the prognostic value of the EOR feature was not
significant in multivariate analysis which means some of the effect is redundant with
preoperative mental status or advanced age. Again, these features could be detection
biologically relevant extent of resection measures or may just be picking up on differences
in tumor volume. Additional scrutiny is required.
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Figure 5.17: Best extent of resection feature for stratifying survival for all WHO
grades (II III IV) for ERG map. Transparent blue curves are the predictions from each
of the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation pre-
dictions. Black curves are in-sample survival predictions. Ideally, the cross-validation
and in-sample predictions coincide perfectly and appear superimposed. Bottom: His-
togram of the feature values with the in-sample cutoff value shown with a black line.
Ki67: Reduction in Overall Proliferation A reduction of 10th percentile esti-
mated Ki67 of less than 45% inside the whole residual tumor VOI tumor region was
associated with worse overall survival and a hazard ratio of 1.616, Figure 5.18. The
concordance with overall survival was one of the highest among EOR features as well at
0.546. The optimal cutoff showed a small amount of variability in cross-validation (stan-
dard deviation 0.040); but there was still good agreement between the average cutoff
and the in-sample value.
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Reduction in Ki67 remained significant in multivariate analysis with age and KPS in-
cluded, the multivariate hazard ratio was 1.455. With WHO grade included as well,
the hazard ratio was actually slightly higher at 1.574. This means reduction in 10th
percentile estimated Ki67 is an independent prognostic factor with a hazard ratio com-
parable to reduction in tumor volume (Table 5.6). Like the reduction in cell density,
this feature measuring reduction in the lower quantiles of Ki67 is detecting cases where
the high Ki67 tumor has been selectively removed, shifting the overall distribution of
values down. It is reasonable why this would correlate with a better prognosis since a
smaller overall proliferative activity should reduce the aggressiveness of residual tumor.
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Figure 5.18: Best extent of resection feature for stratifying survival for all WHO
grades (II III IV) for Ki67 map. Transparent blue curves are the predictions from each
of the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation pre-
dictions. Black curves are in-sample survival predictions. Ideally, the cross-validation
and in-sample predictions coincide perfectly and appear superimposed. Bottom: His-
togram of the feature values with the in-sample cutoff value shown with a black line.
FLAIR: Reduction in Median FLAIR Intensity A reduction in median FLAIR
intensity of less than 21% (on the scale CSF to WM) was associated with a worse
prognosis and a univariate hazard ratio of 1.549. This is very similar to the best EOR
feature based on T2-weighted imaging (threshold 0.23, HR 1.861) which makes sense
due to the similarity between T2-weighted and FLAIR images. Overall, there was very
good stability in the optimal threshold among folds of cross-validation and a majority
of cases had a median change of less than 50% in either direction, see the histogram in
Figure 5.19.
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Reduction in median FLAIR intensity remained an independent prognostic factor in
multivariate analysis. When age and KPS were accounted for, the hazard ratio for
reduction in median FLAIR reduced slightly to 1.388, which is comparable to the haz-
ard ratios for age and KPS themselves. When WHO grade was also included in the
covariates, the hazard ratio increased slightly back to 1.442. Overall, this means that
reduction in median FLAIR intensity if an independent prognostic factor with a hazard
ratio slightly less than the hazard ratio for reduction in tumor volume (1.6).
Reduction in median FLAIR intensity can be achieved by preferentially targeting the
high-intensity FLAIR regions. This is consistent with current surgical treatment that fo-
cuses on T2 and T2-FLAIR hyperintensity in addition to contrast enhancement. Reduc-
tion in FLAIR hyperintense volume has also been established as a favorable prognostic
indicator in high-grade gliomas [15].
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Figure 5.19: Best extent of resection feature for stratifying survival for alll WHO
grades (II III IV) cases for FLAIR image. Transparent blue curves are the predictions
from each of the 10 folds of cross-validation. Solid blue curves are the pooled cross-
validation predictions. Black curves are in-sample survival predictions. Ideally, the
cross-validation and in-sample predictions coincide perfectly and appear superimposed.
Bottom: Histogram of the feature values with the in-sample cutoff value shown with a
black line.
T1: Reduction in T1 Pre-Contrast Intensity A reduction in overall (10th per-
centile) T1 pre-contrast intensity over the enhancing sub-region by less than 0.286 (CSF
to brain scale) was associated with a worse prognosis and hazard ratio of 1.446, Fig-
ure 5.20. The C-index was reasonable at 0.529, comparable to other EOR features.
The in-sample optimal threshold of 0.286 was very stable too and equal to the mean
cross-validated threshold.
In multivariate analysis compared to age and KPS, the hazard ratio decreased slightly
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to 1.349 and remained significant. This is still comparable to the hazard ratios for age
and KPS themselves. With WHO grade included in the analysis as well, the hazard
ratio decreased minimally to 1.317 and remained significant. So, while T1 pre-contrast
intensity was still an independent prognostic factor, its effect is smaller than reduction
in bulk tumor volume (hazard ratio 1.6).
Interpretation of this feature is difficult since it measures an overall brightness of the
pre-contrast intensity over the enhancing sub-region. The change preoperative to post-
operative is also centered around zero (histogram in Figure 5.20) which means the T1
brightness was not systematically reduced on average by surgery. Further investigation
is needed to examine how the reduction in T1 brightness relates to overall survival.
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Figure 5.20: Best extent of resection feature for stratifying survival for all WHO
grades (II III IV) for T1 image. Transparent blue curves are the predictions from each
of the 10 folds of cross-validation. Solid blue curves are the pooled cross-validation pre-
dictions. Black curves are in-sample survival predictions. Ideally, the cross-validation
and in-sample predictions coincide perfectly and appear superimposed. Bottom: His-
togram of the feature values with the in-sample cutoff value shown with a black line.
Subset Analysis For WHO II subset, reduction in median cell density in the per-
itumoral edema was associated with markedly improved prognosis (hazard ratio 4.37,
Table A.14). However, statistical significant was not reached which may be due to the
low number of events in each group. For these tumors, the edema class makes a large
majority of the visible tumor since there is little to no contrast enhancement. This
means that targeting highly cellular tumor may be beneficial for these low-grade cases.
Similarly to the preoperative data, more investigation is warranted. Table A.14 also
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shows how similar features from ERG, Ki67, and predicted grade all potentially outper-
form conventional image features for this low-grade subset with results that are trending
towards multivariate significance.
5.4 Discussion
In this chapter we evaluated postoperative image features and extent of resection (EOR)
measurements based on the difference between preoperative and postoperative features.
We confirmed the existing relationships between reduction in contrast enhancing tumor
and improved survival after surgery. We also found several EOR features based on dif-
ferences (deltas) between preoperative and postoperative features were significantly as-
sociated with survival in cross-validation. For postoperative features alone, conventional
image features from T1 pre-contrast and FLAIR images showed the strongest prognostic
value. This may be simply due to the fact that treatment effect on postoperative data
adds noise to the comparable preoperative feature measurements that may otherwise
be more prognostic. However, when we computed the differences between preoperative
and postoperative features we found several features from estimated cell density maps
and T2-weighted images that correlated best with survival among the combined patient
cohort. The feature with the largest hazard ratio was a reduction in overall cellular-
ity. This is consistent with the overall hypothesis that removing high grade malignancy
(e.g. highly cellular disease) can improve prognosis. We also found some promising and
strongly prognostic postoperative and EOR features for the low-grade WHO II subset
based on cellularity but statistical significance was not achieved.
While extensive work has been done to correlate preoperative image features with sur-
vival in glioma patients, much fewer studies have looked at postoperative imaging or
compared preoperative and postoperative measurements. These sorts of analyses are
generally referred to as “delta radiomics” since they examine changes in image features
to quantify treatment. Previous studies looking at non-small cell lung cancer [157, 158],
colorectal liver metastases [159], and renal cell cancer [160] have found good correlation
between delta radiomic features and survival.
In brain, Zhang et al. used a delta-radiomics approach to differentiate progression
from radiation necrosis after radiosurgery. They found that delta radiomics features
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had increased predictive value than traditional radiomics, although they examined the
(assumed linear) difference over time after treatment rather than before and after treat-
ment [161]. A few studies have used postoperative imaging features to correlate with
survival specifically in glioblastoma patients. A recent study by Garcia-Ruiz et al. found
enhancement thickness was a significant predictor of survival in 144 glioblastoma pa-
tients [162]. The authors also found a radiomics signature composed of 12 radiomics
features (10 form texture) stratified short- and long-term survivors. Peeken et al. also
found contrast enhancing thickness and other postoperative features were predictive of
survival [163] and a large study by Ellingson et al. found a threshold of 12 ml of residual
enhancing volume was significantly associated with glioblastoma patient survival [164].
However, none of these studies examined the difference between preoperative and post-
operative features. Machine learning models have also been previously proposed to guide
surgical treatment. Rathore et al. proposed estimated maps of tumor infiltration to pre-
dict the location of recurrence [165]. They found that areas of future recurrence showed
lower T2w and T2-FLAIR intensity as well as higher T1 and T1CE intensity.
5.4.1 Limitations
One limitation of this work is the use of immediate or early postoperative imaging.
The presence of swelling, bleeding, or inflammation of brain tissues due to surgery
may manifest as treatment effects that can be mistaken for residual tumor. These
effects are maximized on early (within 48 hours) postoperative images [124, 126]. As a
consequence, tumor volume measurements using FLAIR volume overestimate the actual
residual disease [123]. We see this reflected in our data as well. One method for handling
treatment effect related to enhancement is to use T1-subtraction images [164, 166].
However this would need to be performed manually. A better alternative would be
to use intraoperative or late (weeks) postoperative imaging assess residual tumor but
each of these carries its own disadvantages. Intraoperative MRI does not have the
same resolution or variety of sequences present in diagnostic postoperative MRI and
furthermore it is only available at a select few academic centers. Late postoperative
MRI may be a better measurement but cannot be used to inform a patient’s extent of
resection immediately following surgery. Also, it is possible for some tumor recurrence
or progressing between surgery and imaging.
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Another solution to this problem would be to use deformable image registration between
preoperative and postoperative imaging. By mapping the preoperative tumor segmen-
tation to the postoperative image it is possible to see what tumor remained versus what
was removed (i.e. mapped to the operative cavity. However, this registration problem
is difficult and ill-posed due to the necessary missing correspondence of brain tissues.
Finally, we defined potential EOR measures in a way that mimics conventional measure-
ments i.e. as an absolute or fractional reduction. However, fractional reduction produces
values between 0 and 1 only for features that are strictly positive and that decrease be-
tween preoperative and postoperative measurements. Our normalization scheme based
on whole brain modal intensities and cerebrospinal fluid creates some negative image in-
tensities. This means some features like minimum intensity also take on negative values
and therefore provide extent of resection measurements greater than 1. Furthermore,
the non-linear nature of the fractional EOR mapping for values around 0 creates a po-
tentially unstable mapping between actual disease reduction and measured EOR. This
complicates survival analysis since discovered cutoff values may not be physically mean-
ingful. A solution would be to restrict analysis to only features that take on positive
values and are decrease be resection so that EOR lies in [0, 1].
Chapter 6
Discussion
The three goals of this work were to:
1. Establish the degree of correspondence between local image characteristics and
tissue pathology from biopsy samples. This also includes generation of predictive
models to map tumor biological heterogeneity using imaging.
2. Explore the impact of preoperative biological heterogeneity on survival, as pre-
dicted by our models, and compare with the information in raw image features.
3. Determine the ability for prognostic imaging predictions to be used to guide sur-
gical intervention by examining new possible definitions of extent of resection.
In Chapter 2 we found that MR imaging was strongly predictive of cellular proliferation,
cellular density, vascularity, and local grade using advanced MRI techniques. Many of
these models have already been published [49–51]. Techniques like DCE and diffusion
weighted imaging present functional physiologic data that machine learning models like
random forest can leverage to predict pathology in new patients. We also found that
reasonable predictive accuracy could be used to predict pathology using just routine MR
sequences like T1 weighted, T2 weighted, T1 post contrast, and FLAIR. These routine
sequences do not directly provide quantitative or functional information but have been
developed over the years to increase lesion conspicuity and help treat glioma patients.
So, it is not surprising that the intensity characteristics are also predictive of underlying
pathology.
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In Chapter 3 we curated a large historical data set consisting of clinical data, imaging
data, and estimated pathology mappings. This data served as the bases for survival and
extent of resection analysis. This curation effort overcomes tremendous entry barriers to
large scale image analysis. Namely, the organization and labeling of diagnostic images
from the hospital PACS system and translation into a format readily usable by research
software and feature extractors. Through this curation we not only enabled our own
analysis but provide a valuable resource to future research efforts who can use the
retrospective data to generate and explore hypotheses. We also established a robust data
review procedure to ensure that the final products of image processing were high quality.
Without this manual review, it is nearly certain that incorrect data and measurements
would be included in final analysis. This would undermine the credibility and impact of
results.
In Chapter 4 we addressed the prognostic ability of simple image features to designate
prognostic risk groups. Our cross-validated radiomics analysis confirmed the known rela-
tionships between contrast enhancement and survival. Although, we found quantitative
features based on intensity were prognostic, not just total enhancing volume. This possi-
bly suggests ways to better define enhancing tumor and target it for treatment. We also
analyzed measurements related to the predicted biological heterogeneity. Several such
features were still prognostic independently of clinical factors. For low grade (WHO II)
tumors, estimated cellularity was by far the best prognostic feature and outperformed
all the raw image features. These low-grade tumors usually have a homogenous imaging
appearance which presents no focal target for therapy. This means estimated cellularity
may be a novel way to focus treatment for these patients.
Interestingly, no single biological feature out-performed contrast enhancement. Since the
T1 contrast image is an input to the random forests that predict grade, Ki67, CD, and
ERG, we expected to see an increase in prognostic power using the model predictions.
It is possible that the random forest had insufficient training data to fully capture the
information in contrast enhancement. We admit a limitation of the biopsy training
data was that only 7 of the 52 samples were collected from contrast enhancing regions.
More training data covering a wider range of enhancement values may help fill the gap
in prognostic ability. A more detailed subset analysis, for example in non-enhancing
tumors where imaging is more ambiguous, may identify areas where estimated biology
adds additional information over raw imaging.
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In Chapter 5 we showed how postoperative image features and changes in image features
between preoperative and postoperative MRIs showed differences in survival. We found
multiple extent of resection based features that were prognostic, including the known
features like reduction in contrast enhancing volume. Using raw image features we also
discovered several other features based on T2-weighted or FLAIR images that could
be alternative extent of resection measurements. Finally, we also found that features
based on reducing overall cellularity, ERG or Ki67 were also strongly correlated with
prognosis.
It is reasonable to hypothesize that removing highly cellular, vascular, or proliferative
tumor would improve prognosis. But, this hypothesis was previously untestable since
these quantities could only be measured on tissue samples that was actually removed.
Not to mention infeasible to perform on every piece of a surgical specimen. Our models
provide a way to estimate those biological quantities throughout a glioma before and
after surgery, thus finally presenting evidence to support a hypothesis that removing
histologically malignant tumor improves survival.
To the best of our knowledge, there has been no study of preoperative vs postoperative
radiomics features in brain, likely due to the challenge of working with postoperative
data. We avoided the image registration problem by measuring features separately on
preoperative and postoperative images. However, we saw a lot of interference from
treatment effect due to the early time point of the acquisitions. Nonetheless, we found
cross-validated measures of extent of resection that significantly correlated with survival.
Several of which, like reduction in maximum intensity, could be used to guide surgical
intervention.
In summary, this thesis developed models to synthesize MR imaging into predictive
maps of tumor pathology. We validated model predictions as prognostic biomarkers and
targets for intervention. These results can be applied to prospectively guide interven-
tion, identify heightened malignancy, and provide useful information in patients where
gold-standard tissue data is otherwise unavailable. This work greatly improves our un-
derstanding of intratumoral heterogeneity and builds on familiar, well known histologic
characteristics that are interpretable and meaningful to clinicians.
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6.1 Future Work
Immediate future work can start validating predictive models in their ability to estimate
the Ki67 expression, cell density, ERG expression, and local grade of biopsy samples in
new patients. After comparing predictions to actual values, the new pathology data
could be incorporated into the training data to improve the model overall. This is a key
step towards moving these models to clinical use. Another key area of future work would
be expanding the target variables to include key genetic mutations like IDH, p53, ATRX,
and modifications like 1p19q-codeletion. Some of these are heterogeneously expressed
and would add tremendous value to our understanding of clonal evolution of gliomas.
Some work using image guided biopsies to examine genetic heterogeneity has already
been performed [167].
The extensive database of diagnostic images can be further improved in several ways.
First, there are several images that were tabulated but not analyzed including T2*-
weighted images and diffusion weighted imaging. These could be incorporated into the
feature extraction pipeline and correlated with outcomes in the same way as routine
imaging. Diffusion features were a key element of the pathology prediction models
so they will likely be strong correlates of prognosis. Second, the overall quality of
the postoperative data was lower and we had to exclude relatively more data due to
processing failures. Postoperative imaging has several treatment-related effects and
abnormalities that can confuse algorithms developed in preoperative brain images. In
particular, CLARA’s tumor segmentation model systematically overestimated tumor
volume due to treatment effect. Future work could help these algorithms by training on
postoperative imaging directly. Another option is to explicitly accounting for treatment
effect using T1-subtraction [164, 166]. Finally, annotation of postoperative data could
be avoided by using deformable image registration to the preoperative scans. This is a
particularly challenging proposition though due to the missing correspondence caused
by resection and the subsequently large deformations in the brain.
We found strong prognostic biomarkers using relatively simple first-order intensity and
shape features. This was intentional in order to produce interpretable features. Future
work could expand on the feature set by including high order texture or deep-filter
features that may capture local neighborhood information. These features have been
successfully used to develop imaging signatures in previous studies [35, 149]. In addition
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to higher-order features, more advanced predictive modeling techniques like generalized
linear models or LASSO [168] could be used to combine features together and produce
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Figure A.1: Average predicted and observed Ki67 values
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Figure A.2: Average predicted and observed ERG values
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Figure A.3: Average predicted and observed CD values
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A.2 Reference Tissue and MCSF Normalization Compar-
ison
Overall, there is a good correlation between the original NLM values (as used in [49–
51]) and the mode-CSF normalized images used in this work. See Table A.1 for the
correlations between biopsy VOI values under the two schemes. The biggest changes are
in the T1 post-contrast values, probably because they were previously normalized using
the un-reliable putamen gray matter ROIs. Figure A.4 shows the model performance in
repeated cross-validation for the old (reference tissue NLM) and new (MCSF) method.
The “old conv” values are for the NLM normalization and the MCSF values are for
the new normalization scheme. For the old scheme, only T1C SE was used and in the
new scheme there are two models depending on T1C type. The double-cluster nature
of the prediction may be artificially inflating the R2 results, however the RMSE is still
smaller which is good. Overall, the results are comparable or even better with MCSF
normalization.
image Pearson Spearman
1 T1 0.84 0.83
2 T2 0.98 0.92
3 T1C 0.81 0.76
4 FLAIR 0.90 0.89
5 T1C SPGR 0.89 0.71
6 T2* 0.86 0.86
7 SWAN 0.74 0.75
Table A.1: Correlation between NLM and Mode-CSF normalized image intensities.
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Figure A.4: Modeling results for Ki67 using the original NLM normalized and mew
brain-CSF mode normalized data. Top: R2 and RMSE values for 500 rounds of 5-
fold cross-validation. The conventional model with MCSF variables performs better
than the old conventional model but not as well as the advanced variable model. The
predicted and observed values for the three best models are shown on the bottom. The
conventional model still has a high Ki67 sample that it struggles with, limiting the R2
value.
A.3 Stereology and Normal Brain White Matter Cellular-
ity
There are several methods that could be used to estimate of normal white matter cell
density in order to impute values for virtual biopsies. An excellent review of all these
methods is written in 2016 by von Bartheld, Bahney, and Herculano-Houzel [171]
1. The isotropic fractionator method presented by Herculano-Houzel [172, 173]
determines the total number of cortical white matter nuclei present in the brain
by dissolving tissue and counting nuclei in a homogeneous sample. A disadvantage
is that tissue structure is not preserved. Azevedo et al. [174] used this method to
estimate that there are approximately 21.17 ± 2.88 billion cells in half the brain’s
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white matter. This can be combined with total white matter volume given by
Lüders [1] (0.42 ± 0.06 dm3 for the whole brain) to estimate the nuclei per unit
volume. As a note, the patient demographics were quite similar between these
references so the values are comparable. A final assumption is that the nuclei
per area as measured with a microscope will be equal to the nuclei per volume
times the section thickness. While it sounds reasonable, a better understanding of
the stereology involved and references are needed to confirm this is the case. The
isotropic fractionator method also gives uncomfortable low cell density estimates
around 403 nuclei per square mm.
2. Another method is histology. Recently a work by Roetzer [89] scanned 6 µm
coronal sections of a whole brain and measured the cell density in the white matter
directly. This is a much closer method to ours since it involves fixing, section, and
straining tissue. The cell density estimates for white matter, cortex, and tumor,
seem to agree with our measurements but again we have to assume cell density
(per area) is proportional to section thickness. Again, references are needed to
confirm this is the case.
3. Finally. stereology claims to be unbiased and uses uniform random sampling and
some basic assumptions along with Cavalieri’s principle to estimate cell numbers
in sectioned samples. The primary references for this method are by Gunderson
(1985, 1986, 1988).
Summary: much work has been done to quantify the total cell numbers in the brain
but Roetzer seems to be one of the best references for white matter cell density. A
comparison of 2D (i.e. stereology) and 3D methods is given in [179].
A.4 Survival Analysis on Individual Grade Subsets
A.4.1 Preoperative Tumor Volume
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HR CI p
KPS < 70 3.145 [1.300, 7.609] 1.10e-02 *
Age > 55 2.477 [1.130, 5.429] 2.35e-02 *
Table A.2: Multivariate cox proportional hazards model hazard ratios and significance
for grade II cases using only clinical factors that strongly influence survival. Confidence
intervals are 95%
HR CI p
KPS < 70 3.219 [1.786, 5.802] 9.99e-05 ***
Age > 55 2.638 [1.652, 4.212] 4.84e-05 ***
Table A.3: Multivariate cox proportional hazards model hazard ratios and significance
for grade III cases using only clinical factors that strongly influence survival. Confidence
intervals are 95%
HR CI p
KPS < 70 1.587 [1.343, 1.875] 5.63e-08 ***
Age > 55 1.859 [1.557, 2.219] 6.96e-12 ***
Table A.4: Multivariate cox proportional hazards model hazard ratios and significance
for grade IV cases using only clinical factors that strongly influence survival. Confidence
intervals are 95%
HR CI p multivariate HR multivariate CI multivariate p
CLARA PREVOL2 > 73.07 1.910 [0.981, 3.719] 5.71e-02 . 1.964 [1.006, 3.835] 4.80e-02 *
Table A.5: Cox proportional hazards model hazard ratios and significance for tumor
volumes among grade II cases, multivariate ratios include controls for age, and KPS
HR CI p multivariate HR multivariate CI multivariate p
CLARA PREVOL1 > 42.83 1.676 [1.051, 2.673] 3.01e-02 * 1.594 [0.975, 2.608] 6.32e-02 .
CLARA PREVOL2 > 109.17 2.302 [1.468, 3.610] 2.82e-04 *** 1.860 [1.140, 3.035] 1.30e-02 *
Table A.6: Cox proportional hazards model hazard ratios and significance for tumor
volumes among grade III cases, multivariate ratios include controls for age, and KPS
HR CI p multivariate HR multivariate CI multivariate p
CLARA PREVOL1 > 9.55 1.542 [1.260, 1.887] 2.57e-05 *** 1.421 [1.156, 1.747] 8.60e-04 ***
CLARA PREVOL2 > 110.63 0.871 [0.726, 1.045] 1.38e-01 0.771 [0.640, 0.930] 6.59e-03 **
Table A.7: Cox proportional hazards model hazard ratios and significance for tumor
volumes among grade IV cases, multivariate ratios include controls for age, and KPS
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A.4.2 Preoperative Image Features
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
CD wholetumor 10Percentile 0.594 3.51e+03 10.237 [1.41, 74.57] 2e-01 10.757 [1.47, 78.81] 2e-02 *
Ki67 wholetumor 10Percentile 0.572 1.52 6.279 [1.51, 26.06] 2e-01 6.323 [1.51, 26.43] 1e-02 *
T2 nonenh Maximum 0.585 0.758 4.592 [1.11, 19.06] 3e-01 4.818 [1.16, 20.05] 3e-02 *
T1 nonenh Maximum 0.531 1.83 4.197 [2.11, 8.34] 2e-02 * 4.521 [2.13, 9.61] 9e-05 ***
ERG nonenh RootMeanSquared 0.552 2.5 2.240 [0.87, 5.74] 3e-01 1.973 [0.76, 5.09] 2e-01
TC wholetumor Maximum 0.572 1.78 2.127 [0.98, 4.64] 3e-01 1.892 [0.86, 4.18] 1e-01
GR higher Maximum3DDiameter 0.529 52.2 1.772 [0.94, 3.36] 3e-01 1.761 [0.93, 3.34] 8e-02 .
- brainNoCSF VoxelVolume 0.500 1.24e+03 1.730 [0.76, 3.93] 4e-01 1.696 [0.74, 3.89] 2e-01
FL brainNoCSF IntensityAtVolume10 0.582 2.71 1.685 [0.82, 3.46] 4e-01 1.589 [0.77, 3.27] 2e-01
Table A.8: Best preoperative image features from each image type among patients
with WHO grade(s) II in terms of univariate hazard ratio. For each feature, the concor-
dance index (C) is listed alongside hazard ratios between high-risk and low-risk groups
using an optimized threshold. The same threshold is used for the univariate and mul-
tivariate models. Uncorrected p-values are listed along with significance levels (0 ***
0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for
multiple comparisons. IS = in sample
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
TC wholetumor IntensityAtVolume100 0.554 1.36 2.745 [1.42, 5.31] 4e-02 * 2.655 [1.37, 5.16] 4e-03 **
T1 edema Mean 0.522 0.844 2.500 [1.29, 4.84] 5e-02 . 2.702 [1.39, 5.25] 3e-03 **
Ki67 brainNoCSF 92Percentile 0.565 6.26 2.282 [1.18, 4.42] 7e-02 . 2.124 [1.08, 4.20] 3e-02 *
- wholetumor VoxelVolume 0.577 109 2.037 [1.30, 3.19] 4e-02 * 1.672 [1.03, 2.71] 4e-02 *
CD brainNoCSF Minimum 0.588 2.27e+03 2.008 [1.29, 3.13] 4e-02 * 1.949 [1.24, 3.05] 4e-03 **
FL brainNoCSF 91Percentile 0.577 1.56 1.843 [1.16, 2.93] 6e-02 . 1.692 [1.04, 2.74] 3e-02 *
T2 edema TotalSum 0.576 1.68e+04 1.809 [1.15, 2.84] 6e-02 . 1.218 [0.74, 2.02] 4e-01
ERG nonenh TotalEnergy 0.516 3.83e+05 1.771 [1.13, 2.77] 7e-02 . 1.903 [1.19, 3.04] 7e-03 **
GR higher Maximum3DDiameter 0.517 59.1 1.442 [0.90, 2.31] 3e-01 1.334 [0.82, 2.17] 2e-01
Table A.9: Best preoperative image features from each image type among patients
with WHO grade(s) III in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate and
multivariate models. Uncorrected p-values are listed along with significance levels (0
*** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected
for multiple comparisons. IS = in sample
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IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
TC wholetumor RootMeanSquared 0.572 1.07 1.825 [1.47, 2.26] 1e-05 *** 1.616 [1.30, 2.01] 1e-05 ***
T1 wholetumor 10Percentile 0.547 0.476 1.563 [1.27, 1.92] 3e-04 *** 1.479 [1.20, 1.82] 2e-04 ***
- enhanc Maximum3DDiameter 0.590 40.5 1.553 [1.28, 1.89] 2e-04 *** 1.465 [1.20, 1.79] 2e-04 ***
FL nonenh 10Percentile 0.527 0.972 1.528 [1.23, 1.90] 2e-03 ** 1.659 [1.33, 2.06] 5e-06 ***
CD brainNoCSF 98Percentile 0.513 7.07e+03 1.452 [1.17, 1.81] 6e-03 ** 1.271 [1.02, 1.59] 4e-02 *
Ki67 brainNoCSF 92Percentile 0.583 8.19 1.445 [1.23, 1.70] 2e-04 *** 1.219 [1.03, 1.45] 2e-02 *
ERG enhanc IntensityAtVolume100 0.552 3.81 1.435 [1.18, 1.74] 2e-03 ** 1.221 [1.00, 1.49] 5e-02 *
T2 enhanc Maximum 0.515 0.925 1.284 [1.05, 1.57] 4e-02 * 1.159 [0.94, 1.42] 2e-01
GR higher Maximum3DDiameter 0.535 43.8 1.128 [0.95, 1.34] 2e-01 1.043 [0.88, 1.24] 6e-01
Table A.10: Best preoperative image features from each image type among patients
with WHO grade(s) IV in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate and
multivariate models. Uncorrected p-values are listed along with significance levels (0
*** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected
for multiple comparisons. IS = in sample
Figure A.5: Best features for stratifying survival for WHO grade II cases for each
raw image type (T1, TC, T2, FLAIR)
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Figure A.6: Best features for stratifying survival for WHO grade III cases for each
raw image type (T1, TC, T2, FLAIR)
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Figure A.7: Best features for stratifying survival for WHO grade IV cases for each
raw image type (T1, TC, T2, FLAIR)
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Figure A.8: Best features for stratifying survival for WHO grade II cases for each
pathology map estimate (Ki67, CD, ERG)
Figure A.9: Best features for stratifying survival for WHO grade III cases for each
pathology map estimate (Ki67, CD, ERG)
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Figure A.10: Best features for stratifying survival for WHO grade IV cases for each
pathology map estimate (Ki67, CD, ERG)
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A.4.3 Postoperative Image Features
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
CD edema Median 0.490 4.65e+03 NA [0.00, Inf] 1e+00 NA [0.00, Inf] 1e+00
ERG edema Maximum 0.569 4.17 7.192 [1.70, 30.51] 2e-01 7.292 [1.72, 30.97] 7e-03 **
TC nonenh 91Percentile 0.542 1.64 3.191 [1.40, 7.26] 2e-01 3.334 [1.36, 8.16] 8e-03 **
- wholetumor VoxelVolume 0.666 28.8 2.723 [1.27, 5.86] 2e-01 2.735 [1.25, 5.99] 1e-02 *
Ki67 wholetumor IntensityAtVolume1000 0.603 9.31 2.664 [1.28, 5.55] 2e-01 2.602 [1.24, 5.47] 1e-02 *
T1 nonenh 91Percentile 0.525 1.38 2.075 [0.90, 4.76] 3e-01 2.042 [0.89, 4.70] 9e-02 .
GR higher Maximum3DDiameter 0.615 57.6 1.822 [0.80, 4.14] 4e-01 1.748 [0.75, 4.07] 2e-01
T2 nonenh TotalSum 0.568 2.1e+03 1.350 [0.64, 2.86] 6e-01 1.294 [0.60, 2.81] 5e-01
FL nonenh TotalEnergy 0.536 1.06e+03 1.220 [0.59, 2.54] 7e-01 1.176 [0.56, 2.49] 7e-01
Table A.11: Best postoperative image features from each image type among patients
with WHO grade(s) II in terms of univariate hazard ratio. For each feature, the concor-
dance index (C) is listed alongside hazard ratios between high-risk and low-risk groups
using an optimized threshold. The same threshold is used for the univariate and mul-
tivariate models. Uncorrected p-values are listed along with significance levels (0 ***
0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for
multiple comparisons. IS = in sample
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
FL edema 10Percentile 0.665 1.27 3.912 [2.27, 6.73] 2e-04 *** 4.106 [2.30, 7.33] 2e-06 ***
CD wholetumor 10Percentile 0.607 3.47e+03 3.211 [1.61, 6.39] 9e-03 ** 4.482 [2.15, 9.36] 6e-05 ***
T1 wholetumor IntensityAtVolume1000 0.616 1.53 2.876 [1.63, 5.08] 6e-03 ** 2.428 [1.35, 4.37] 3e-03 **
ERG edema Mean 0.563 2.02 2.265 [1.07, 4.80] 1e-01 2.532 [1.16, 5.52] 2e-02 *
TC enhanc 10Percentile 0.555 1.1 2.109 [1.22, 3.64] 3e-02 * 2.237 [1.30, 3.86] 4e-03 **
T2 nonenh Mean 0.535 0.301 2.102 [0.90, 4.91] 2e-01 2.596 [1.09, 6.20] 3e-02 *
Ki67 edema RootMeanSquared 0.538 4.87 1.980 [1.02, 3.84] 1e-01 1.907 [0.97, 3.74] 6e-02 .
- enhanc VoxelVolume 0.565 2.23 1.638 [0.96, 2.80] 2e-01 1.428 [0.83, 2.46] 2e-01
GR higher VoxelVolume 0.520 0.111 1.106 [0.62, 1.97] 8e-01 0.873 [0.48, 1.60] 7e-01
Table A.12: Best postoperative image features from each image type among patients
with WHO grade(s) III in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate and
multivariate models. Uncorrected p-values are listed along with significance levels (0
*** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected
for multiple comparisons. IS = in sample
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IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
T2 nonenh 92Percentile 0.534 0.554 1.476 [1.12, 1.94] 2e-01 1.503 [1.14, 1.98] 4e-03 **
FL enhanc IntensityAtVolume100 0.508 1.9 1.386 [1.08, 1.78] 2e-01 1.436 [1.11, 1.85] 5e-03 **
ERG enhanc IntensityAtVolume100 0.545 3.3 1.373 [1.06, 1.78] 2e-01 1.346 [1.04, 1.74] 2e-02 *
TC wholetumor 94Percentile 0.537 1.2 1.361 [1.05, 1.76] 2e-01 1.374 [1.06, 1.78] 2e-02 *
- enhanc Maximum3DDiameter 0.546 70.3 1.344 [1.06, 1.71] 2e-01 1.280 [1.00, 1.63] 5e-02 *
T1 enhanc RootMeanSquared 0.508 0.83 1.317 [1.05, 1.66] 2e-01 1.192 [0.94, 1.50] 1e-01
CD wholetumor IntensityAtVolume1000 0.548 7.09e+03 1.305 [1.03, 1.65] 2e-01 1.250 [0.99, 1.58] 6e-02 .
GR higher VoxelVolume 0.524 0.0192 1.242 [1.01, 1.52] 3e-01 1.165 [0.95, 1.43] 1e-01
Ki67 enhanc Maximum 0.510 10.3 1.217 [0.97, 1.53] 4e-01 1.153 [0.91, 1.46] 2e-01
Table A.13: Best postoperative image features from each image type among patients
with WHO grade(s) IV in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate and
multivariate models. Uncorrected p-values are listed along with significance levels (0
*** 0.001 ** 0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected
for multiple comparisons. IS = in sample
Figure A.11: Best extent of resection (EOR) measures for stratifying survival for
WHO grade II cases for each raw image type (T1, TC, T2, FLAIR)
Appendix A. Appendix A 198
Figure A.12: Best extent of resection (EOR) measures for stratifying survival for
WHO grade III cases for each raw image type (T1, TC, T2, FLAIR)
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Figure A.13: Best extent of resection (EOR) measures for stratifying survival for
WHO grade IV cases for each raw image type (T1, TC, T2, FLAIR)
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Figure A.14: Best extent of resection (EOR) measures for stratifying survival for
WHO grade II cases for each pathology map estimate (Ki67, CD, ERG)
Figure A.15: Best extent of resection (EOR) measures for stratifying survival for
WHO grade III cases for each pathology map estimate (Ki67, CD, ERG)
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Figure A.16: Best extent of resection (EOR) measures for stratifying survival for
WHO grade IV cases for each pathology map estimate (Ki67, CD, ERG)
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A.4.4 Extent of Resection
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
CD edema EORreduc-Median 0.537 504 4.374 [0.59, 32.20] 9e-01 4.478 [0.61, 33.09] 1e-01
ERG edema EORreduc-98Percentile 0.585 0.174 3.134 [0.95, 10.36] 9e-01 3.069 [0.92, 10.20] 7e-02 .
GR lower EORfrac-Maximum3DDiameter 0.492 0.0704 2.520 [0.60, 10.62] 9e-01 2.485 [0.59, 10.54] 2e-01
Ki67 edema EORfrac-98Percentile 0.595 0.0173 2.292 [1.02, 5.18] 9e-01 2.318 [1.03, 5.24] 4e-02 *
T1 wholetumor EORfrac-10Percentile 0.497 0.151 1.822 [0.78, 4.28] 9e-01 2.064 [0.84, 5.04] 1e-01
FL wholetumor EORfrac-10Percentile 0.496 0.183 1.747 [0.77, 3.95] 9e-01 1.722 [0.76, 3.91] 2e-01
T2 edema EORfrac-Mean 0.448 0.309 1.628 [0.56, 4.71] 9e-01 1.668 [0.57, 4.85] 3e-01
- edema EORfrac-Maximum3DDiameter 0.496 0.0739 1.591 [0.48, 5.29] 9e-01 1.555 [0.47, 5.19] 5e-01
Table A.14: Best EOR image features from each image type among patients with
WHO grade(s) II in terms of univariate hazard ratio. For each feature, the concordance
index (C) is listed alongside hazard ratios between high-risk and low-risk groups using
an optimized threshold. The same threshold is used for the univariate and multivariate
models. Uncorrected p-values are listed along with significance levels (0 *** 0.001 **
0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for multiple
comparisons. IS = in sample
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
CD wholetumor EORfrac-10Percentile 0.672 0.194 6.091 [2.20, 16.89] 3e-02 * 7.097 [2.52, 19.99] 2e-04 ***
ERG wholetumor EORreduc-10Percentile 0.664 0.828 5.836 [2.10, 16.18] 4e-02 * 6.224 [2.20, 17.57] 6e-04 ***
T2 edema EORreduc-Median 0.605 0.12 5.467 [1.70, 17.54] 1e-01 7.491 [2.23, 25.13] 1e-03 **
Ki67 wholetumor EORfrac-10Percentile 0.635 0.526 4.729 [1.88, 11.90] 4e-02 * 4.632 [1.82, 11.79] 1e-03 **
FL enhanc EORfrac-Median 0.575 0.321 3.526 [1.39, 8.92] 1e-01 3.250 [1.28, 8.28] 1e-02 *
- nonenh EORfrac-VoxelVolume 0.462 0.944 2.670 [1.20, 5.94] 1e-01 2.144 [0.95, 4.86] 7e-02 .
T1 enhanc EORreduc-RootMeanSquared 0.566 0.262 1.871 [0.88, 3.97] 3e-01 1.947 [0.91, 4.15] 8e-02 .
GR higher EORreduc-VoxelVolume 0.570 3.99 1.703 [0.84, 3.45] 3e-01 1.345 [0.65, 2.78] 4e-01
TC enhanc EORfrac-95Percentile 0.534 0.124 1.501 [0.87, 2.60] 3e-01 2.139 [1.16, 3.93] 1e-02 *
Table A.15: Best EOR image features from each image type among patients with
WHO grade(s) III in terms of univariate hazard ratio. For each feature, the concordance
index (C) is listed alongside hazard ratios between high-risk and low-risk groups using
an optimized threshold. The same threshold is used for the univariate and multivariate
models. Uncorrected p-values are listed along with significance levels (0 *** 0.001 **
0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for multiple
comparisons. IS = in sample
IS Univariate Multivariate (age+KPS)
image region feature C Cut HR 95% CI p HR 95% CI p
ERG edema EORfrac-IntensityAtVolume100 0.541 0.0897 1.551 [1.20, 2.00] 4e-02 * 1.550 [1.20, 2.00] 8e-04 ***
T2 enhanc EORreduc-10Percentile 0.519 0.174 1.538 [1.19, 1.98] 4e-02 * 1.478 [1.15, 1.91] 3e-03 **
- wholetumor EORfrac-VoxelVolume 0.538 0.61 1.463 [1.12, 1.90] 8e-02 . 1.305 [1.00, 1.71] 5e-02 .
Ki67 wholetumor EORreduc-10Percentile 0.525 0.695 1.435 [1.17, 1.77] 4e-02 * 1.386 [1.12, 1.71] 2e-03 **
FL edema EORfrac-98Percentile 0.527 0.107 1.423 [1.14, 1.78] 5e-02 . 1.385 [1.11, 1.73] 4e-03 **
CD edema EORfrac-10Percentile 0.518 0.107 1.318 [1.05, 1.66] 1e-01 1.276 [1.01, 1.61] 4e-02 *
GR higher EORreduc-Maximum3DDiameter 0.528 20.4 1.306 [1.05, 1.63] 1e-01 1.254 [1.01, 1.56] 4e-02 *
TC enhanc EORfrac-98Percentile 0.511 0.36 1.183 [0.96, 1.46] 3e-01 1.194 [0.97, 1.47] 9e-02 .
T1 enhanc EORreduc-94Percentile 0.500 0.16 1.128 [0.91, 1.40] 6e-01 1.063 [0.85, 1.32] 6e-01
Table A.16: Best EOR image features from each image type among patients with
WHO grade(s) IV in terms of univariate hazard ratio. For each feature, the concordance
index (C) is listed alongside hazard ratios between high-risk and low-risk groups using
an optimized threshold. The same threshold is used for the univariate and multivariate
models. Uncorrected p-values are listed along with significance levels (0 *** 0.001 **
0.01 * 0.05 . 0.1). For Univariate p-values only, significance is corrected for multiple
comparisons. IS = in sample
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Figure A.17: Best extent of resection (EOR) measures for stratifying survival for
WHO grade II cases for each raw image type (T1, TC, T2, FLAIR)
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Figure A.18: Best extent of resection (EOR) measures for stratifying survival for
WHO grade III cases for each raw image type (T1, TC, T2, FLAIR)
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Figure A.19: Best extent of resection (EOR) measures for stratifying survival for
WHO grade IV cases for each raw image type (T1, TC, T2, FLAIR)
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Figure A.20: Best extent of resection (EOR) measures for stratifying survival for
WHO grade II cases for each pathology map estimate (Ki67, CD, ERG)
Figure A.21: Best extent of resection (EOR) measures for stratifying survival for
WHO grade III cases for each pathology map estimate (Ki67, CD, ERG)
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Figure A.22: Best extent of resection (EOR) measures for stratifying survival for
WHO grade IV cases for each pathology map estimate (Ki67, CD, ERG)
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A.5 Survival Analysis on Known IDH Mutation Subset
For the cases with known IDH mutation status, we redid the multivariate survival anal-
ysis including now age, KPS, grade, and IDH mutation status. The resulting univariate
and multivariate hazard ratios are listed in the following tables: Table A.17 (preop),
Table A.18, (postop) and Table A.19 (extent of resection). The results on postoperative
generally suffered due to a lack of numbers of patients overall.
IS Univariate Multivariate (age+KPS+IDH) Multivariate (age+KPS+grade+IDH)
image region feature C Cut HR 95% CI p HR 95% CI p HR 95% CI p
TC wholetumor IntensityAtVolume10 0.706 1.81 6.185 [3.49, 10.97] 4e-09 *** 4.574 [2.55, 8.20] 3e-07 *** 2.859 [1.55, 5.28] 8e-04 ***
CD enhanc IntensityAtVolume100 0.700 7.99e+03 5.648 [3.77, 8.46] 2e-15 *** 4.084 [2.67, 6.25] 1e-10 *** 2.548 [1.61, 4.02] 6e-05 ***
Ki67 enhanc IntensityAtVolume10 0.682 13.1 3.732 [2.71, 5.15] 2e-14 *** 2.709 [1.92, 3.82] 1e-08 *** 1.833 [1.28, 2.62] 9e-04 ***
- enhanc VoxelVolume 0.616 0.645 3.197 [2.05, 4.99] 1e-06 *** 2.574 [1.63, 4.06] 5e-05 *** 1.759 [1.10, 2.81] 2e-02 *
T1 wholetumor Median 0.608 0.72 3.137 [1.97, 4.98] 5e-06 *** 2.368 [1.47, 3.81] 4e-04 *** 2.395 [1.46, 3.92] 5e-04 ***
ERG enhanc 92Percentile 0.599 3.38 2.846 [1.93, 4.20] 7e-07 *** 2.333 [1.57, 3.47] 3e-05 *** 1.870 [1.25, 2.79] 2e-03 **
FL brainNoCSF IntensityAtVolume100 0.617 2.44 2.462 [1.62, 3.75] 8e-05 *** 1.777 [1.15, 2.74] 9e-03 ** 1.571 [1.01, 2.45] 5e-02 *
T2 edema Maximum 0.606 1.2 2.447 [1.76, 3.39] 4e-07 *** 1.577 [1.12, 2.22] 9e-03 ** 1.361 [0.97, 1.90] 7e-02 .
Table A.17: Best image features from each image type among patients with WHO
grade(s) II III IV with known IDH mutation status in terms of univariate hazard ratio.
For each feature, the concordance index (C) is listed alongside hazard ratios between
high-risk and low-risk groups using an optimized threshold. The same threshold is
used for the univariate and multivariate models. No local grade features had significant
univariate hazard ratios on this subset. Uncorrected p-values are listed along with
corrected significance levels (0 *** 0.001 ** 0.01 * 0.05 . 0.1).
IS Univariate Multivariate (age+KPS+IDH) Multivariate (age+KPS+IDH+grade)
image region feature C Cut HR 95% CI p HR 95% CI p HR 95% CI p
T1 nonenh RootMeanSquared 0.587 0.721 2.353 [1.44, 3.85] 1e-02 * 2.063 [1.26, 3.39] 4e-03 ** 0.697 [0.49, 1.00] 5e-02 *
FL enhanc 91Percentile 0.577 1.8 2.038 [1.25, 3.33] 3e-02 * 1.966 [1.19, 3.24] 8e-03 ** 0.729 [0.52, 1.02] 7e-02 .
- wholetumor VoxelVolume 0.601 50.6 1.969 [1.35, 2.87] 9e-03 ** 1.233 [0.82, 1.86] 3e-01 0.846 [0.59, 1.21] 4e-01
TC enhanc 10Percentile 0.572 0.615 1.931 [1.19, 3.12] 4e-02 * 1.759 [1.09, 2.85] 2e-02 * 1.008 [0.69, 1.47] 1e+00
Table A.18: Best postoperative image features from each image type among patients
with WHO grade(s) II III IV in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate and
multivariate models. No local grade, T2, or synthetic pathology features had significant
univariate hazard ratios on this subset. Uncorrected p-values are listed along with
corrected significance levels (0 *** 0.001 ** 0.01 * 0.05 . 0.1).
IS Univariate Multivariate (age+KPS+IDH) Multivariate (age+KPS+IDH+grade)
image region feature C Cut HR 95% CI p HR 95% CI p HR 95% CI p
ERG nonenh EORreduc-IntensityAtVolume10 0.602 0.554 2.196 [1.40, 3.45] 9e-03 ** 1.643 [1.03, 2.63] 4e-02 * 1.654 [1.01, 2.70] 4e-02 *
- nonenh EORfrac-VoxelVolume 0.354 0.699 2.021 [1.40, 2.91] 3e-03 ** 1.450 [0.99, 2.12] 6e-02 . 1.255 [0.85, 1.84] 2e-01
CD wholetumor EORfrac-10Percentile 0.549 0.213 2.007 [1.25, 3.21] 4e-02 * 1.422 [0.88, 2.30] 2e-01 1.609 [0.99, 2.63] 6e-02 .
T2 nonenh EORreduc-10Percentile 0.545 0.249 1.732 [1.19, 2.51] 4e-02 * 1.577 [1.08, 2.29] 2e-02 * 1.529 [1.05, 2.23] 3e-02 *
Table A.19: Best EOR image features from each image type among patients with
WHO grade(s) II III IV in terms of univariate hazard ratio. For each feature, the
concordance index (C) is listed alongside hazard ratios between high-risk and low-risk
groups using an optimized threshold. The same threshold is used for the univariate
and multivariate models. No local grade, Ki67, CD, T1, TC, or FLAIR features had
significant univariate hazard ratios on this subset. Uncorrected p-values are listed along
with corrected significance levels (0 *** 0.001 ** 0.01 * 0.05 . 0.1).
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A.5.1 Validation on BraTS 2018 Data
Among the 163 brain tumor segmentation challenge (BraTS) cases with known survival,
147 of them passed QA with acceptable data quality. We expanded the features from
Table A.10 to include the best feature from each image type and attempted to validate
the prognostic stratification on the BraTS cases. For each feature, we tuned an optimal
cutoff on all the WHO grade IV historical cases then applied the cutoff to the BraTS
cohort to identify high risk and low-risk groups. The results are shown in Table A.20.
Surprisingly, none of the raw image features showed significant survival differences be-
tween groups for the BraTS data. For features based on predicted pathology, one fea-
ture did pass the validation: 98th percentile CD over the whole brain minus CSF. The
in-sample hazard ratio for the historical cases was 1.43 and the validated hazard ra-
tio among BraTS cases was 1.55 which is very similar. The cutoff of 7.07E3 almost
evenly divided the BraTS cases as well with 74 cases above the threshold and 89 below.,
although this was not the case for the historical data (147 cases above, 581 below cut-
off). Overall, this suggests 98th percentile whole-brain CD may be a strong prognostic
biomarker for grade IV gliomas.
feature image region Cutoff Training HR Validation HR 95% CI p
RootMeanSquared TC wholetumor 1.067e+00 1.847 1.190 [0.832, 1.702] 0.340
10Percentile T1 wholetumor 4.765e-01 1.693 1.182 [0.800, 1.746] 0.400
Maximum3DDiameter highres enhanc 4.051e+01 1.680 1.199 [0.803, 1.790] 0.375
10Percentile FL nonenh 9.716e-01 1.587 0.962 [0.572, 1.620] 0.885
98Percentile CD brainNoCSF 7.065e+03 1.432 1.547 [1.110, 2.155] 0.010 *
92Percentile Ki67 brainNoCSF 8.187e+00 1.726 1.423 [0.843, 2.400] 0.187
IntensityAtVolume100 ERG enhanc 3.810e+00 1.629 1.392 [0.897, 2.160] 0.140
Maximum T2 enhanc 9.247e-01 1.311 1.112 [0.787, 1.570] 0.547
Table A.20: Survival stratification using the in-sample cutoffs for raw image features
trained on the historical data and applied to the BraTS 2018 data. Results are for
univariate analysis. Validation HRs marked * are significantly different from 1 (log-
rank p<0.05)
A.6 Mathematical Methods
A.6.1 Proportional Hazard Model and Partial Likelihood Fitting
Here, a toy example for the Proportional Hazards model. The Cox model optimized the
partial likelihood for failure given the observations. Suppose we have a set of survival
times for n patients Xi : i = 1, ..., n and for each Xi there is an associated δi where
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δi = 1 if patient i has an event and δi = 0 if patient i is censored at time Xi. Denote the
set of covariate(s) of interest as Zi. The proportional hazard model assumed the form
of the hazard ratio




Denote the n (distinct) ordered event times t1 < ... < tn. For any time t we have R(t)
patients at risk of failure within the time interval: R(t) = {i : Xi ≥ t}. This is called
the risk set. Since the Cox model is non-parametric, its parameters only depend on the
order of the failures and not their explicit time values. The discrete failures give rise to
a set of time intervals where only one failure occurs. We seek to find the parameters
that maximize the failures occurring in that order. For every failure time Xj (note:
the number of failures ≤ n due to censoring) there is a single time interval [tj , tj+1]
that contains the failure and no other failures (since we do not allow ties). So, we can
compute the likelihood of observing this one failure in that interval:





The full partial likelihood is the product over the likelihoods for all uncensored patients.

























The maximum partial likelihood can be obtained by maximizing the log partial likelihood
to fit coefficients to the proportional hazard model.
























k=1 I(Xk ≥ Xj)Zk exp(βTZk)∑n
k=1 I(Xk ≥ Xj) exp(βTZk)
]
(A.6)
Where I(Xk ≥ Xj) is an indicator to sum over only the terms in the risk set R(Xj).
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Where wk = I(Xk ≥ Xj) exp(βTZk) is non-negative. Using Equation A.9 we can see the
information matrix is semi-positive definite and therefore logL(β) is a concave function.
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[56] G Çoban, S Mohan, F Kural, S Wang, D M O&#039;Rourke, and H Poptani. Prog-
nostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted
MR Imaging in Patients with Glioblastomas. American Journal of Neuroradiology,
36(7):1247 LP – 1252, jul 2015.
[57] Meng Law, Stanley Yang, James S Babb, Edmond A Knopp, John G Golfinos,
David Zagzag, and Glyn Johnson. Comparison of cerebral blood volume and vas-
cular permeability from dynamic susceptibility contrast-enhanced perfusion MR
imaging with glioma grade. American Journal of Neuroradiology, 25(5):746–755,
2004.
[58] Natalie R Boonzaier, Sara G M Piccirillo, Colin Watts, and Stephen J Price.
Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has
multimodal imaging come? CNS Oncol., 4(6):399–410, 2015.
[59] Kenneth Clark, Bruce Vendt, Kirk Smith, John Freymann, Justin Kirby,
Paul Koppel, Stephen Moore, Stanley Phillips, David Maffitt, Michael Pringle,
Lawrence Tarbox, and Fred Prior. The Cancer Imaging Archive (TCIA): Maintain-
ing and Operating a Public Information Repository. Journal of Digital Imaging,
26(6):1045–1057, dec 2013.
[60] Fred W. Prior, Ken Clark, Paul Commean, John Freymann, Carl Jaffe, Justin
Kirby, Stephen Moore, Kirk Smith, Lawrence Tarbox, Bruce Vendt, and Guillermo
Marquez. TCIA: An information resource to enable open science. Conference
proceedings : ... Annual International Conference of the IEEE Engineering in
Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society.
Annual Conference, 2013.
[61] Stephen J Price, H A L Green, A F Dean, J Joseph, P J Hutchinson, and J H
Gillard. Correlation of MR Relative Cerebral Blood Volume Measurements with
Cellular Density and Proliferation in High-Grade Gliomas: An Image-Guided
Biopsy Study. Am. J. Neuroradiol., 32(3):501–506, 2011.
Bibliography 221
[62] P. D. Chang, H. R. Malone, S. G. Bowden, D. S. Chow, B. J.A. Gill, T. H. Ung,
J. Samanamud, Z. K. Englander, A. M. Sonabend, S. A. Sheth, G. M. McKhann,
M. B. Sisti, L. H. Schwartz, A. Lignelli, J. Grinband, J. N. Bruce, and P. Canoll. A
multiparametric model for mapping cellularity in glioblastoma using radiographi-
cally localized biopsies. American Journal of Neuroradiology, 38(5):890–898, 2017.
[63] Adam Autry, Joanna J. Phillips, Stojan Maleschlijski, Ritu Roy, Annette M. Moli-
naro, Susan M. Chang, Soonmee Cha, Janine M. Lupo, and Sarah J. Nelson. Char-
acterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-
Enhancing versus Non-Enhancing Tumor. Translational Oncology, 10(6):895–903,
dec 2017.
[64] Paul S Tofts, Gunnar Brix, David L Buckley, Jeffrey L Evelhoch, Elizabeth Hen-
derson, Michael V Knopp, Henrik B W Larsson, Ting-Yim Lee, Nina a Mayr,
Geoffrey J M Parker, Ruediger E Port, June Taylor, and Robert M Weisskoff.
Estimating Kinetic Parameters From Dynamic Contrast-Enhanced T1-Weighted
MRI of a Diffusable Tracer: Standardized Quantities and Symbols. J Magn Reson
Imag, 10(July):223–232, 1999.
[65] Huijun Chen, Feiyu Li, Xihai Zhao, Chun Yuan, Brian Rutt, and William S Ker-
win. Extended graphical model for analysis of dynamic contrast-enhanced MRI.
Magnetic Resonance in Medicine, 66(3):868–878, sep 2011.
[66] Paul S Tofts. Modeling Tracer Kinetics in Dynamic Gd-DTPA MR Imaging. J.
Magn. Reson. Imaging, 7(1):91–101, 1997.
[67] Leif Østergaard, Robert M Weisskoff, David A Chesler, Carsten Gyldensted, and
Bruce R Rosen. High Resolution Measurement of Cerebral Blood Flow Using In-
travascular Tracer Bolus Passages. Part I: Mathematical Approach and Statistical
Analysis. Magn. Reson. Med., 36(5):715–725, 1996.
[68] Leif Østergaard, Alma Gregory Sorenson, Kenneth K Kwong, Robert M Weiskoff,
Carsten Gyldensted, and Bruce R Rosen. High Resolution Measurement of Cere-
bral Blood Flow Using Intravascular Tracer Bolus Passages. Part II: Experimental
Comparison and Preliminary Results. Magn. Reson. Med., 36(5):726–736, 1996.
[69] Leif Østergaard. Principles of Cerebral Perfusion Imaging by Bolus Tracking. J.
Magn. Reson. Imaging, 22(6):710–717, 2005.
Bibliography 222
[70] Lori Arlinghaus and Thomas E Yankeelov. Diffusion-Weighted MRI. In T E
Yankeelov, D R Pickens, and R R Price, editors, Quantitative MRI in Cancer,
pages 81–98. Taylor & Francis, Boca Raton, FL, 2011.
[71] Denis Le Bihan, Eric Breton, Denis Lallemand, Philippe Grenier, Emmanuel Ca-
banis, and Maurice Laval-Jeantet. MR Imaging of Intravoxel Incoherent Mo-
tions: Application to Diffusion and Perfusion in Neurologic Disorders. Radiology,
161(2):401–407, 1986.
[72] Peter J Basser, James Mattiello, and Denis LeBihan. MR Diffusion Tensor Spec-
troscopy and Imaging. Biophys. J., 66(1):259–267, 1994.
[73] Peter J Basser and Carlo Pierpaoli. Microstructural and Physiological Features
of Tissues Elucidated by Quantitative-Diffusion-Tensor MRI. J. Magn. Reson. B,
111:209–219, 1996.
[74] Stephen M Smith. Fast Robust Automated Brain Extraction. Hum. Brain Mapp.,
17(3):143–155, 2002.
[75] Brian B Avants, Nicholas J Tustison, Michael Stauffer, Gang Song, Baohua Wu,
and James C Gee. The Insight ToolKit image registration framework. Front.
Neuroinf., 8:1–13, 2014.
[76] Brian B Avants, Nicholas J Tustison, Gang Song, Philip A Cook, Arno Klein, and
James C Gee. A reproducible evaluation of ANTs similarity metric performance
in brain image registration. NeuroImage, 54(3):2033–2044, 2011.
[77] Jonathan S Lin, David Fuentes, Adam Chandler, Sujit Prabhu, Jeffrey S Weinberg,
Veera Baladandayuthapani, John D Hazle, and Dawid Schellingerhout. Perfor-
mance Assessment for Brain Magnetic Resonance Imaging Registration Methods.
Am. J. Neuroradiol., 38(5), 2017.
[78] Kelvin K Leung, Matthew J Clarkson, Jonathan W Bartlett, Shona Clegg, Clif-
ford R Jack Jr, Michael W Weiner, Nick C Fox, Sébastien Ourselin, and the
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